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Abstract 
Asthma is a chronic inflammatory disease of the airways.  The current cornerstone for 
asthma treatment is glucocorticoids (steroids), and the majority of patients respond to 
steroids with an improvement in lung function (Steroid Sensitive; SS). However a 
proportion of asthmatics do not respond to steroids with improvement in lung function 
(Steroid Resistant; SR), who represent those patients most at risk. Epidemiological 
studies demonstrate that asthma severity and poor responsiveness to treatment, is 
associated with vitamin D insufficiency and deficiency. Vitamin D is an 
immunomodulatory molecule which induces the synthesis of antimicrobial peptides and 
anti-inflammatory molecules, and inhibits pro-inflammatory cytokine synthesis. The 
overall goal of this work was to investigate immunological differences between SS and 
SR asthma patients, and effects of vitamin D that may explain the epidemiological 
observations. 
Peripheral blood from a clinically well-characterized cohort of SS (n=14; mean 
improvement in lung function or FEV1 post 2-weeks oral prednisolone 16.1%) and SR 
(n=23; no improvement in FEV1) asthmatics was studied by ex vivo flow cytometry. 
Major findings included evidence for significantly higher frequency of myeloid dendritic 
cells, and lower frequency of Foxp3+ CD4+ T cells in the peripheral blood of SR as 
compared to SS asthmatics. The accepted measure of vitamin D status is serum 25-
hydroxyvitamin D3, 25(OH)D, and the severe asthmatics had significantly lower levels 
of serum 25(OH)D as compared to healthy controls. A significant positive correlation 
between the number of Foxp3+ T cells in the peripheral blood and serum 25(OH)D was 
observed. 
Following culture of PBMCs with anti-CD3 activation it was found that severe 
asthmatics synthesised significantly higher IL-17A levels than healthy controls, which 
was most striking in the SR patients. The steroid Dexamethasone (Dex) enhanced IL-
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17A production in culture, whereas the active form of vitamin D 1,25-hydroxyvitamin D3 
(1,25(OH)2D3) significantly reduced IL-17A production in a Dex-independent manner. 
This work proposed that IL-17A inhibition by 1,25(OH)2D3 may be partially due to a 
CD39-dependent mechanism. 
In vivo evidence for a positive association between serum 25(OH)D and Foxp3+Treg 
numbers was further investigated in vitro. High concentrations of 1,25(OH)2D3 (10
-6M) 
increased the frequency of Foxp3+ T cells in culture through two main mechanisms: 
the induction of IL-2, on which Foxp3+Treg are dependent, as well as less inhibition of 
Foxp3+ over Foxp3- T cell proliferation. Lower, and likely more physiological 
concentrations of 1,25(OH)2D3 (10
-7M), which are known to enhance IL-10 synthesis, 
failed to significantly increase the frequency of Foxp3+ CD4+ T cells. However upon 
modulation of the cytokine environment to one of low IL-10 and high TGFβ, this 
concentration of 1,25(OH)2D3 significantly increased Foxp3+ Treg frequency. 
Collectively this data highlights additional immunoregulatory properties of 1,25(OH)2D3 
including induction of anti-inflammatory cytokines such as IL-10 and TGFβ, inhibition of 
pro-inflammatory cytokines such as IL-17A and IL-22 as well as the direct induction of 
Foxp3+ Tregs. In conclusion evidence for a number of immunomodulatory effects of 
1,25(OH)2D3 exists that may help to reduce uncontrolled inflammatory responses 
associated with severe asthma. 
  
4 | P a g e  
 
Acknowledgements 
Firstly I would like to thank my supervisor Professor Kasia Hawrylowicz. Kasia has 
provided an immense amount of help, guidance and support throughout my time here. 
Through her I have learned to love Vitamin D and have thoroughly enjoyed my time 
working on it!  
I would like to thank the past and present members of Kasia’s lab particularly Dave 
Richards for all the help in the lab and Alexandra Nanzer for the team effort in 
completing the clinical trial work. I would also like to thank: Zoe Urry. Emmanuel 
Xystrakis, Sarah Dimeloe, Louise Rice, Cheryl Black, Kimuli Ryanna, Eve Hornsby, 
Winston Lu, Paul Pfeffer, Nicolas Matthews and Hebe Chen. The clinicians and nurses 
who have helped with the clinical trial and blood donation: Anna Freeman, Grianne 
Colligan, Chris Corrigan, Chris Griffiths, Kheem Jones, Helen Bull and Cherylin 
Reinholtz. Also the AARS family who have made it such a great department to work in 
with special thanks going to Holly Foster, Batika Rana, Celine Wu, Elisabeth Fuerst,  
and Audrey and Paul Lavender. 
I would like to thank my family, especially my parents for their support in getting me to 
this stage. A massive thanks to my Aunt Denise Nee (Nese), who put up with me 
moaning whilst running and cycling at the weekends, you were a great listener and 
helped me keep sane. Nana Margaret, sadly you are not here to see me finish this, 
your words of support and encouragement are remembered. 
I would also like to thank my cat Klaus for all the cuddles and company whilst writing 
up. But most of all I would like to thank Phill, for his seven and a half years of love, 
patience and support. Without you I would have struggled, Thank you.  
5 | P a g e  
 
Abbreviations 
1,25-(OH)2D3 - 1,25-Dihydroxyvitamin D3 
25(OH)D - 25,hydroxyvitamin D 
A467  -  Alexa Fluor 647 
ab  - antibody 
AP-1  - activator protein 1 
APC  - allophycocyanin 
APCs  - antigen presenting cells 
ATP   - Adenosine Triphosphate 
BAL  - bronchoalveolar lavage 
BDCA  - blood dendritic cell antigen 
Bregs   - B regulatory cells  
BTK  - Bruton’s typrosine kinase 
C  - Celsius 
CBA  - Cytometric Bead Array 
CD  - Cluster of differentiation 
CNS   - Conserved Non-coding Sequences  
CTLA4  -  Cytotoxic T Lymphocyte Associated Protein 4 
DAMPs  - Danger Associated Molecular Patterns 
DC  - Dendritic Cell 
6 | P a g e  
 
Dex  - Dexamethasone 
dNTPs  - Deoxynucleotide triphosphates 
EAE  - Experimental Autoimmune Encephalomyelitis 
EdU  - 5-ethynyl-2’-deoxyuridine 
ELISA  - Enzyme-Linked ImmunoSorbent Assay 
ERK  - extracellular-signal-regulated kinase 
FACS  - Fluorescence-Activated Cell Sorting 
FEV1  - forced expired volume in 1 second 
FITC  - fluorescein isothiocyanate 
FoxP3  - Forkhead box P3 
GARP  - glycoprotein A repetitions predominant 
GATA-3  - GATA binding protein 3 
GITR               - Glucocorticoid-Induced Tumour necrosis Factor Receptor 
Related Protein  
GM-CSF - Granulocyte-macrophage colony-stimulating factor 
GR  - glucocorticoid receptor 
GRE  - Glucocorticoid Response Element 
HATs   - Histone acetyl transferases  
HBSS  - Hanks balanced salt solution 
HDAC  - Histone deacetylase  
7 | P a g e  
 
IFN  -  Interferon 
IL  - Interleukin  
IL-10R  -  IL-10 Receptor 
ILC   - Innate Lymphoid cells  
ILT3  - Immunolglobulin-like transcript 3 
iTreg  - induced Treg 
JNK  - JUN amino-terminal kinase 
L  - Litre 
LAG3  - Lymphocyte Activating Gene 3  
LAP   - Latency Associated Protein  
m  - milli 
M  - Molar (moles per L) 
MAPK  -  mitogen-activated protein kinases 
min(s)   - minute(s) 
MMPs  - Matrix metalloproteinases 
MS  - Multiple Sclerosis 
MyD88  - Myeloid differentiation primary response protein 88 
n  - nano 
Na2CO3 - Sodium carbonate 
NaHCO3 - Sodium bicarbonate 
8 | P a g e  
 
NFκB        -          nuclear factor kappa-light-chain-enhancer of activated B cells 
NK  - Natural Killer 
NODs   - Nod-like Receptors 
NOD2  - nucleotide-binding oligomerization domain containing 2 
nTreg  - natural T regulatory  
o  - degrees 
OD  - Optical density 
PAMPs - Pathogen Associated Molecular Patterns  
PBMCs - Peripheral blood mononuclear cells 
PD-1  - Programmed death 1  
PDL-1  - Programmed death ligand 1 
PBS  - Phosphate-buffered saline 
PE  - phycoerythrin 
PerCp  - peridinin-chlorophyll-protein complex 
pH  - potential hydrogen  
PRR  - Pathogen recognition receptors 
q  - quantitative  
RNA  - Ribonucleic acid 
RNApol - RNA polymerase  
rpm  - revolutions per minute 
9 | P a g e  
 
RPMI  - Roswelli Park Memorial Institute 
RSV  - Respiratory Syncytial Virus  
RT  - Room temperature 
RT-PCR - Real Time Polymerase Chain Reaction 
RAR  - retinoic A receptor 
RXR  - retinoic X receptor 
secs  - Seconds 
SR  - glucocorticoid resistant 
SS  - glucocorticoid sensitive 
Syk   - Spleen tyrosine kinase   
TGFβ  - Transforming growth factor β 
TIMP-1 - Tissue inhibitor of metalloproteinases – 1 
TLRs   - Toll-like Receptors 
Tr1  - T regulatory cell 1 
Treg  - T regulatory cell 
TSDR  - Treg-specific demethylated region  
U  - unit 
U.K.  - United Kingdom 
U.S.A.  - United States of America 
VDBP  - Vitamin-D Binding Protein  
10 | P a g e  
 
VDR  - vitamin D receptor 
VDRE  - vitamin D3 response element 
μ  - micro 
  
11 | P a g e  
 
Table of Contents 
 
1. Introduction .......................................................................................................... 22 
1.1 Immune mechanisms of respiratory health ................................................... 23 
1.1.1 Mechanisms of a healthy lung ............................................................... 23 
1.1.2 Innate Immune system .......................................................................... 25 
1.1.3 Pattern recognition receptors ................................................................. 26 
1.1.4 Innate Immune cells .............................................................................. 31 
1.1.5 Dendritic cells ........................................................................................ 32 
1.1.6 Adaptive Immune System ...................................................................... 33 
1.2 Regulatory T cells (Tregs)............................................................................. 38 
1.2.1 Discovery of Tregs ................................................................................. 38 
1.2.2 Foxp3 the Lineage Defining Transcription Factor ................................... 40 
1.2.3 Genetics of Foxp3 ................................................................................. 40 
1.2.4 Induced Tegs (iTregs)............................................................................ 43 
1.2.5 Mechanisms of Treg Function ................................................................ 47 
1.3 Asthma ......................................................................................................... 51 
1.3.1 Immune Mechanisms of Asthma ............................................................ 51 
1.3.2 The role of Tregs in Asthmatic Disease ................................................. 54 
1.3.3 Asthma Therapies ................................................................................. 55 
1.3.4 Asthma Development ............................................................................ 59 
1.4 Vitamin D ...................................................................................................... 63 
1.4.1 Vitamin D insufficiency ........................................................................... 65 
12 | P a g e  
 
1.4.2 Vitamin D and Respiratory Health .......................................................... 67 
1.4.3 Vitamin D effects on Innate Immune Responses ................................... 70 
1.4.4 Vitamin D effects on Adaptive Immune Responses ............................... 70 
1.4.5 Vitamin D effects on Dendritic cells ........................................................ 71 
1.4.6 Vitamin D effects on Regulatory T cells ................................................. 72 
1.4.7 The steroid enhancing properties of 1,25(OH)2D3 ................................. 73 
1.5 Hypothesis and aims of the Thesis ............................................................... 74 
2. Materials and Methods ........................................................................................ 75 
2.1 Patient/Donor Details .................................................................................... 76 
2.2 Materials ....................................................................................................... 76 
2.3 Cell Culture ................................................................................................... 76 
2.3.1 Media .................................................................................................... 76 
2.3.2 Cell Purification and Isolation ................................................................. 77 
2.3.3 Cell culture ............................................................................................ 79 
2.4 Flow cytometric Analysis .............................................................................. 79 
2.4.1 Cell surface staining .............................................................................. 79 
2.4.2 Intracellular FoxP3 Staining ................................................................... 81 
2.4.3 Intracellular Cytokine Staining ............................................................... 82 
2.4.4 Phospo-STAT5 Staining ........................................................................ 82 
2.5 Proliferation Assays ...................................................................................... 83 
2.5.1 CellTrace Violet ..................................................................................... 83 
2.6 Cytometric Bead Array (CBA) ....................................................................... 83 
2.7 Isolation of Total RNA ................................................................................... 84 
13 | P a g e  
 
2.8 Reverse Transcription to cDNA .................................................................... 84 
2.9 qRT-PCR ...................................................................................................... 85 
2.9.1 qRT-PCR analysis ................................................................................. 86 
2.10 Flow Cytometric and Statistical Analysis ....................................................... 86 
3. Ex vivo phenotyping of Steroid Sensitive and Steroid Resistant Asthma .............. 88 
3.1 Introduction ................................................................................................... 89 
3.1.1 Severe asthma ...................................................................................... 89 
3.1.2 Steroid Resistant (SR) Asthma .............................................................. 89 
3.1.3 Steroid Enhancement by Vitamin D ....................................................... 91 
3.2 Results: ........................................................................................................ 93 
3.2.1 Patient characteristics. ........................................................................... 94 
3.2.2 Healthy and Severe asthma donors had similar frequencies of 
lymphocytes. ........................................................................................................ 96 
3.2.3 Severe asthmatics have an increased frequency of myeloid DC as 
compared to healthy donors. ............................................................................... 99 
3.2.4 Comparison between healthy and severe asthmatics after 2-weeks of 
steroids 100 
3.2.5 Steroid Sensitive patients had a similar frequency and number of 
lymphocytes as compared to Steroid Refractory asthmatics at Baseline. The 
impact of steroid treatment in vivo. .................................................................... 101 
3.2.6 CD19+ lymphocyte numbers significantly increase post-prednisolone in 
both SS and SR asthmatics; CD3+ numbers decrease in SS asthmatic donors 
only. 107 
14 | P a g e  
 
3.2.7 SR asthmatics have a higher frequency of myeloid DC as compared to 
SS at baseline. .................................................................................................. 109 
3.2.8 The phenotype of mDCs and pDCs is the same at baseline (pre steroid) 
in SS and SR asthma patients ........................................................................... 112 
3.2.9 The frequency of total DCs and pDC significantly decreases post-
prednisolone. ..................................................................................................... 112 
3.2.10 The expression of HLA-DR and ILT3 on pDCs, and CD86 and HLA-DR 
on mDCs from SS asthmatics is significantly decreased post-steroids. .............. 114 
3.2.11 The frequency and number of Foxp3+ Tregs is lower in SR as compared 
to SS asthmatics pre- and post-prednisolone. .................................................... 118 
3.2.12 Severe asthmatics had significantly lower levels of serum 25(OH)D as 
compared to non-asthmatics. ............................................................................. 122 
3.2.13 Serum 25(OH)D positively correlated with the number of Foxp3+ Tregs.
 124 
3.3 Discussion .................................................................................................. 126 
4. Severe asthmatics have enhanced IL-17A production which is ameliorated by 
1,25(OH)2D3. Potential role for CD39. ...................................................................... 134 
4.1 Introduction ................................................................................................. 135 
4.2 Results ....................................................................................................... 138 
4.2.1 Comparison of IL-17A and IL-22 production by CD8-depleted PBMCs 
from Steroid Sensitive (SS) and Refractory (SR) asthma patients compared to 
healthy controls in vitro. ..................................................................................... 138 
4.2.2 Dexamethsone fails to inhibit whereas 1,25(OH)2D3 decreases IL-17A 
production. ......................................................................................................... 140 
15 | P a g e  
 
4.2.3 Dexamethsone significantly inhibits proliferation, whereas 1,25(OH)2D3 
does not in culture. ............................................................................................ 143 
4.2.4 Comparison of CD39 and CD73 expression ex vivo in severe asthma and 
healthy control peripheral blood. ........................................................................ 145 
4.2.5 1,25(OH)2D3 increases CD39 and CD73 expression on CD4+ T cells in 
vitro 151 
4.2.6 Inhibition of CD39 enzymatic activity with POM-1 ................................ 155 
4.3 Discussion .................................................................................................. 157 
5. In vitro induction of 1,25(OH)2D3-induced T regulatory Cells: role of cytokine 
milieu. ....................................................................................................................... 165 
5.1 Introduction ................................................................................................. 166 
5.2 Results ....................................................................................................... 169 
5.2.1 High dose 1,25(OH)2D3 (10
-6M) exerts greater inhibition of Foxp3- T cell 
proliferation than Foxp3+ T cell proliferation ...................................................... 169 
5.2.2 1,25(OH)2D3 is less inhibitory on Treg as compared to T effector cell 
proliferation ........................................................................................................ 173 
5.2.3 10-6M 1,25(OH)2D3  increases the frequency of IL-2+ CD4+ T cells .... 177 
5.2.4 IL-2 signalling predominantly occurs in Foxp3+ Tregs over Foxp3- T 
effector cells in cultures containing 10-6M 1,25(OH)2D3 ..................................... 180 
5.2.5 1,25(OH)2D3 increases TGFβ expression in CD4+ T cell cultures ....... 184 
5.2.6 TGFβ increases the frequency of Foxp3+ CD4+ T cells in culture in the 
presence of a lower concentration of 1,25(OH)2D3 ............................................ 188 
5.2.7 A combination of 10-7M 1,25(OH)2D3 and TGFβ  greatly increases the 
frequency of IL-2+ CD4+ T cells in culture. ........................................................ 192 
16 | P a g e  
 
5.2.8 IL-10 inhibits the increase in frequency of Foxp3+ CD4+ Cells in cultures 
containing 1,25(OH)2D ....................................................................................... 194 
5.2.9 The combination of anti-IL-10R antibody, TGFβ and 10-7M 1,25(OH)2D3 
increases the frequency of Foxp3+ CD4+ T cells ............................................... 197 
5.3 Discussion .................................................................................................. 200 
6. General Discussion ............................................................................................ 206 
6.1 Conclusions ................................................................................................ 207 
6.2 Future Perspectives .................................................................................... 214 
6.2.1 SS versus SR gene arrays .................................................................. 214 
6.2.2 Does active Vitamin D restore response to steroids? ........................... 214 
6.2.3 Future Clinical Trials ............................................................................ 215 
6.2.4 Are CD73, LAP and GARP markers of IL-10+Tregs? .......................... 216 
6.2.5 Application of these findings into other immune-mediated disease ...... 216 
Appendix I................................................................................................................. 217 
7. References ........................................................................................................ 220 
8. Publications ....................................................................................................... 283 
 
  
17 | P a g e  
 
List of Tables 
Table 1-1 TLR family members and their ligands. ....................................................... 27 
Table 1-2 NOD-like receptors and their ligands........................................................... 30 
Table 1-3 Mechanisms of action of regulatory T cells ................................................. 50 
Table 1-4 Asthma phenotypes. ................................................................................... 53 
Table 1-5 Current and proposed therapies in asthma. ................................................ 58 
Table 1-6 Polymorphisms in genes associated with asthma ....................................... 60 
Table 1-7 Table showing the definition of vitamin D deficiency and insufficiency ........ 66 
Table 2-1 A Table of antibodies used for flow cytometric analysis .............................. 81 
Table 2-2 A Table showing the probes used for qRT-PCR analysis ............................ 85 
Table 3-1 Patient Characteristics ................................................................................ 95 
Table 3-2 Table showing the Frequency of Lymphocytes in the peripheral blood of 
healthy (non-asthmatic) donors and severe asthma donors. ....................................... 98 
Table 3-3 Frequency of Lymphocyte populations in SS and SR asthmatics was not 
different pre- and post-steroids ................................................................................. 102 
Table 3-4 Frequency of Lymphocyte populations in SS and SR asthmatics pre- and 
post-steroids ............................................................................................................. 104 
Table 3-5 Lymphocyte numbers in SS and SR asthmatics pre-steroids. ................... 107 
Table 3-6 Expression of HLA-DR, ILT3 and CD86 on pDCs and mDCs of peripheral 
blood obtained from SS and SR. ............................................................................... 112 
Table 3-7 A summary Table showing the similarities and differences between SS and 
SR asthmatics .......................................................................................................... 126 
Table 3-8 A summary Table showing the impact of 2-weeks of Prednisolone on 
lymphocyte and dendritic cell numbers in severe asthmatics .................................... 127 
  
18 | P a g e  
 
List of Figures 
Figure 1-1 Mechanisms of the epithelium preventing activation of alveolar 
macrophages during lung homeostatsis. ..................................................................... 24 
Figure 1-2 Schematic of signalling cascade post TLR ligation..................................... 28 
Figure 1-3 Schematic of CD4+ T cell subtypes and effector functions. ....................... 34 
Figure 1-4 Schematic Representation of the Foxp3 Loci ............................................. 41 
Figure 1-5 Schematic showing the different populations of Tregs. .............................. 44 
Figure 1-6 A Schematic diagram representing two known mechanisms of action for 
glucocorticoids. ........................................................................................................... 55 
Figure 1-7 Vitamin D metabolic pathway ..................................................................... 64 
Figure 1-8 The role of vitamin D in the maintenance of pulmonary health. .................. 69 
Figure 2-1 Purity of CD4+ and CD8-depleted cells isolated by bead-based selection . 78 
Figure 3-1 Representative lung function data of Steroid Sensitive and Steroid 
Refractory asthmatics after 2-weeks of Prednisolone ................................................. 89 
Figure 3-2 Schematic showing the Clinical Trial protocol ............................................ 93 
Figure 3-3 Example gating performed during ex vivo analysis of lymphocyte, dendritic 
cell and Foxp3+ populations ....................................................................................... 97 
Figure 3-4 The frequency of Myeloid and Plasmacytoid DC in healthy and severe 
asthma donors ............................................................................................................ 99 
Figure 3-5 The ratio of CD3+ to CD19+ cells in the peripheral blood of severe 
asthmatics pre- and post- steroids ............................................................................ 106 
Figure 3-6 The number of lymphocytes in the peripheral blood of severe asthmatics 
pre- and post-steroids ............................................................................................... 108 
Figure 3-7 The Frequency of mDCs and pDCs in SS versus SR severe asthmatics. 110 
Figure 3-8 mDCs have higher expression of CD86 and HLA-DR but lower ILT3 as 
compared to pDCs. ................................................................................................... 111 
Figure 3-9 Dendritic cell frequencies significantly decrease post-steroids ................. 113 
19 | P a g e  
 
Figure 3-10 Expression of ILT3, CD86 and HLA-DR on pDCs in peripheral blood of SS 
and SR asthmatics pre- and post-steroids ................................................................ 115 
Figure 3-11 Expression of ILT3, CD86 and HLA-DR on mDCs in peripheral blood of SS 
and SR asthmatics pre- and post-steroids ................................................................ 117 
Figure 3-12 The frequency of Foxp3+ Tregs is lower in SR as compared to SS 
asthmatics pre- and post-steroids ............................................................................. 119 
Figure 3-13 The frequency of Foxp3+ Tregs decreases post-steroids ...................... 121 
Figure 3-14 Foxp3+ Tregs pre- and post-steroids ..................................................... 122 
Figure 3-15 Serum levels of 25(OH)D changed with season and Severe asthmatics had 
significantly lower levels of serum 25(OH)D as compared to healthy controls. .......... 123 
Figure 3-16 Positive correlation between serum 25(OH)D and Foxp3+ Tregs numbers 
in severe asthmatics. ................................................................................................ 125 
Figure 4-1 Severe asthma patients express higher levels of IL-17A and IL-22 .......... 139 
Figure 4-2 Dexamethasone enhances IL-17A conversely to 1,25(OH)2D3 ................ 142 
Figure 4-3 Dexamethasone inhibits proliferation whereas 1,25(OH)2D3 does not ..... 144 
Figure 4-4 Schematic of the CD39/CD73 pathway. ................................................... 145 
Figure 4-5 Representative staining showing the gating strategy for CD39 and CD73 ex 
vivo analysis ............................................................................................................. 147 
Figure 4-6 Increased frequency of CD39+ T cells in the peripheral blood of healthy 
donors as compared to severe asthmatics ................................................................ 148 
Figure 4-7 Serum 25(OH)D moderately correlated with CD39+ but not CD73+ T cell 
frequencies ............................................................................................................... 150 
Figure 4-8 1,25(OH)2D3 increased the frequency and expression of CD39 and CD73 
on healthy CD4+ T cells in vitro. ............................................................................... 152 
Figure 4-9 1,25(OH)2D3 increased the frequency and expression of CD39+CD73+ but 
not CD39+Foxp3+ or CD73+ Foxp3+  CD4+ T cells in vitro. ..................................... 154 
Figure 4-10 Inhibition of CD39 by POM-1 partially abrogates the inhibition of IL-17A by 
1,25(OH)2D3 ............................................................................................................. 156 
20 | P a g e  
 
4-11 Schematic representation of our proposed role for glucocorticoids and 
1,25(OH)2D3 in IL-17A-mediated severe asthma ...................................................... 158 
Figure 5-1 1,25(OH)2D3 can increase the frequency of Foxp3+ and IL-10+ Treg 
populations. .............................................................................................................. 167 
Figure 5-2 High dose 1,25(OH)2D3 (10
-6M) inhibits proliferation of CD4+ T cells in vitro
 ................................................................................................................................. 170 
Figure 5-3 1,25(OH)2D3 is less inhibitory on Foxp3+ as compared to Foxp3- CD4+ T 
cell proliferation ........................................................................................................ 172 
Figure 5-4 Sorting strategy to isolate Tregs and Teffectors ....................................... 174 
Figure 5-5 1,25(OH)2D3 is less inhibitory on Treg as compared to T effector cell 
proliferation ............................................................................................................... 176 
Figure 5-6 A high concentration of 1,25(OH)2D3 (10
-6M)  increases the frequency of IL-
2+ CD4+ T cells ........................................................................................................ 179 
Figure 5-7 CD25 expression is significantly inhibited by 1,25(OH)2D3 at 10
-6M  on 
Foxp3- CD4+ T cells but not Foxp3+ CD4+ T cells ................................................... 181 
Figure 5-8 IL-2 signaling predominantly occurs in Tregs in cultures containing 10-6M 
1,25(OH)2D3 ............................................................................................................. 183 
Figure 5-9 1,25(OH)2D3 upregulates TGFβ gene and protein expression ................. 185 
Figure 5-10 1,25(OH)2D3 predominantly upregulates LAP and GARP in Foxp3- CD4+ T 
cells .......................................................................................................................... 187 
Figure 5-11 1,25(OH)2D3 and TGFβ increase the frequency of Foxp3+ CD4+ T cells
 ................................................................................................................................. 189 
Figure 5-12 A combination of TGFβ and 10-7M 1,25(OH)2D3 is less inhibitory on 
proliferation of  Foxp3+ as compared to Foxp3- CD4+ T cells................................... 191 
Figure 5-13 A combination of TGFβ and 10-7M 1,25(OH)2D3 increase the frequency of 
IL-2+ CD4+ T cells .................................................................................................... 193 
Figure 5-14 The addition of IL-10 in culture reduced the frequency of 1,25(OH)2D3 (10
-
6M)–induced Foxp3+ Tregs ....................................................................................... 195 
21 | P a g e  
 
Figure 5-15 Anti IL-10R antibody increases the frequency of 1,25(OH)2D3 (10
-7M)-
induced Foxp3+ T cells by promoting the proliferation of  Foxp3+ over Foxp3- CD4+T 
cells .......................................................................................................................... 196 
Figure 5-16 Combination of TGFβ and anti-IL-10R greatly increases the frequency of 
Foxp3+ Tregs at lower concentrations of 1,25(OH)2D3 ............................................. 198 
Figure 5-17 Proposed model for 1,25(OH)2D3 Treg generation ................................ 201 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  







23 | P a g e  
 
1.1 Immune mechanisms of respiratory health 
The ultimate aim of the immune system in the lung is to maintain respiratory health 
involves the clearance of pathogens from the lung in the absence of excessive 
inflammation. There are a number of mechanisms in place to prevent inappropriate 
immune responses to innocuous stimuli such as environmental and commensal stimuli 
that constantly bombard the lungs. Environmental insults inhaled can include diesel 
exhaust particles, metals, allergen (House dust mite, cat dander, grass etc.), 
lipopolysaccharide (LPS), amongst others [1]. As well as the external environmental 
stimuli there are also a large number of commensal bacterial present in the airways, 
reports of up to 2000 bacterial genomes detected in just a cm2 of lung surface [2]. 
However, in healthy individuals the lungs need to ignore non-harmful external and 
internal stimuli and maintain respiratory health. When a pathogen or environmental 
trauma occurs in the lung an immune response is only initiated once the stimuli 
received is over a certain threshold [1]. However there are some individuals where an 
inappropriate immune response is initiated to an innocuous antigen, an example of this 
is asthma, where there is an inappropriate immune response to antigen such as 
allergens.  
When an environmental insult or pathogen enters the lung the components of the 
immune system need to work in harmony to eliminate the pathogen, and then restore 
the lung back to homeostasis. The two main sections of the immune system include; 
the innate cells (immediate response, non-specific) and the adaptive immune system 
(slower, specific-immune response).  
 
1.1.1 Mechanisms of a healthy lung 
In a healthy lung the predominant cell type in the alveolar lumen is alveolar 
macrophages and they make up around 95% of the cell population [1]. These cells are 
less efficient at antigen uptake and presentation as they do not express high levels of 
24 | P a g e  
 
costimulatory molecules such as HLA and CD80 or CD86 in high levels. The epithelium 
cells lining the airways are proposed to modulate alveolar macrophage function. The 
mechanisms employed by the epithelium prevent an inappropriate immune response in 
the lung via activation of alveolar macrophages are shown below: 
 
Figure 1-1 Mechanisms of the epithelium preventing activation of alveolar 
macrophages during lung homeostatsis.  
Alveolar macrophages interact with the epithelium through a number of receptors including IL-
10R (brown) which binds IL-10, TGFβR (blue) which binds TGFβ and CD200R (blue) which 
binds CD200, these interactions under homeostatic conditions prevent the activation of alveolar 
macrophages. Alveloar macrophages also express Toll-like receptors (red) which detect 
invading pathogens and can initiate an immune response. Taken from [1] 
Alveolar macrophages are known to secrete a number of immunomodulatory mediators 
such as Prostaglandins and Transforming growth Factor β (TGFβ) which are broadly 
anti-inflammatory [3]. The secreted TGFβ can bind to the TGFβR expressed on the 
surface of alveolar macrophages and has inhibitory effects on the cell. TGFβ is 
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pleiotropic and as well as controlling alveolar macrophages also plays a role in wound 
healing and repair as well as fibroblast remodelling [4]. CD200R is highly expressed by 
airway macrophages and binds to the ligand CD200 expressed on airway epithelium. 
Binding of CD200 to CD200R on airway macrophages results in an inhibitory signal 
being sent to the macrophage [5].  
A number of lipids and surfactant (SPD) proteins are also present in the airway. The 
primary function of these molecules is to decrease the surface tension of the air fluid 
and keep the lungs open. Goblet cells secrete mucus which contains the glycoprotein 
Mucin, this acts as a trap for potential invading pathogens and prevents them binding 
to the epithelium [6]. Mucin-1 and also Surfactant proteins (SPD-A and –D) play an 
additional role of binding to pattern recognition receptors (discussed later) and prevents 
ligand binding and activation of these receptors [7-9]. 
The other 5% of cells that can found in the airway lumen include Dendritic cells (DCs) 
and T cells (γδ and αβ TCR). The DC predominantly sits under the airway epithelium 
constantly sampling the airway lumen and in steady-state conditions has been shown 
to secrete large amounts of IL-10 [10].  
When a pathogen or environmental stimuli enter the lung and stimulate the immune 
receptors and cells over the required threshold there is initiation of an immune 
response and this begins with the innate immune system. 
 
1.1.2 Innate Immune system 
The first line of defence in the lung is the mucosal epithelium, which acts as a 
mechanical barrier to invading pathogens. On top of the epithelium, there is a thick 
layer of mucus, produced by goblet cells, this acts as a mechanical trap for invading 
pathogens. Then due to the pulsation of the cilia present on the epithelial cells the 
pathogen is expelled. Anti-microbial peptides such as β-Defensins and Cathelicidin are 
present in the present in the lung, and in particular the mucus layer. Anti-microbial 
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peptides are predominantly made by the epithelium and innate cells; they are cationic 
proteins that disrupt the cell membrane and thus kill the pathogen [11,12].  
 
1.1.3 Pattern recognition receptors 
The epithelium detects invading pathogens and directs the immune response 
accordingly through recruitment of further innate and adaptive immune cells. It does 
this through receptors present called Pattern Recognition Receptors (PRR) which 
detect Pathogen Associated Molecular Patterns (PAMPs) on the invading pathogen [6]. 
Examples of PRRs include Toll-like Receptors (TLRs), C-type lectins and Nod-like 
Receptors (NODs).  
 
1.1.3.1 Toll-like receptors (TLR) 
There are a number of TLRs in mice and humans and they recognise common 
components on pathogens.  
TLR family member Ligands (origin) 
TLR1  Tri-acyl lipopeptides (bacteria, mycobacteria) 
TLR2 Lipoprotein/lipopeptides (a variety of pathogens) 
Peptidoglycan (Gram-positive bacteria) 
Lipoteichoic acid (Gram-positive bacteria) 
Lipoarabinomannan (mycobacteria) 
TLR3 Double-stranded RNA (virus) 
TLR4 LPS (Gram-negative bacteria) 
Taxol (plant) 
Fusion protein (RSV) 
Envelope proteins (MMTV) 
TLR5  Flagellin (bacteria) 
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TLR6  Di-acyl lipopeptides (mycoplasma) 
TLR7  Imidazoquinoline (synthetic compounds) 
Loxoribine (synthetic compounds) 
Bropirimine (synthetic compounds) 
TLR8  ssRNA (viruses) 
Imidazoquinoline (synthetic) 
TLR9  CpG DNA (bacteria) 
TLR10 Unknown 
Table 1-1 TLR family members and their ligands. Taken from [13] 
TLRs act as adjuvants for the immune system as upon ligand engagement of TLRs 
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Figure 1-2 Schematic of signalling cascade post TLR ligation.  
TLRs can be extracellular such as TLR2 and TLR4 or intracellular such as TLR3 and TLR7/9 
found in endosomes. When TLRs bind to their antigen, there is initiation of a signalling cascade 
which can be either Myeloid differentiation primary response protein 99 (MyD88)-dependant or 
MyD88-independant. These signalling cascade results in activation of a number of transcription 
factors such as IRF5 and NFκB which initiate transcription of inflammatory cytokines, as well as 
IRF7 and IRF3 which activate transcription of Interferon (IFN) genes (IFNβ and IFNα). Taken 
from [14] 
Upon TLR engagement by their respective ligand, the TLR signals through TIR-
containing adapters (labelled in green), and the resulting signalling cascade results in 
the translocation of their respective transcriptions factors (labelled in orange) and 
upregulation of inflammatory cytokines [14]. Examples of inflammatory cytokines 
include Interleukin (IL) -6, CXCL8, IL-1β, CCL20, GM-CSF and G-CSF). These 
cytokines then function by recruiting innate and adaptive immune cells to the lung and 
also by activating DCs [6,11].  
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1.1.3.2 C-type lectins 
These PRRs are important for recognising fungal pathogens, examples of C-type 
lectins include Dectin-1 and -2, DC-sign and Mannose receptor [15]. These receptors 
recognise key components of the fungal cell wall such as Mannan and β-glycan. 
Ligation of the C-type lectins results in a signalling cascade which results in 
upregulation of inflammatory cytokines [15]. There is diverse usage of signalling 
pathways for C-type lectins, as every receptor seems to use a different pathway. 
Examples of C-type lecting signalling pathways include DC-SIGN, which when bound 
by ligand results in activation of RAF1, which through an unknown mechanism 
enhances TLR-mediated production of IL-10 [16]. RAF1 activation in combination with 
a co-receptor, suggested to be CD4, has also been shown to activate MAPK pathway, 
which through an unknown mechanism degrades inflammatory cytokine mRNA (such 
as TNFα and IL-6) [16]. Another C-type lectin, BDCA-2 (CD303) signals through 
activation of Spleen tyrosine kinase (Syk), which further activate Bruton’s typrosine 
kinase (BTK), which in combination with PLCγ2 activates BLNK. This then leads to 
enhance Calcium mobilisation in the cell and inhibits TLR-mediated MyD88 signalling 
[16]. 
 
1.1.3.3 Nod-like Receptors (NODs) 
Nod-like Receptors (NODs) are intracytoplasmic receptors whose structure consists of 
a C-terminal leucine-rich repeat domains, a central nucleotide oligomerisation domain 
and a N-terminal signalling domain [6]. 
NOD (alternative names) 
 
Ligand or pathogen 
NOD1 (CARD4)  γ -D-glutamyl-meso-diaminopimelic acid (iE-DAP) (a 
dipeptide) from Bacillus subtilis, Listeria monocytogenes, 
entropathogen (Escherichia coli), Shigella Flexneri, 
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Pseudomonas aeruginosa, Chlamydia pneumoniae, 




Muramyl dipeptide (MDP) from Streptococcus 
pneumonia, Mycobacterium tuberculosis, Listeria 
monocytogenes, Salmonella typhimurium, 
Shigella Flexneri and Staphylococcus aureus 





Crystals (uric acid, calcium pyrophosphade dehydrate), 
extracellular ATP, fibrillar amyloid-β peptide, hyaluronan, 
pollutants (silica and asbestos), bacterial and viral RNA, 
poly IC, toxins (nigericin andmaitotoxin), UV light,  vaccine 
adjuvant (alum), fungi (Candida albican and 
Saccharomyces cerevisiae), β-glucan, bacteria (Listeria 
monocytogenes and 
Staphylococcus aureus), Viruses (Sendai virus, 
adenovirus and influenza virus) 
Table 1-2 NOD-like receptors and their ligands. Taken from [17] 
In general members of the NODs contain three domains. Firstly a caboxy-terminal LRR 
domain which is responsible for ligand recognition, a central NOD (also known as a 
NACHT domain) which has ATPase activity, as well as a amino-terminal domain which 
has protein-protein interaction domains [18]. Ligation of NODs results in an intracellular 
signalling cascade with upregulation of inflammatory cytokines. For example, ligation of 
NOD1 and NOD2 by its ligand prevents the proteosomal degradation of NFκB through 
ubiquitination of the NFκB inhibitor, IKKγ [18]. Additionally NOD1 and 2 have been 
shown to activate the mitogen-activated protein kinases (MAPK) signalling pathway 
which results in activation of a number of inflammatory mediators such as JUN amino-
terminal kinase (JNK), extracellular-signal-regulated kinase (ERK) and p38 MAPK [18]. 
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1.1.4 Innate Immune cells 
The innate cells of the respiratory system include polymorphonuclear leukocytes 
(granulocytes), neutrophils, eosinophils, basophils, mast cells and also alveolar 
macrophages.  
 
1.1.4.1 Polymorphonuclear leukocytes  
Eosinophils, Basophils and Mast cells contain granules which when activated by either 
cytokines or receptor (for example FcεRI) binding results in exocytosis of their granular 
content. The granular content is a number of inflammatory mediators which act in 
concert to recruit more immune cells; examples of content include Histamine, 
Prostaglandins and Leukotrienes amongst others [19]. Neutrophils eliminate microbes 
through phagocytosis and fusion with granules that contain reactive oxygen species 
and reactive nitrogen species, these free radicals result in efficient killing of the 
pathogen [20]. As well as this Neutrophils have also been shown to secrete Neutrophil 
Extracellular Traps (NETs) which contain DNA, histones, neutrophil elastase, 
myeloperoxidase as well as Cathelicidin. NETs act as traps for extracellular bacteria 
and immobilise the pathogen making killing more efficient [21].  
 
1.1.4.2 Alveolar Macrophages 
As stated before in a healthy lung around 95% of the cells within the airway lumen are 
alveolar macrophages, in steady-state conditions they produced anti-inflammatory 
cytokines and receive signals from the epithelium such as CD200 sending inhibitory 
signals to the cell [1,5]. However in an inflammatory environment, there can be 
upregulation of TLR receptors on the surface of alveolar macrophages [22]. 
Subsequently signalling through TLRs can result in inhibition of IL-10R signal 
transduction and hence release from the inhibitory signals received from the epithelium 
[23]. Activation of the alveolar macrophages results in increased phagocytosis and 
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enhanced production of reactive oxygen species and reactive nitrogen species [24]. 
There is also upregulation of costimulatory molecules allow alveolar macrophages to 
become more efficient antigen presenting cells for infiltrating T cells [24]. Upon 
activation alveolar macrophages also increase expression of pro-inflammatory 
cytokines such as IL-6 and TNFα [24]. 
 
1.1.5 Dendritic cells 
The sentinels of the immune system are Dendritic Cells (DCs). DCs are constantly 
sampling the environment, through phagocytosis and macropinocytosis.  DCs express 
a full array of PAMP receptors such as TLRs and NODS, and also express a number of 
stress receptors such for Danger Associated Molecular Patterns (DAMPs) which also 
detect cell death or stress (examples of such include uric acid and Adenosine 
Triphosphate (ATP)) [25]. When a DC either detects cell stress or a pathogen, the DC 
will mature and migrate to the lymph node to initiate an adaptive immune response. 
The DC will present peptides from the foreign antigen on MHC, and in the presence of 
costimulation (CD80 and CD86), this binds to the T Cell Receptor (TCR) and CD28 
respectively on the naïve T cell and activates this cell.  
There are two classes of DCs, plasmacytoid DCs (pDCs) and myeloid (mDCs). 
Plasmacytoid DCs were primarily identified as interferon producers, hence were 
proposed to be important for combating viral infections. Plasmacytoid DCs have also 
been shown to be important for cross-presentation of exogenous antigens to CD8+ T 
cells [26]. Additionally pDCs have been shown to be important for tolerance as pDCs 
have the capacity to prevent autoimmunity through deletion of autoreactive T cells in 
the liver [27]. mDCs have been further characterised into a number of subsets based 
on function and phenotype. One such of these subsets include BDCA-3+ (CD141+) 
mDCs which have been shown to be efficient at cross-presentation as well as 
enhancing Th1 cells [28]. These BDCA-3+ mDCs have also been shown to be 
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enhanced in the skin by Vitamin D, and were shown to enhance IL-10 secretion [29]. 
More recently CD56 expression on human mDCs has been described as cytotoxic 
mDCs, with potent anti-tumour capability [30]. 
 
1.1.6 Adaptive Immune System 
There are two classes of T cells CD8+ (cytotoxic) and CD4+ (helper). If antigen is 
presented in the context of MHC Class I then this activates CD8+ T cells, also known 
as cytotoxic T cells. These cells function by killing cells expressing peptide and MHC I 
molecules, and specifically kill the infected cell via secretion of molecules such as 
Granzymes A and B. They can also synthesize significant quantities of cytokine [31]. 
 
1.1.6.1 T helper cell differentiation 
CD4+ T cells also known as T Helper (Th) (or T effector) cells were originally described 
to be either Th1 or Th2 cells as defined by expression of the transcription factors Tbet 
and GATA3 respectively [32-35]. These cells recognise antigen presented on MHC II 
molecule, together with costimulation molecules on the surface of antigen presenting 
cells and this results in production of effector cytokines such as Interferon γ (IFNγ) (for 
Th1) and IL-4 (for Th2).  More recent research has shown that there are more than just 
these two subtypes of CD4+ cells. 
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Figure 1-3 Schematic of CD4+ T cell subtypes and effector functions.  
A number of CD4+ T cell subsets have been shown to play a role in lungs function. These 
include Nuocytes which differentiate in the presence of IL-33 and IL-25, produce the cytokines 
IL-13, IL-4, IL-9 and IL-5 all of which have a role in mucus production and mast cell and 
eosinophil recruitment. Th2 cells generated in an environment high in IL-4, produce IL-5 and IL-
3 and recruit and activate basophils. Th9 cells generated in an environment high in IL-4 and 
TGFβ, secrete IL-9 and this increases mucus production. Th17 cells generated by an 
environment high in TGFβ and IL-6, secrete IL-17A, IL-17F and IL-22 and enhance smooth 
muscle proliferation and recruit neutrophils to the lung. Th1 cells result from an environment 
high in IL-12, secret IFNγ and enhance neutrophil recruitment to the lungs. iTregs differentiate in 
the presence of IL-10 and TGFβ, and are important cells for controlling the other CD4+ T cells 
through a number of inhibitory mechanisms discussed later. Cytokines in the black box indicate 
what cytokines direct Th0 differentiation into which CD4+ subsets. Taken from [36] 
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The cytokine milieu plays a role in instructing the naïve CD4+ T cell in what it becomes. 
For example IL-4 instructs the naïve cell to become Th2 and IFNγ and IL-12 instructs 
the naïve cell to become Th1, whereas IL-6 and TGFβ instructs the cell to become 
Th17. There is also a level of plasticity within the CD4+ T cell subsets as the cytokine 
environment can also change the subset of Th cell [37]. 
Th1 cells (as defined by the transcription factor T-bet) orchestrate the killing of 
intracellular pathogens through production of IFNγ, TNFα and Granzymes. Th2 cells 
(as defined by the transcription factor GATA3) are involved in increasing mucus 
production and IgE synthesis through IL-4 and IL-13, as well as activating basophils 
through production of GM-CSF and IL-13, and actions on mast cells and eosinophils 
through IL-9 and IL-5 respectively. 
Th17 cells are defined by the transcription factor RORyt (RORc in humans) and are 
known to secrete the cytokines IL-17A and IL-22 [38,39]. IL-17A is known to be 
important for smooth muscle hyperplasia and also for neutrophil activation. Other 
transcription factors that have been suggested to be important in Th17 development 
include BATF, IRF4 and STAT3, also the Arylhydrocarbon receptor (AhR) has been 
implicated as being important for Th17 development [40-44]. What is clear in the lung is 
that IL-17A and IL-22 is important for maintenance of epithelium and clearance of 
extracellular pathogens, however too much of these cytokines is associated with poor 
respiratory health, as discussed later. 
Th9 cells either differentiate directly from naïve cells when the cytokine IL-4 and TGFβ 
are present.  It is unclear as of yet whether these are distinct from Th2 cells or are just 
Th2 cells with a different phenotype and Th2 cells can be skewed towards a Th9 
phenotype with the addition of IL-25, or IL-4 and TGFβ [45,46]. The Th9 cells do not 
seem to express the lineage defining transcription factors (GATA-3, Tbet or RORc) 
thus they have been defined as a new subset [45]. Th9 cells secrete large amounts of 
IL-9 which is important for eosinophilia and mucus hyperplasia [47].  
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Additionally to these CD4+ T cell subsets implicated in asthma pathogenesis there are 
also Th22 and T follicular helper cells. Th22 cells were originally described in the skin 
and these cells secret large amounts of IL-22 and TNFα [48]. Th22 cells have been 
shown to be important for wound healing, tissue remodelling and repair as well as 
protection against enteropathogenic bacteria and HIV infection; these functions are 
dependent on the secretion of the cytokine IL-22 [48-50]. T follicular helper cells are 
defined by expression of the transcription factor Bcl-6, express CXCR5 and secrete IL-
21, their main role is to support B cells in germinal centres [51]. T follicular helper cells 
enhance antigen-specific B cell differentiation and antibody production and class 
switching [51]. 
There are also populations of regulatory cells present within the lung which play an 
important role in ameliorating and controlling inflammation and these are discussed 
later. 
 
1.1.6.2 Innate Lymphoid Cells 
Innate lymphoid cells (ILC), lack the specificity of the adaptive immune system, as 
there is little antigen receptor editing. Examples of such cells include; Natural Killer 
(NK) cells, γδ T cells, Lymphoid tissue-inducer (LTi) cells, Nuocytes, ILC17 and ILC22 
[52]. Whether these cells are distinct populations or are the same cells going through 
different stages is still under extensive investigation.  
Nuocytes (also called natural helper cells and innate helper cells (Ih2)) are one of the 
newest ILC, and they secrete large amount of Th2-associated cytokines [53]. These 
cells do not express the markers CD19 or CD3 and thus are termed non-B non-T cells. 
They have been associated with airway disease in mouse models of allergic asthma 
however they are yet to be fully characterised in humans [54].  
ILCs such as γδ T cells, ILC17 and ILC22, secrete the cytokines IL-17A and IL-22 
which are known to activate neutrophils and epithelium. There is conflicting data of the 
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role of IL-17A and IL-22 production by these cells with some reports suggesting that 
they are important for tissue homeostasis and other suggesting they may play a role in 
inflammation [55-58]. Certainly one study looking at the role of IL-17A production from 
γδ T cells in the lung, was involved in resolution of allergic airway disease [59]. But 
research is ongoing in this area, before any conclusions can be drawn.  
 
1.1.6.3 B cells 
B cells produce antibodies which play a role in neutralising and opsonising antigen and 
also in activating the complement cascade. Additionally B cells are antigen presenting 
cells, and can present MHC Class II restricted antigen to CD4+ T cells.  
B cells originate from the bone marrow and after deletion of autoreactive B cells enter 
the periphery, these transitional B cells are defined in humans by the expression of 
CD21 and IgD, these cells are antigen naive [60]. A population of transitional B 
regulatory cells (Bregs) has been identified, these cells secrete large amounts of the 
anti-inflammatory cytokine IL-10 and are defined as having high cell surface expression 
of CD24 and CD38 [61]. 
As discussed previously T follicular helper cells assists activation and antibody 
production from B cells after encounter with antigen. B cells in the lymph node undergo 
somatic hypermutation enabling them to become more specific for the antigen. All B 
cells start by making Immunoglobulin (Ig)M and isotype switching occurs in the 
presence of cytokine produced from CD4+ T cells.  ‘B1’ B cells are primed in the 
presence of Th1 cytokines IFNγ and IL-12 and secrete high amounts of IL-10, TNFα 
and IL-6 [62]. ‘B2’ B cells are primed in the presence of Th2-associated cytokines IL-4 
and IL-13, they secrete large amounts of IL-2, IL-4 and IL-13 [62]. Cytokines originating 
from CD4+ T cells are known to be important for class switching from Immunoglobulin 
(Ig)M to IgG, IgA or IgE. IgE is important in the lung as it binds to the FcεRI, the high 
affinity receptor for IgE present on mast cells and basophils, and when antigen (or 
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allergen) crosslinks the receptor this leads to degranulation of these cells [36].B cells 
after antibody isotype switching either become memory B cells (CD38+ B cells) or 
plasma B cells (CD138+ B cells), which are terminally differentiated B cells [63,64].  
 
All these immune cells of the innate and adaptive immune system work together to 
successfully fight invading pathogens with limiting inflammation. However there are 
times when there is a breakdown of respiratory health; and this can lead to diseases 
such as Chronic Obstructive Pulmonary Disease (COPD) and the focus of this work, 
Asthma. 
 
1.2 Regulatory T cells (Tregs) 
In addition to immune cells (effector cells) initiating and driving immune responses, 
there are also CD4+ T cells that play an important role in ameliorating inflammation and 
promoting tolerance. Under normal homeostasis Tregs exist in balance with effector T 
cells [65].  
 
1.2.1 Discovery of Tregs 
It was known since the 1960s, that if the thymus was removed from the female mice 
then an autoimmune disease in the ovaries developed, however if the thymus was 
returned before 7-days then autoimmunity was prevented [66]. In the early 1970s, 
Gershon and colleges were credited with coining the term suppressor T cells. It was 
believed that suppressor T cells worked via secretion of soluble factors (called I-J) 
which were encoded in the mouse MHC; functioning in a similar way to B cells. 
Research into suppressor cells in the 1970-80s focussed on this I-J region, and 
attempts were made to identify the suppressive secreted protein. When there was no 
progression in this area of research the area of suppressor T cells became less popular 
[67,68]. 
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The “modern era” of Tregs emerged from studies by Sakaguchi and others in the mid-
1990s, as they described “natural” Tregs (nTregs) produced in the thymus [69]. These 
cells were characterized by the constitutively high expression of the CD25 antigen, the 
α-chain of the interleukin (IL)-2 growth factor receptor. CD25 is normally only 
transiently expressed at moderate levels on effector T cells upon activation. CD25+ 
regulatory cells were subsequently also identified in human peripheral blood [70-72], 
cord blood [72,73] and thymus [74]. The suppressive ability of human nTregs as 
determine by in vitro suppression assays, was as efficient as seen in mice, [71,75]. 
Following the identification of these nTreg the characteristics of these cells were further 
researched. CD4+CD25+ nTregs were defined as being: 
 Anergic – nTregs do not proliferate in response to TCR stimulation in vitro [76-
78] 
 Inhibitory of CD4+ and CD8+ T cell proliferation [79,80] 
 Inhibitory of cytokine production from effector T cells [79] 
 Unable to produce their own IL-2 and yet dependent upon IL-2 [81]– 
requirement of  IL-2 to be produced by effector T cells; CD25+ nTregs are 
absent in IL-2 knockout mice [82] 
 Preventative of autoimmune diseases [76,83] - this is due to the fact that T cell 
receptor (TCR) repertoire of the nTregs whilst being diverse has been found to 
often be specific for ‘self-peptides’, hence important for preventing 
autoimmunity [84,85] 
To investigate whether it was the expression of CD25 that rendered the Tregs 
suppressive, CD25 expression was investigated on CD4+ effector cells. Upregulation 
of CD25 by in vitro stimulation did not render the CD4+ T cells suppressive [86]. 
Therefore identifying that the nTregs and T effector cells were distinct T cell 
populations and additionally that there must be a ‘Treg’ factor upregulated in nTregs to 
render them suppressive. 
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1.2.2 Foxp3 the Lineage Defining Transcription Factor  
The field of nTregs was further enhanced when the lineage defining transcription factor 
for nTregs was discovered. It was identified first in mice, and subsequently confirmed in 
humans, that the lineage-specific transcription factor for nTregs was forkhead box P3 
(FoxP3) [87-90]. Foxp3 continual expression in Tregs is required for the development 
and functionality of the nTreg [91]. FoxP3+ nTregs are vitally important for self-tolerance 
and immune homeostasis, as best highlighted by cases of immune dysregulation 
polyendocrinopathy, enteropathy X-linked syndrome (IPEX), in which patients lack 
Tregs due to mutations in the gene FOXP3. IPEX is a fatal condition due to widespread 
autoimmune and inflammatory disease from a very early age unless it is treated 
aggressively by bone marrow transplantation or profound immune suppression. A 
similar condition, scurfy, was also described in mice [87-89].  
 
Due to the fixation and permeabilisation of cells required to identify Tregs by Foxp3 
expression, a lot of research has been performed to identify cell surface antigens that 
uniquely distinguish Tregs from T effector cells or differentiate between different Treg 
populations.  However these unique cell surface antigens have proven elusive. The 
best cell surface markers to date to identify Tregs, are low to no expression of CD127 
(interleukin seven receptor α) as well as high CD25 [92]. More recently several groups, 
have tried to further characterise surface markers of Foxp3+ Tregs using antigens such 
as CD45RA or CD49d, however to date there is still no consensus agreement on which 
markers can be utilised to identify all Tregs without permeabilising the cells to stain for 
Foxp3 [93,94]. 
 
1.2.3 Genetics of Foxp3 
The Foxp3 locus is shown in Figure 1-4: 
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Figure 1-4 Schematic Representation of the Foxp3 Loci 
a. Figure showing a schematic of the Foxp3 gene loci CNS1-3 which also contains a 
Foxp3 promoter, TGFβ sensor enhancer and a TSDR region which all play an 
important role in Foxp3 gene expression b. Chromatin formation at the Foxp3 promoter 
region in Foxp3- conventional T cells where the gene is ‘off’, in TGFβ-induced Foxp3+ 
cells where the promoter and TGFβ the TGFβ enhancer region are ‘open’ with 
transcription factors bound and stable Foxp3+ Tregs where all the promoter and 
enhancer regions of the Foxp3 gene are in the ‘open’ position and Foxp3 is stably 
expressed. Taken from [95,96] 
 
42 | P a g e  
 
As can be seen from figure 1-4 above there are eleven exons in the Foxp3 gene found 
on the X chromosome, preceded by the promoter region. The promoter region of the 
Foxp3 gene is a TATA-and CAAT box containing promoter, which is activated post 
TCR-signalling with binding of the transcription factors AP1, NFAT, TIEG1, SP1 and 
STAT5 [97]. Due to the fact that TCR signalling can initiate Foxp3 expression, there is 
low level Foxp3 gene induction in T effector cells which is not maintained [97]. As 
shown in the figure above for Foxp3 to be stably expressed a region within the Foxp3 
locus called Treg-specific demethylated region (TSDR) needs to be demethylated [98].  
The Foxp3 region also contains three Conserved Non-coding Sequences (CNS), these 
regions are important for gene induction and maintenance of Foxp3 expression [95]. It 
has been determined that CNS3 may facilitate opening of the FoxP3 locus making the 
locus more amenable for transcription. CNS3 has a c-Rel motif, and it is believed to be 
important for increasing the frequency of Foxp3+ Tregs in the thymus [95]. CNS2 is not 
required for Foxp3 induction but for maintenance of expression; Foxp3 is known to bind 
to this element to maintain Foxp3 expression in the Tregs and progeny of dividing cells 
[95]. CNS1 contains a TGFβ-NFAT response element and is not required for nTreg 
differentiation; however it is required for iTreg induction [95,99]. When CNS1 KO mice 
are used it is seen that there is extensive Th2 mediated inflammation in the intestine 
and the lung [100]. Mucosal sites are known to be important sites for iTreg induction 
(discussed later).
Although a lot of research has been performed to establish how Foxp3 is expressed it 
is still relatively unknown how Foxp3 targets its genes as there is no clear Foxp3 target 
sequence like those seen for other transcription factors, e.g. GATA3 binds to 5’-
(A/T)GATA(A/G)-3’ [101]. Foxp3 when bound to Runx1 inhibits the expression of IL-
17A thus prevents naive CD4+ differentiation into Th17 cells and favours Foxp3+ Treg, 
conversely RORyt has been shown to inhibit Foxp3 gene expression. Implying that 
there is a complex interaction where Foxp3+ Tregs negatively regulate Th17 cells, yet 
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conversely RORγt can inhibit Foxp3+ Tregs generation and thus promote Th17 cell 
differentiation [102]. 
Foxp3 and its associated transcription complex was purified from Foxp3 expressing 
cells and it was found to be in a complex of around 400-800kDa in size [103]. The 
composition of this complex was suggested to be important for targeting Foxp3 to its 
target gene as it included a number of sequence-specific transcription factors. It has 
also been shown that Foxp3 can interact with chromatin modifying enzymes such as 
histone acetyl transferases (HATs) and histone deacetylases (HDACs) [103]. Thus 
Foxp3 has the ability to make genes open to transcription via HATs acetylation of 
histones, making the DNA permissive for transcription. Conversely, Foxp3 can also 
inhibit transcription with HDACs, which remove the acetyl group and thus the histone 
and DNA become more packed and thus less available for transcription [104]. 
 
1.2.4 Induced Tegs (iTregs) 
A  number of non-nTregs have been identified to date and these have been collectively 
termed induced or adaptive Tregs (iTregs) [105]. 
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Figure 1-5 Schematic showing the different populations of Tregs.  
Foxp3+ Tregs can either originate from the thymus (nTregs) or can be generated from naive 
Foxp3-CD4+ T cell from the periphery, the combination of these Foxp3+ Tegs form the total 
peripheral Foxp3+ Treg cell population. Additionally Foxp3- CD4+ Tregs can be generated from 
naive CD4+ T cells in the periphery, and they can be termed Tr1 or Th3. Taken from [106] 
 
Induced Tregs are generated in the periphery from CD4+Foxp3- cells. iTregs cells may 
or may not express Foxp3; however they all collectively exhibit regulatory function.  
 
1.2.4.1 Foxp3+ iTregs 
Early evidence of conversion of naïve CD4+ T cells into Foxp3+ Tregs was observed 
when naïve CD4+ T cells were transferred into lymphopenic hosts. It was shown that 
there was a generation of suppressive Foxp3+ Tregs from the donors cells [107]. In 
conjunction with this it has been observed in humans that the frequency of Tregs 
increases with age, and yet conversely the thymus produces fewer cells with age [108]. 
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Together these data provided evidence that there were additional populations of 
Foxp3+ Tregs that were not nTregs.  
Low dose antigen exposure, predominantly at mucosal sites has been demonstrated to 
be enough to generate a population of iTregs [109,110]. This conversion was 
enhanced in the presence of TGFβ [109]. TGFβ on its own, was subsequently shown 
to be capable of generating a population of Foxp3+ iTregs, however the expression of 
Foxp3 in these cells is unstable [111-113]. However if TGFβ and Retinoic Acid (RA) 
(which is found in abundance in the gut) are present at the same time this generates a 
stable Foxp3+ iTreg population [114-116]. This predominantly occurs in the gut, and in 
mice has been identified to be facilitated by CD103+ DCs, the human equivalent of 
these DCs is yet to be fully established [117].  
More recently evidence suggests that the microbiota at mucosal surfaces can play an 
important role in iTreg induction. It has been found that human commensals have the 
ability to drive iTreg induction, as mice colonised with human commensals generated 
Foxp3+ Tregs with suppressive capacity that genetically resembled iTregs [118,119]. It 
is believed that these commensal bacteria work by generating an environment which 
promotes Treg generation in particular through production of TGFβ [119]. The TCR of 
these Tregs are different to nTregs as they have TCRs specific for components of 
commensal bacteria [120]. 
As both nTregs and iTregs express Foxp3, extensive research has been carried out to 
identify a marker which could distinguish between these two Treg populations. 
Originally it was believed that Helios an ikaros family member was a marker for nTregs, 
hence Foxp3+ iTregs could be identified by a lack of Helios [121]. However subsequent 
work, found that it actually depends on the nature of stimulation in vitro, and Helios can 
be expressed in induced Tregs [122,123]. Helios expression has now been associated 
as being involved in Th2 differentiation [124], and also may be a marker of CD4+ T cell 
activation and proliferation [125]. Neuropilin, a receptor which was identified to be 
involved with neuron axon guidance, has subsequently been shown to be important at 
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the immune synapse and vital for DC-T cell interaction [126].  Has become a new 
candidate marker for nTregs, as it is not expressed on Foxp3+ iTregs, however more 
research will need to be performed to identify how good a marker this is as Neuropilin 
is upregulated on all Tregs at sites of inflammation [127,128]. In addition  this work was 
carried out exclusively in mice and a human study has shown that Neuropilin is not 
expressed on any Foxp3+ Treg population, and is actually suggested to be a T cell 
activation marker [129]. So to date, a clear marker that can distinguish between these 
two Foxp3+ Treg populations has yet to be found. 
 
1.2.4.2 IL-10+ Tregs (Tr1) 
There is also a population of iTregs that do not express Foxp3 but instead secrete a 
large amount of the anti-inflammatory cytokine IL-10, called T regulatory 1 cells (Tr1). 
One of the earliest identifications of IL-10+ Tregs was observed in severe combined 
immunodeficiency (SCID) patients, where CD4+ T cells secreting large amounts of IL-
10 were important for successful transplantation of hematopoietic stem cells [130]. 
These cells were subsequently recreated in vitro, when OVA-specific CD4+ T cells 
were cultured in the presence of IL-10, this generated CD4+ T cells that secreted large 
amounts of IL-10 and lacked proliferative potential [131]. When the IL-10+CD4+ T cells 
were transferred to a model of colitis, it was found that they controlled the disease. 
These cells were coined Tr1 cells [131]. Tr1 cells are generated in vivo by immature 
DCs secreting large amounts of IL-10 in the presence of antigen [10,132]. Conversion 
of Th1 and Th2 cells to Tr1 cells can be induced in mouse models of autoimmunity 
through repeated exposure to antigen [133]. The generation of these antigen-specific 
Tr1 cells is dependent on strong signal strength, peptides with less avidity for the TCR 
are less likely to become Tr1 cells [134].  There is also evidence that T cells when 
stimulated in the presence of CD46 (the complement regulator protein), under 
homeostatic conditions, give rise to Tr1 cells [135].  
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1.2.5 Mechanisms of Treg Function 
There has been much research trying to identify the numerous mechanisms by which 
Tregs control immune responses, and these are listed below.
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Mechanism Function Reference 
CD39/CD73 CD39 and CD73 are cell surface markers involved in the breakdown of extracellular ATP 
(performed by CD39) to AMP which is then converted to the immunoregulatory molecule 
Adenosine (performed by CD73). Adenosine then binds to A2A receptors on T effector 
cells and inhibits their function. Also, CD39 expression on Tregs has been proposed to 
play an important role in controlling Th17 cells. 
[136-140] 
Cytotoxic T-lymphocyte 
Antigen 4 (CTLA-4) 
Originally it was believed that CTLA-4 functions through competitive inhibition with CD28 
for binding to CD80 and CD86, thus preventing T effector cell activation. Also there is 
evidence that CTLA-4 delivers a cell-intrinsic negative-signal which inhibits T-cell 
activation. However, more recent data has identified that CTLA-4 can capture CD80 and 
CD86 from opposing T cells by a process of trans-endocytosis and targeted these 
molecules for degradation by the lysosome. Certainly, a genetic defect in CTLA-4 leads to 
a widespread autoimmune disease. 
[141-146] 
Galectin-10 Unknown function and regulation. However highly expressed in human Tregs, and 
knockdown by siRNA prevented Treg suppression of effector T cells.  
[147] 
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Granzyme/ Perforin Although originally thought to be only expressed in CD8+ T cells, it has now been identified 
that CD4+ Tregs express cytotoxic granules including Granzyme B and Perforin. When 
exocytosed these cause apoptosis of target cells. 
[148-150] 
IL-2 consumption Tregs have high expression of CD25 and also the inability to make their own IL-2. Thus 
one of the main mechanisms by which Tregs inhibit T effector cells is through consumption 
of IL-2 and thus generate cytokine-deprivation induced apoptosis in the T effector cells. 
[151] 
IL-10 An anti-inflammatory cytokine produced by a wide range of immune cells, including DCs, 
macrophages and Tregs. IL-10 has many functions these include inhibiting T effector 
proliferation and also rendering DC more tolerogenic. Also suppresses IgE production from 
B cells and also through some mechanism yet to be identified mast cells, eosinophils and 
basophils. 
[152-154] 
IL-35 An immunosuppressive cytokine a member of the IL-12 family, that is made up of two 
subunits Ebi3 (Epstein-Barr-virus-induced gene 3) and IL12a (interleukin 12a), and is 
highly upregulated in Tregs. It is believed to have an important role for Tregs in 
suppressing T effector proliferation. 
[152,155] 
Lymphocyte Activating LAG-3 is an MHC-class-II-binding CD4 homolog and is expressed by Tregs. LAG-3 is [156] 
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Gene 3 (LAG3) proposed to inhibit T effector cell proliferation 
Programmed death 1 
(PD-1) 
PD-1 engagement with its ligand PDL-1 generates an inhibitory signal, resulting in 
inhibition of proliferation and cytokine secretion in the PDL-1 expressing cell. 
[157,158] 
Transforming Growth 
Factor β (TGFβ) 
TGFβ is important in development and maintenance of Tregs, with TGFβ-specific binding 
site present in the promoter region of Foxp3. Also TGFβ has been shown to be expressed 
by activated Tregs, and inhibits effector T cells in the gut and in maintaining tolerance. Also 
suppresses IgE production from B cells and also through some mechanism yet to be 
identified mast cells, esoinophils and basophils. 
[95,154,159
,160] 
Table 1-3 Mechanisms of action of regulatory T cells 
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1.3 Asthma 
Asthma is considered to be one of the most common chronic diseases with an 
estimated 300 million people with the disease worldwide, and an estimated 5000 
deaths annually from the disease alone in the U.S.A. [161,162]. It is estimated that over 
15% of the U.K. population are asthmatic (5.4 million people), and the NHS spends one 
billion pounds a year to treat and care for  people with asthma (Asthma U.K., 
www.asthma.org.uk accessed January 2013) [161]. 
The main characteristic of asthma is episodic wheeze/cough with obstructive lung 
function, as determined by Forced Expiratory Volume (FEV1) to Forced Vital Capacity 
(FVC) ratio. Common triggers that exacerbate asthmatic disease include allergens, 
pollution, cold air, exercise, virus infection and smoking. Asthma significantly impacts 
the quality of life of patients by day-to-day symptoms of wheeze, cough and 
breathlessness limiting their quality of life. Asthma exacerbations often require 
hospitalisation and can be life-threatening. 
 
1.3.1 Immune Mechanisms of Asthma  
Asthma is a chronic inflammatory airway disease characterised by airway 
hyperresponsiveness, reversible bronchoconstriction, mucus hyperplasia and tissue 
remodelling. Asthma was historically thought to be a Th2-mediated disease with a 
predominantly allergic response to an innocuous antigen with high levels of Th2 
cytokines within the airways including IL-4, IL-5, and IL-13. These mediators stimulate 
IgE-mediated mast cell degranulation (leading to a release of bronchoconstrictors), 
eosinophil infiltration and activation, mucus hyperplasia and airway remodelling [163]. 
This chronic inflammation, due to the inflammatory milieu leads to disease specific 
airway remodelling, where there is progressive loss of function and eventual permanent 
irreversible airway obstruction. Factors which contribute to airway remodelling, 
including airway muscle cell hyperplasia, and an imbalance of Matrix 
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metalloproteinases (MMPs) and Tissue inhibitor of metalloproteinases (TIMP) leading 
to deposition of extracellular matrix [164]. 
However asthma is in fact heterogenous and can present in many different phenotypes 
with different distinctive features.  
 
Asthma phenotype  
 
Description 
Atopic (allergic) asthma o Reactivity to one or more known allergens 
(determined by skin prick test)  
o Higher than normal IgE levels  
o Specific IgE to allergen  
o Often associated with a history of eczema 
and/or hayfever 
Non-allergic asthma o No known allergy  
o Normal serum IgE  
o No reactivity to allergen  
Mild asthma o Occasional symptoms, but well controlled by 
therapy (low-dose glucocorticoids and/ or 
short-acting β2 agonists) 
Stable asthma o Well-controlled symptoms  
o No lung function variability or asthma 
exacerbations 
Severe asthma o Poor control of symptoms despite using 
maximal therapy (high-dose glucocorticoids 
and long-acting β2 agonists, and often other 
therapies) 
o Associated with Th17-mediated disease 
Asthma exacerbations o Mild or severe asthma with sudden worsening 
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of symptoms, often requiring medical 
consultation or hospitalization and possible 
oral glucocorticoid intervention 
Neutrophilic asthma o Increased number of neutrophils in 
bronchoalveolar lavage or sputum samples 
(can be allergic or non-allergic asthma) 
High Th2-associated asthma o Th2 cell-associated gene expression is typical 
(for example, expresses IL13 and 
IL-13-inducible genes)  
o Responds well to glucocorticoids  
o Prone to asthma exacerbations 
Low Th2-associated asthma o A mixed phenotype of asthma  
o Less prominent Th2 type cytokine responses  
o More refractory to glucocorticoid treatment 
than patients with high Th2-associated 
Table 1-4 Asthma phenotypes.  
Taken from [165,166]. 
Thus asthma is no longer seen as just a predominantly Th2-mediated disease and as 
such each phenotype has clearly different clinical and immunological features 
[166,167]. It has become important to phenotype the asthma presented and then 
specifically administer a therapeutic that targets the specific asthmatic disease. An 
example of this Lebrikizumab, anti-IL-13 monoclonal therapy, was particularly 
efficacious in asthmatics that had high serum levels of periostatin (an IL-13 responsive 
gene) prior to treatment [168]. 
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1.3.2 The role of Tregs in Asthmatic Disease 
In mouse models of allergic asthma it has been shown that Foxp3+ Tregs are able to 
alleviate disease [148,169,170]. Conversely asthmatic disease worsens in these 
models when Foxp3+ Tregs are depleted [169].  In humans in adult and paediatric 
cohorts it has been shown that asthmatics have lower Foxp3 expression as well as less 
suppressive function of their Foxp3+ as compared to healthy controls [171-174]. 
Certainly environmental exposure to pollution and early life virus infection, known risk 
factors for asthma development can prevent Foxp3+ gene expression and also inhibits 
the suppressive function of Foxp3+ Tregs [175-177]. This could be a result of there 
being a high Th2 environment in asthma, as TGFβ-driven iTreg generation in culture 
has shown to be inhibited by the presence of IL-4 [178,179]. 
Immunotherapy is the process of allergen desensitisation, and it involves the 
subcutaneous injection of increasing doses of the specific allergen the patient is 
sensitive to. It is a specific treatment for allergic disorders in particular allergic asthma. 
The mechanisms of action include skewing the immune response to the specific 
allergen from Th-2 to Th-1 and also induction of Tr1 cells [180,181]. Tr1 cells are vital 
in immunotherapy as the IL-10 produced by these cells is essential for induction of 
tolerance to the allergens [181,182]. As well as the role of Tr1 cells in immunotherapy 
in mouse models of allergic asthma, they have been shown to be important for 
preventing allergy induced airway hyperresponsiveness [10]. 
There is clearly a dysfunction of Tregs in allergic and asthmatic disease, Tregs 
represent an exciting therapy as they can specifically target allergic disease as seen 
with immunotherapy. Therefore investigating ways to enhance Treg numbers and 
activity represents an active and exciting area of research in targeting asthma, and 
modulation of these cells by drugs such as vitamin D holds much potential for 
combating asthma [153]. 
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1.3.3 Asthma Therapies 
1.3.3.1 Glucocorticosteroids 
The current cornerstone treatment for asthma is glucocorticosteroids (steroids) 
Steroids are believed to work via induction of anti-inflammatory genes and turning off of 
pro-inflammatory genes [183,184].  
 
Figure 1-6 A Schematic diagram representing two known mechanisms of action 
for glucocorticoids.  
Glucocorticoids (GC) enter the cell and bind to the glucocorticoid receptor (GR) in the cytoplasm 
and this binding result in the translocation of this complex into the nucleus. The GC-GR complex 
can either bind to HDAC and inhibit NFκB and AP-1 transcription or bind to a Glucocorticoid 
response element (GRE) element in combination with RNA polymerase (RNApol) and initiate 
transcription of anti-inflammatory genes. 
 
Glucocorticoids enter the cell and diffuse in the cytoplasm where they interact with the 
Glucocorticoid Receptor (GR). GR is a ligand activated transcription factor, which when 
bound to GC is translocated into the nucleus. Once in the nucleus GR can either bind 
to HDAC (an enzyme that acetylates DNA and hence closes the gene for transcription) 
and turns off genes such as NFκB and AP-1 which are important transcription factors 
for the inflammatory cytokines [184]. AP-1 and NFκB are important activators of 
 








NFκB and AP-1 
transcription 
56 | P a g e  
 
inflammatory genes, hence glucocortioids turn off inflammatory genes like IL-5 and IL-
13 and decrease inflammation via this pathway [183,185]. Alternatively the GR can 
bind to anti-inflammatory genes via binding as a homodimer to Glucocorticoid 
Response Elements (GRE) promoters upstream of the anti-inflammatory genes. RNA 
polymerase is recruited and transcription of anti-inflammatory genes is switched on 
[183,184]. One of the key anti-inflammatory genes upregulated by steroids is IL-10, and 
it is believed that the mechanisms for this is GR binding to the GRE in the promoter 
region of the IL-10 gene [185-187]. Steroids have also been shown in asthmatic 
patients to upregulate Foxp3+ gene expression [188]. Together steroids induce a 
regulatory environment through decreasing pro-inflammatory cytokine production and 
induction of anti-inflammatory cytokines and increase in Tregs. 
Steroids work in the majority of patients particularly moderate to mild asthmatics, these 
patients are known as steroid sensitive (SS) asthmatics. However, there is a proportion 
of patients that fail to show an improvement in lung function after treatment with a dose 
of oral steroids and assessment of compliance [189]; these patients pose a serious 
clinical and a financial burden on the health care system, and are known as steroid 
insensitive or resistant (SR). There is still an unmet clinical burden in asthma and 
particularly at the severe end of the asthma spectrum, thus other therapies have 
been/are being developed for use in asthma. 
 
1.3.3.2 Other Asthma Therapies 
The side effects to prolonged and high dose steroids therapy are many, and these 
include effects on the: 
 Skin (acne, delayed wound healing) 
 Skeleton (osteoporosis, bone necrosis) 
 Eye (glaucoma, cataract) 
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 Central Nervous System (disturbances in mood, behaviour, memory and 
cognitive function), Electrolytes (Cushings syndrome, growth retardation) 
 Cardiovascular system (hypertension, thrombosis)  
 There is increased risk of infection (examples of which include Candida spp.) 
[190].  
 
Additionally to this there is the additional complication that steroids do not work in all 
phenotypes of asthma, particularly Th2-low asthma [191]. Therefore a number of 
additional therapies are used and also being developed to reduce the steroid burden in 
asthma.  
Treatment   
 
Description References 
β2 agonists    
 
o Widely used therapies that reduce 
contraction of airway smooth muscle and 
result in bronchodilation  





o Prevent cysteinyl leukotrienes from binding 
the CysLT1 receptor and inducing airway 
smooth muscle contraction, mucus 
secretion and airway inflammation  
o For example, montelukast 
[193,194] 
Therapies against 
Th2 type cytokines 
o Monoclonal antibodies and soluble 
receptors against IL-4, IL-13 and IL-5  





o Monoclonal antibodies (for example, 
omalizumab)  
[196] 
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o Soluble TNF receptors or TNF-specific 
antibodies  
o Reduce levels of circulating TNF  
o Proposed for use in severe asthma 
[197,198] 
IFNs o IFNα had a clinical benefit in steroid-
resistant asthma 
[199] 
Theophyllines o Therapy for severe/steroid resistant asthma 
o Mechanisms of action: Adenosine receptor 
antagonism, increase in  Histone 
deacetylase activity (HDAC)  
[200] 
Table 1-5 Current and proposed therapies in asthma. 
Taken from [165]. 
The only currently approved biological therapy for asthma is Omalizumab; it is a 
humanised murine monoclonal antibody which is specific to the FcεR1-binding domain 
of IgE. It has been shown to reduce serum levels of IgE as well as preventing the 
allergic asthma exacerbations [196,201]. There are a number of clinical trials that have 
recently concluded that specifically target Th-2 cytokines; in particular anti-IL-13 with 
Lebrikizumab and anti-IL-5 with Mepolizumab [168,195]. Lebrikizumab was particularly 
efficacious in asthmatics that had high serum levels of periostatin prior to treatment 
[168].  Mepolizumab has been targeted at asthmatics that have severe eosinophilic 
asthma, and it has just recently been found to reduce asthma exacerbation and hence 
hospital admissions [195]. Also there have been clinical trials investigating Pitrakinra, a 
competitive inhibitor of the IL-4Rα receptor which is a shared receptor chain for both IL-
4 and IL-13 receptors. This trial was specifically targeted to allergic-asthmatics, it was 
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observed that there were fewer asthma-related adverse events as compared to the 
placebo control group [202].  
What these data collectively indicate is that asthma therapy is becoming more 
individual, and targeting specific phenotypes of asthma may be more effective than a 
non-specific anti-inflammatory drug.  
 
1.3.4 Asthma Development 
Although it is not clear what causes a breakdown in respiratory health and initiation of 
asthma, it is clear that asthma is a complex disease with genetic and environmental 
associations [203].  
 
1.3.4.1 Genetic associations 
Below is a table of some of the gene polymorphisms associated with asthma. 
 
Gene Function (chromosome position) Reference 
ADAM33 Metalloproteinase (20p13) [204] 
ADRB2 Β2—adrenoreceptor; involved in broncial smooth-muscle 
relaxation (5q31-32) 
[205,206] 
CD14 Co-receptor with TLR4 in recognition of LPS (15q31) [207] 
DENND1B Gene expressed by  dendritic cells and NK cells and 
believed to interact with tumour necrosis factor α (TNFα) 
(1q31) 
[208] 
FcERIB High-affinity receptor for IgE (11q13) [209,210] 
GSTP1 glutathione S‑transferase T1; protects cells from reactive 
oxygen species (22q11) 
[211-213] 
HLA-DRB1 MHC molecule s (6p21) [214-218] 





IL4Rα Receptor for IL-4 and IL-13 (16p11) [219,220] 
IL4 Th2-cytokine (5q31) [221] 
IL10 Immunomodulatory cytokine (1q31-32) [222-226] 
IL13 Th2-cytokine (5q31) [214,220] 
IL1RL1 The receptor for the Th2-cytokine IL-33 (2q12) [215,227] 
LTA Inflammatory cytokine (also known as TNFβ) (6p21)  [209] 
ORMDL3 Gene expressed in epithelial cells involved in 
metalloproteinase and chemokine production (17q12-21) 
[227-230] 
PTGDR Prostaglandin DR receptor gene (14q22) [231] 
PDE4D Phosphodiesterase 4D a cAMP-specific gene (5q12) [232] 
STAT6 Downstream of IL-4 and IL-13 signalling (12q13) [233,234] 
TNF Inflammatory cytokine (6p21) [209,235] 
Table 1-6 Polymorphisms in genes associated with asthma 
Although not an exclusive list it includes genes implicated in asthma susceptibility in 
over 10 publications according to the following reference [236] and recent genetic 
associations since publication of that review. 
 
Predominantly these genetic associations occur in genes either involved in immunity in 
particular Th2 cells and also with maintenance of respiratory health. However, all these 
genetic associations seem only to be present in certain ethnic populations, thus 
suggesting that they only increase the susceptibility to asthma [229,237,238]. A 
number of twin studies have shown there is up to 68% heritability of asthma [239-241], 
however there is a clear environmental role in asthma development, as these genes 
only render the individual susceptible to asthma development. The environmental 
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factors that are also associated with asthma development include vitamin status, 
infection history, and pollution exposure.  
 
1.3.4.2 Hygiene Hypothesis 
The two main hypothesis that still exist around the development of immune mediated 
diseases including asthma are the ‘hygiene hypothesis’ and the ‘sunshine hypothesis’. 
Vitamin D will be discussed in more detail in the next section 
The hygiene hypothesis was first proposed by Strachan [242]. It proposed that the lack 
of exposure to microbes in early life, due to the westernised lifestyle of improved 
sanitation, smaller family size, and the introduction of vaccination and antibiotic 
resulted in fewer infections in early life.  The implication was that the immune response 
was not ‘educated’ and therefore develops inappropriate Th2-associated immune 
responses to innocuous antigens, as in the development of asthma and atopy 
[165,243]. Subsequently a number of associations were reported between infection 
history and asthma development. Individuals that had early life exposure to farms, had 
increased risk of infections of Hepatitis A and Toxoplasma gondii, had reduce 
incidences of asthma and atopy [243-249].  However there were also some studies that 
countered these earlier findings, as some reports stated that children who grow up on 
farms had increased incidence of atopy [250], with some data suggesting early life 
exposure to Helminths was not protective for asthma development [251,252].   
However this theory proposed by Strachan, has been suggested to be an 
oversimplification hence the hygiene hypothesis was modified. This modified hygiene 
hypothesis proposed that the microbiome of the individual particularly during early  had 
an important role in the education of the immune response particularly as the 
microbiome is important for development of mucosal tolerance [242,253,254]. It is 
believed that the neonatal immune system is primed for a more Th-2 associated 
response, and that there is a requirement for commensals to instruct the immune 
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system  towards a more Th1 and Treg phenotype [255,256]. As in mice reproduced in 
Germ free conditions have an immune system have a less mature immune system 
more prone to Th2-asscoiated cytokine production, the additional of communal 
bacterial products can correct this defect [257]. Additionally there is a report that shows 
that early life exposure of antibiotics reduces the number of bacteria species in the gut 
and hence leads to increased incidence of asthma [258]. A recent study, investigating 
the microbiome in lungs of asthmatics and healthy controls, found that asthmatic lungs 
contained much fewer species of bacteria. Also it was determined that asthmatics had 
much higher frequencies of pathogenic bacteria such as Proteobacteria and 
Haemophilus spp, whereas the healthy lungs contained a wider variety of commensal 
bacteria [2].  
So clearly the microbiome gut as well as the lung is important for asthma development, 
as well as educating the immune systems and clearly plays a role in asthma 
development.  However there are also confounding factors for the hygiene hypothesis 
including Vitamin D sufficiency, diet, socioeconomic status, recurrent viral infections 
and genetics associated.  
 
1.3.4.3 Pollution 
Pollution has long been known to be trigger for asthma exacerbations and has been 
strongly correlated with hospital admissions [259,260]. The composition of pollutant 
matter has been assessed and it has been determined that there are many 
constituents to it including: diesel exhaust particles, heavy metals (such as copper and 
Zinc), LPS, tyre rubber, and also allergens [261,262]. The presentation of allergens 
together with the other inflammatory milieu associated with pollutant particulate matter 
may alter the immune response to the allergen and facilitate atopy and asthma 
development [261]. Whether early life exposure to the high pollution levels, preludes 
asthma development is currently being assessed at Kings College London. A 
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longitudinal study is currently being performed to investigate the implication of the 
introduction of the low emission zone in London [262,263]. 
 
1.3.4.4 Infectious history 
Additionally, early life upper respiratory viral infections such as Respiratory Syncytial 
Virus (RSV) and Rhinovirus that lead to bronchiolitis and/or hospital admission, 
predisposes to wheeze and asthma development in children and adolescence [264-
266]. It has been proposed that RSV infection may be one of the biggest independent 
risk factors for asthma development [266]. In conjunction with this the time of year you 
were born has an impact on virus infection and asthma development. Children born 4 
months prior to ‘winter virus’ peak as compared to children born earlier, had 29% 
increased odds of developing asthma [267]. The mechanism behind how RSV 
predisposes to asthma has been investigated in a mouse model of allergic asthma, 
where it was shown that RSV promotes a Th2-environment and also may render Tregs 
less suppressive [177]. So certainly the hygiene hypothesis and asthma development 
seems to apply for extracellular pathogens, however there is increasing evidence that 
intracellular pathogens such as virus actually may predispose to asthma development. 
 
1.4 Vitamin D 
The active form of vitamin D is a secosteroid hormone. The majority of Vitamin D is 
generated in the skin from 7-dehydrocholesterol following exposure to UVB rays from 
sunlight. It can also originate from diet via fortified dairy products as in the U.S.A., 
meat, eggs and oily fish [268-270]. The biosynthesis pathway of Vitamin D is shown 
below: 
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Figure 1-7 Vitamin D metabolic pathway 
80-90% of vitamin D is synthesised from 7-dehydrocholesterol in the skin, made into 
PreVitaminD3 catalysed by UVB light from sunlight. This is rapidly made into Vitamin D3, which 
can also be obtained from the diet. Vitamin D3 is then made into 25-hydroxyvitamin D in the 
liver, and then this is subsequently synthesised to the active form of vitamin D 
1,25dihydroxyvitaminD3 in a variety of cell types. 
Sunlight is absorbed by the epidermal and dermal cells; UVB light splits the B ring of 7-
dehydrocholesterol and leads to the production of previtamin D3 [268]. Pre-vitamin D3 
is then rapidly converted to Vitamin D3, which leaves the skin and enters the liver. In 
the liver it is converted to 25-hydroxyvitamin D by cytochrome p450 enzymes (25-
hydroxylases). 25-hydroxyvitamin D (25(OH)D) a circulating metabolite is absorbed 
mainly by kidney cells. More recent evidence has shown that as well kidney cells, a 
number of other cell types including epithelial cells, macrophages, T lymphocytes and 
dendritic cells (DC), convert 25(OH)D to the active form 1,25 dihydroxyvitamin D3 
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(1,25(OH)2D3) utilising the mitochondrial enzyme 25-hydroxyvitamin D-1α-hydroxylase 
[271-274].  
When 1,25(OH)2D3 enters the cell it binds to the vitamin D receptor (VDR) which is a 
member of the superfamily of nuclear hormone receptors [275]. Binding of 1,25(OH)D3 
leads to a conformational change in the VDR and enables binding to the retinoic X 
receptor (RXR) and formation of a heterodimer [276].  RXR is a shared nuclear 
hormone receptor as it can also bind as a homodimer or as a heterodimer with retinoic 
A receptor (RAR) to the active form of vitamin A, retinoic acid. After heterodimer 
formation it is translocated to the nucleus where it can exert three different effects: it 
can bind to a vitamin D3 response element (VDRE) in the promoter region of target 
genes and turn on genes including genes involved in bone remodelling and bone 
matrix protein formation, like osteocalcin and osteopontin; it can bind to what is termed 
a 'negative' VDRE and prevent gene transcription; or it can bind to transcription factors 
present in the nucleus and prevent them from binding to target genes. These last two 
effects tend to result in a broad anti-inflammatory effect which is discussed later 
[276,277].  
 
1.4.1 Vitamin D insufficiency 
Vitamin D status is measured by assessing serum levels of 25(OH)D, and it is currently 
an area of active discussion as to what levels constitute sufficiency and deficiency. 
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Vitamin D status Concentration of 25(OH)D within blood: 
Vitamin D deficiency < 50nmol/L 
Vitamin D insufficiency 50-75nmol/L 
Vitamin D sufficient >75nmol/L 
Table 1-7 Table showing the definition of vitamin D deficiency and insufficiency 
[269,278]  
Due to the fact that we get the majority of our Vitamin D from a sunlight catalysed 
reaction, it is not that surprising that during the Winter and Spring months ~90% of the 
U.K. population is vitamin D insufficient, that only decreases to ~60% in the summer 
[279]. To achieve vitamin D sufficiency it has been shown during the winter months in 
Ireland the average person is required to have a daily intake of 9 µg per day of Vitamin 
D3 [270]. Vitamin D insufficiency has a genetic component leading to susceptibility to 
low vitamin D status with SNPs being identified in genes associated with cholesterol 
synthesis, hydroxylation and also vitamin D transport [280]. However the majority of 
vitamin D insufficiency in Western society has been suggested to occur due to the 
sedentary lifestyle where there is reduced exposure to sunlight due to sunshine 
avoidance and working indoors during daylight hours. However there are additional 
factors which are known to play a role in vitamin D sufficiency including skin colour and 
obesity. In the U.K. there is no vitamin D supplementation of food as seen in the 
U.S.A., but even this supplementation programme is not optimum as there is still huge 
insufficiency in the U.S.A. [268,270]. 
Vitamin D deficiency results in an increased risk of bone conditions and is strongly 
linked with rickets and osteomalacia. However, there is also an increased health risk by 
being vitamin D insufficient and it has been linked to a number of non-skeletal diseases 
including heart disease [281], breast, prostate and colon cancer incidence and survival 
[282-286], type 2 diabetes [287], and autoimmune disease such as type 1 diabetes and 
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multiple sclerosis [288-290]. Certainly there are also SNPs in the VDR gene that is 
associated with development of immune-mediated diseases such as type-1 diabetes 
and asthma [291-293]. It has been shown that some Multiple Sclerosis patients have a 
mutation in Cyp27B1 which means they are less efficient at generating the 
1,25(OH)2D3  [294,295]. 
 
1.4.2 Vitamin D and Respiratory Health 
There is also a strong positive association with Vitamin D sufficiency and respiratory 
health [296]; it has been shown that insufficiency in vitamin D is associated with 
increased incidences of Tuberculosis [297,298], infections like Respiratory Syncytial 
Virus (RSV) and Influenza [299,300],  Chronic Obstructive Pulmonary Disease (COPD) 
[301] and Asthma.  
 
1.4.2.1 Vitamin D and Asthma 
There is increasing evidence showing that Vitamin D insufficiency correlates with 
asthma development and severity [278,302]. Certainly low Vitamin D status during 
pregnancy increases the incidence of wheeze, a surrogate marker used at 3 and 5-
years of age before asthma can be readily diagnosed [303,304].  Children and adults 
with low vitamin D status are most likely to have severe asthma and are less likely to 
respond to asthma treatment [305-307].  
Components of the Vitamin D metabolism and signalling axis have also been 
associated with asthma. There are a number of SNPs in the VDR gene that has been 
associated with increased risk of developing asthma [293,308,309]. Another 
component of the Vitamin D signalling axis associated with asthma is Vitamin-D 
binding protein (VDBP), VDBP is a protein found in the serum and tissues that has high 
affinity for 25(OH)D and 1,25(OH)2D3 hence sequesters Vitamin D away from target 
68 | P a g e  
 
cells [310]. BAL levels of VDBP were shown to inversely correlate with asthma severity 
[311].  
Collectively this data is driving a research effort that proposes vitamin D 
supplementation to promote respiratory health. It may in fact be a cheap and 
efficacious way to help asthma, particularly those at the severe end of the asthma 
spectrum. 
 
1.4.2.2 Vitamin D and Immune Mechanisms of Respiratory Health 
Evidence that the active form of vitamin D is important within the lung is further 
supported by the fact that respiratory epithelial cells and immune cells that can enter 
the lung environment have been shown to express the enzyme 25-hydroxyvitamin D-
1α-hydroxylase, and hence can generate the active form of vitamin D, 1,25(OH)2D3 
[271-274]. This suggests that there is a role for local synthesis in lung environment and 
hence may play an important regulatory role. It is believed that vitamin D maintains 
respiratory health via modulating the immune system as shown in the figure below:  
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Figure 1-8 The role of vitamin D in the maintenance of pulmonary health. 
Vitamin D has wide ranging immunomodulatory properties. Vitamin D effects on the innate 
immune system include induction of antimicrobial peptides, such as cathelicidn and defensin β2 
and induction of autophagy. Vitamin D controls the effector CD4+ T cell response through 
decreasing expression of TLR molecules and costimulatory molecules on the antigen presenting 
cells. Additionally Vitamin D enhances regulatory T cell populations (IL-10+ and Foxp3+) as well 
as enhancing IL-10 production and inhibitory molecule expression on antigen presenting cells. * 
= this is still under investigation and is still considered controversial by some. Adapted from 
[312,313]. 
Vitamin D has been proposed to play a role in maintaining respiratory health in three 
ways as shown above: firstly by inducing innate immune responses which help with 
defence against respiratory pathogens; secondly by reducing inflammatory responses 
and finally by inducing regulatory cells [313,314]. Thus 1,25(OH)2D3 is proposed to 
1.) Induction of Innate
Immune Responses:
- ↑ Cathelicidin
- ↑ Defensin β2
- ↑ Autophagy
2.) Control of Effector Responses:
APCs: T cells:
- ↓ TLR2 and TLR4 - ↓ proliferation
- ↓ MHC - ↓ IFNγ
- ↓ costimulation - ↓ Th2 cytokines*
molecules - ↓ IL17
Vitamin D
3.) Promotion of Regulatory
Immune Response:
APCs: T cells:
- ↑ IL-10 - ↑ IL-10
- ↑ ILT3 - ↑ Foxp3
- ↑ PDL-1 - ↑ PD-1
- ↑ CTLA-4  
Maintenance of Respiratory Health
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have broad anti-inflammatory effects on the innate and adaptive immune response 
within whilst still maintaining anti-microbial defence through synthesis of anti-microbial 
peptides. 
 
1.4.3 Vitamin D effects on Innate Immune Responses 
1,25(OH)2D3 has been shown to play an important role in innate immunity in particular 
in inducing the antimicrobial peptides such as Cathelicidin, an essential innate 
component for combating M.tuberculosis  [315-317]. This induction of Cathelicidin by 
1,25(OH)2D3 also results in the induction of autophagy (process of the cells degrading 
its own cellular components via lysosomes) which is  involved in killing the 
mycobacterium in M.tuberculosis infected cells [318,319]. 1,25(OH)2D3 has also been 
shown to upregulate the pattern recognition receptor Nucleotide-binding 
oligomerization domain containing 2 (NOD2) which when activated in the presence of 
bacteria leads to release of the antimicrobial peptide defensin β2 [320]. This is an anti-
microbial peptide which has been shown to play an active role in combating bacterial 
infections like Pseudomonas aeruginosa [321]. M.tuberculosis has been shown to 
induce the expression of Matrix metalloproteinases (MMPs), which can degrade 
components of pulmonary extracellular matrix; however 1,25(OH)2D3 has been shown 
to significantly decrease the production of MMPs thus reducing destruction of the lungs 
[322]. 
 
1.4.4 Vitamin D effects on Adaptive Immune Responses 
When airway epithelium and Dendritic cells are exposed to 1,25(OH)2D3, there is a 
reduction in the production of pro-inflammatory cytokines which can instruct the 
adaptive immune response. The predominant mechanism for this is the induction of 
IκBα, and subsequent inhibition of the transcription factor NF-κB, a key transcription 
factor for cytokine production [271,323]. IL-2 cytokine production is also believed to be 
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inhibited by 1,25(OH)2D3 through inhibition of the transcription factor NF-AT [324,325]. 
1,25(OH)2D3 has also been shown to reduce the proliferation of CD4
+ T cells in culture 
[324]. It is well documented that 1,25(OH)2D3 inhibits the production of the cytokine 
Inteferon γ (IFNγ) via inhibition of Th1 cell polarisation [324,326,327]; however it is less 
clear the effect that 1,25(OH)2D3 has on Th2-cytokines. A study reported that 
1,25(OH)2D3 enhanced Th2 development and cytokine production from naive splenic 
CD4+ T cells cultured in the presence of irradiated APCs in an antigen-dependent 
manner [328]. Subsequent studies showed that when splenocytes were cultured in 
Th1- or Th2-skewing conditions (in the absence of irradiated APCs and peptides), 
1,25(OH)2D3 significantly inhibited the development of Th1 and Th2 cells from naïve 
CD4+ T cells in culture [327]. 1,25(OH)2D3  inhibits the generation of Th2 cells in CD4+ 
T cells from cord blood (a good source of naïve cells), cultured in Th1 and Th2 skewing 
conditions [329].  However it has been suggested that the Th2 response to 
1,25(OH)2D3 may be non-linear as high and low 25(OH)D serum levels in a large 
human study (>7000), corresponded with elevated IgE concentrations [330]. Thus very 
high and low levels of 1,25(OH)2D3 may enhance Th2-mediated disease.  
More recently 1,25(OH)2D3 has also been shown to inhibit Th17 cytokine production in 
murine autoimmune disease models, and recently in human CD4+ T cells in vitro [331-
333]. It was also shown that 1,25(OH)2D3 can inhibit Th9 generation in vitro [333]. 
 
1.4.5 Vitamin D effects on Dendritic cells 
1,25(OH)2D3 has been reported to promote tolerance and regulation through inhibiting 
the maturation of Dendritic Cells (DCs) and promoting T regulatory cell (Treg) 
populations. 1,25(OH)2D3 has been shown to prevent the maturation of DCs, resulting 
in  reduced expression of the costimulatory molecules CD80, CD86, and HLA-DR and 
the maturation marker CD83 [334-336]. It has also been shown to induce the 
expression of the inhibitory receptor Immunoglobulin-like transcripts 3 (ILT3); these 
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effects of 1,25(OH)2D3 seem to selectively target myeloid DCs not plasmacytoid DCs 
[337]. 1,25(OH)2D3 also induces the expression of the chemokine CCL22 from myeloid 
DCs which is a chemoattractant for Tregs [337]. It has subsequently been shown that 
1,25(OH)2D3 upregulates the expression of programmed death ligand 1 (PD-L1) on the 
DC cell surface  which results in inhibition of T effector cells [338]. Overall, 
1,25(OH)2D3 renders the DCs more immature and hence more tolerogenic, and also 
upregulates molecules on the DC cell surface that result in inhibition of effector T cells 
whilst promoting induction and recruitment of Tregs [334].  
 
1.4.6 Vitamin D effects on Regulatory T cells 
Early mouse studies demonstrated that 1,25(OH)2D3 alone or in combination with 
immunosuppressive drugs can enhance CD25hi Tregs in murine autoimmune models, 
and the induction of these Tregs ameliorated disease [339,340]. In humans, 
1,25(OH)2D3 can induce a population of Foxp3
+ T cells, and this induction is dependent 
on the presence of IL-2 [341,342]. These Foxp3+ Tregs also expressed high levels of 
Cytotoxic T Lymphocyte Associated Protein 4 (CTLA-4) [341]. A potential mechanism 
by which 1,25(OH)2D3 may enhance Foxp3
+ Tregs is through VDR binding to the 
Foxp3 promoter region and subsequent enhancement of Foxp3 expression [343].  
As well as Foxp3+ Tregs, we and others have shown that 1,25(OH)2D3 increases the 
frequency of IL-10+ Tregs [344-347]. Subsequent studies demonstrated that human 
peripheral blood CD4+ T cells polyclonally activated in the presence of 1,25(OH)2D3  
promoted IL-10 secreting Treg cells. TLR9, was described as a biomarker of 
1,25(OH)2D3 induced IL-10
+Treg and ligation of TLR9 with its agonist CpG 
oligonucleotide turned off IL-10 production, suggesting a control mechanism, whereby 
Treg function may be abrogated [346]. This may be of relevance, for example during 
infection, where the capacity to transiently block inhibitory function would facilitate a 
more effective immune response for clearance of the pathogen. Elimination of the 
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pathogen would lead to diminished TLR ligation, allowing restoration of the Treg 
response and thereby minimise tissue damage [348].  
 
1.4.7 The steroid enhancing properties of 1,25(OH)2D3   
Glucocorticoids, such as dexamethasone have the capacity to enhance production of 
the cytokine IL-10 from CD4+ and CD8+ T cells in culture [185,187]. Dexamethasone 
inhibition of Th2-associated cytokines implicated in the pathogenesis of asthma is 
partially modulated through the upregulation IL-10. CD4+ T cells from SR asthma 
patients fail to produce IL-10 when cultured in the presence of dexamethasone, which 
is in contrast to CD4+ T cells obtained from SS asthmatics [349].  
 
Further work demonstrated that 1,25(OH)2D3 when used in conjunction with the 
steroid, dexamethasone induced a population of IL-10-producing regulatory cells which 
showed increased and more sustained IL-10 production in healthy donors. These IL-
10+ cells were highly inhibitory in both an animal model of Experimental Autoimmune 
Encephalomyelitis (EAE) and in human in vitro suppression assays [347,350]. 
Importantly when 1,25(OH)2D3  was added to cultures of cells from SR asthma patients 
it was able to overcome the defect in steroid-induced IL-10 synthesis. It was found that 
in healthy CD4+ T cells that although 1,25(OH)2D3 alone did not increase the 
expression of GRα, it prevented the dexamethasone-dependent downregulation of 
GRα receptor [350]. Collectively this data provided a potential mechanism through 
which 1,25(OH)2D3 enhanced dexamethasone-induced IL-10 responses.  These 
results provided evidence for a proof of concept study where 4 healthy volunteers and 
3 SR patients were administered Calcitriol (active from of Vitamin D; 1,25(OH)2D3) 
orally at 2.5ng twice daily. Blood was taken at days 1, 3 and 7 after ingestion and 
cultured in vitro. Calcitriol treatment restored or enhanced responsiveness to 
dexamethasone in SR asthmatics for induction of IL-10 production in vitro [350]. This 
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data formed the basis of the clinical trial that forms part of this project, with the aim of 
the trial to investigate the capacity of calcitriol to restore the SR asthmatics clinical 
response to steroid. 
 
1.5 Hypothesis and aims of the Thesis 
The working hypothesis of the study was that SS and SR asthmatics had different 
phenotypes immunologically. The addition of 1,25(OH)2D3 in vivo has therapeutic 
potential through induction of regulatory cells and inhibition of inflammatory mediators. 
The aims of the project were therefore three fold: 
 To investigate the lymphocyte and dendritic cell populations in SS versus SR 
asthma to identify any differences that could contribute to steroid 
responsiveness 
 To identify the role of IL-17A in severe asthma and to investigate the potential 
use of 1,25(OH)2D3 in combating Th17-mediated disease. 
 To identify the impact of cytokine milieu of 1,25(OH)2D3-induced Treg induction 
in culture; to identify potential mechanisms of Treg induction.  





2. Materials and Methods 
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2.1 Patient/Donor Details 
The clinical trial was approved by the Regional Ethics committee (REC) and the 
Medicine and Health Regulatory Authority (MHRA) with reference numbers; REC Ref 
Number: 08/H0804/84 and EudraCT Number: 2008-002244-42. Full written informed 
consent was obtained from all subjects. Patients were selected for the clinical trial if 
they met the criteria shown in Appendix I: 
Experiments on healthy controls were from donors approved by Guy’s Hospital Ethics 
Committee (09/H0804/77) and full written informed consent was obtained from all 
subjects. Atopy was defined by the presence of a positive wheal at 15 minutes after 




RPMI and HBSS cell culture media along with other cell culture materials were 
obtained from Invitrogen Ltd. (Paisley, U.K.).  2-mercaptoethanol, Sodium Citrate and 
other general laboratory chemicals were obtained from Sigma Aldrich, (Gillingham 
U.K.) unless otherwise stated. Anti-mouse Ig, κ/negative control (FBS*) compensation 
particles set (Compbeads), FACs Flow and FACs lysing buffer were obtained from BD 
biosciences (Oxford U.K.).  
 
2.3 Cell Culture 
2.3.1 Media 
All wash steps performed during isolation of peripheral blood cells were washed in 
HBSS supplemented with 2% FCS obtained from PAA Laboratories (Yeovil, U.K.) 
(referred to as 2% HBSS). Isolated cell populations were cultured in RPMI 
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supplemented with 10% FCS, 2mM L-glutamine and 50 µg/ml gentamycin (referred to 
as 10% RPMI). 
 
2.3.2 Cell Purification and Isolation 
Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood 
collected by venepuncture into the anti-coagulant sodium citrate at a ratio of 10:1. 
Peripheral blood was diluted 1:1 in HBSS then layered at a ratio of 3:1 onto 
Lymphoprep® density gradient (Axis-Shield; Oslo, Norway) and centrifuged at 800g for 
20 minutes at 18ºC. PBMCs were removed from the Lymphoprep®:plasma interface 
and cell pellet was obtained by centrifugation at 600g for 10 minutes at 4ºC. The cell 
pellet was washed twice in 2% HBSS (200g; 10 minutes at 4ºC). CD4+ T Cells were 
isolated by positive selection using CD4+ Dynal beads obtained from Invitrogen 
(Paisley, U.K.) CD4 beads were added at 50 l per 107 PBMCs for 20 minutes at 4ºC 
under continuous rotation. The sample was then placed on a magnet for 2 minutes and 
the supernatant removed.  The bead-bound cells were washed by gently resuspending 
in 2% HBSS and then re-applying to a magnet and removing supernatant. This process 
was repeated six times then finally resuspended in 500 l of 2% HBSS. 
DETACHaBEAD® (Dynal) was added (CD4 beads 3μl: Detachabead 1 l ratio) and the 
cells were incubated for at least 30 mins at room temperature under continuous 
rotation. The sample was applied to a magnet and the supernatant containing the 
released, purified CD4+ cells was transferred to a fresh tube. The beads were washed 
once in 2% HBSS to collect residual cells. Purity was routinely assessed with typical 
purity 97%, as seen below in Figure 2.1.  
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Figure 2-1 Purity of CD4+ and CD8-depleted cells isolated by bead-based 
selection 
CD8-depleted PBMCs and CD4+ T cells were isolated from PBMCs by positive bead selection 
using antibody-coated Dynal  beads. Purity was assessed by surface staining using CD19-
FITC, CD8-PE, CD3-PerCP, CD4-APC antibodies.  10,000 live cells were analysed for 
fluorescence by FACS Calibur. Values shown are indicative of the percentage of positive cells 
within the relevant quadrant. 
For Treg and T effector isolation, CD4+ cells were isolated by negative selection using 
the Rosette CD4+ enrichment kit obtained from StemCell Technologies (Grenoble, 
France) from cones obtained from the National Blood Service. To Identify 'Treg' T cells 
(CD25++CD127lo) and 'effector' T cell (CD25-CD127hi) isolation was performed using a 
FACSARIA Flow Cytometer (BD Biosciences) and sort criteria was based on CD127 
and CD25 surface staining.  
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2.3.3 Cell culture 
Cells were counted using Trypan Blue to determine the number of viable cells. Cells 
were washed once in 2% HBSS (200g; 10mins 4oC) then resuspended at 1x106 
cells/ml in 10% RPMI. CD4+ T cells were cultured for either one or two rounds of 7 day 
culture on an anti-CD3 coated plate (1μg/ml) with 50IU IL-2 obtained from Eurocetus 
(Harefield U.K.), with or without drugs as indicated were added to the culture. TGF-β, 
isotype control and anti-IL-10R antibodies were obtained from R&D systems 
(Abingdon, U.K.). 1α,25-dihydroxyvitaminD3 (1,25(OH)2D3) was obtained from 
BIOMOL Research Laboratories (Exeter, UK). POM-1 was obtained from Tocris 
Biosceince  (Abingdon, U.K.).                 
 
2.4 Flow cytometric Analysis 
2.4.1 Cell surface staining 
Samples were incubated with fluorescently-labelled antibodies in the dark on ice for 45 
mins. Whole peripheral blood samples were lysed using Facs lysing solution at working 
dilution (1:10), and incubated for 5 mins at room temperature and then centrifuged 
(200g; 5mins, 4oC). All samples then were washed twice in FACs Flow (1ml; 200g; 5 
mins at 4oC). The samples were resuspended in 250-500µl of FACs Flow and 
subsequently run on the FASCalibur.  
For clinical trial samples 80,000 total events were collected for lymphocyte 
phenotyping; 200,000 for DC phenotyping cells and 2000 (lineage negative, HLA-DR+) 
events were attempted to be gained for phenotyping makers on DCs. For other 
experiments 20,000 lymphocyte events were collected, except CellTrace proliferation 
experiments where 100,000 lymphocyte events were collected. 
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2.4.1.1 Antibodies  





CD73 (APC)  
CD127 
FoxP3 (FITC, PE) 
ILT3 (PE) 
mouse IgG1a, Isotype control (FITC) 













CD3 (FITC, PerCp) 
CD4 (PE, APC) 
CD8 (PE, APC) 
CD11c (PE, APC) 






















IL-10 (PE,  APC) 

























Table 2-1 A Table of antibodies used for flow cytometric analysis 
 
2.4.2 Intracellular FoxP3 Staining 
Samples were incubated with fluorescently-labelled antibodies as described above in 
2.4.1. Samples were resuspended in 1ml of 1X Fixation/Permeabilisation solution and 
incubated for 45 minutes at room temperature in the dark.  The samples were washed 
twice in 1X Permeabilisation buffer (1ml; 200g for 5 minutes at 4ºC). 5μl (0.25µg) of 
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FoxP3 antibody or 5µl of isotype control antibody was added to the appropriate tube 
and the samples were incubated for 45 minutes at room temperature in the dark. 
Following one wash in permeabilisation buffer and one wash in Facs Flow (1ml; 200g 
for 5mins at 4oC); the cells were resuspended in FACS flow prior to FACS analysis. 
 
2.4.3 Intracellular Cytokine Staining 
Prior to staining, samples were restimulated for 4 hours with 5 ng/ml phorbol 12-
myristate 13-acetate (PMA) and 500 ng/ml ionomycin, with 2 µM monensin (Sigma-
Aldrich) added for the final 2 hours. 2μM of 7-aminoactinomycin D (7AAD) was added 
to the samples (live dead stain), and incubated on ice for 15mins. Samples were then 
washed twice in ice cold FACs Flow (1ml; 200g for 5mins at 4oC) and were 
resuspended in Cytofix/Cytoperm (BD Biosciences) for 20 mins at room temperature.  
Following one wash in FACs Flow (1ml; 200g for 5mins at 4oC), samples were 
resuspended in 1ml of 1x Permeabilisation buffer (BD Biosciences) for 10 minute 
incubation at room temperature. Intracellular antibodies were then added and 
incubated with the samples at room temperature for 30 minutes. Finally, cells were 
washed once in 1x Permeabilisation buffer followed by once in Facs Flow (1ml; 200g 
for 5mins at 4oC). Samples were resuspended in Facs Flow and either on a FACS 
Calibur or a FACS Canto flow cytometry machine (BD Biosciences). 
 
2.4.4 Phospo-STAT5 Staining 
An equal volume of CytoFix/CytoPerm Buffer (warmed to 37oC) was added to the 
sample and this was incubated at 37oC for 10 mins. Samples were washed twice in 
Facs Flow (1ml; 200g for 5mins at 4oC), then 0.5ml of Perm Buffer III (chilled to -20oC), 
obtained from BD Biosciences, was added to the samples whilst being vortexed. 
Samples were then incubated on ice for 30mins, then washed twice in FACs Flow (1ml; 
83 | P a g e  
 
200g for 5mins at 4oC), and resuspended in 250μl of FACS Flow for analysis on a 
FACS Canto (BD Biosciences).  
 
2.5 Proliferation Assays 
2.5.1 CellTrace Violet 
In some culture experiments, cell populations were labelled with CellTrace Violet 
obtained from Invitrogen. Cells were resuspended at 1x106/ml in HBSS with no protein 
and CellTrace Violet added at 10μM, cells were vortexed for 30 secs and then 
continuously mixed for 25 mins at RT. For the final 5 mins cold FCS was added, to stop 
the labelling reaction, make a final concentration of 10%. Cells were washed once in 
2% HBSS (200g; 10mins at 4oC), and then cultured as described in 2.3.4. Proliferation 
was assessed at Day 3, Day 7 and Day 14 by looking at the loss of fluorescence of 
CellTrace Violet using FACS Canto machine (BD Biosciences). 
 
2.6 Cytometric Bead Array (CBA) 
Cytokines were measured by Cytometric Bead Array (CBA) (BD Biosciences) 
according to a modified manufacturers protocol. The lower limit of detection was 1.5 
pg/ml. Briefly, 50µl of sample was incubated with 20µl of cytokine specific-beads in a 
microtitre plate. The plate was shaken for (10mins; 80rpm), and then incubated for 3 
hours (RT; in the dark). The plate is then centrifuged (200g; 5 mins) and washed twice 
in facs flow (200g; 5mins). 20 µl of Detection antibody is then added incubated for a 
further 2 hours (RT; in the dark). The plate is then centrifuged (200g; 5 mins) and 
washed with facs flow once (200g; 5mins) and resuspended in 150µl/well of facs flow, 
and cytokine profile is analysed using the BD Fortessa (BD Biosciences). Events were 
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collected on a BD Fortessa (BD Biosciences) and analysed using FlowJo (Treestar 
Inc.; Ashland, U.S.A.). 
 
2.7 Isolation of Total RNA 
RNA was isolated from the cell pellets using the QIAGEN RNeasy kit (QIAGEN Ltd., 
Crawley, UK) following the manufacturer’s protocol. RNA was quantified using the 
Nanodrop ND-1000 spectrophotometer (ThermoScientific, Wilmington, U.S.A.) using 
ND-1000 software version 3.2.0. The purity and integrity of the RNA was assessed by 
A260/A280 spectrophotometric measurements.   
 
2.8 Reverse Transcription to cDNA 
250ng of RNA was reverse-transcribed into total volume of 30µl. 0.2 µg of random 
hexamers (Amersham Biosciences, Buckinghamshire, U.K.) and 250ng of RNA was 
heated to 70oC for 10mins, and allowed to cool on ice. A master mix for each reaction, 
contained the following reagents:  1.5x reaction buffer, 40U of Ribolock RNase 
inhibitor, 200U of RevertAid H Minus M-MuLV and 1µM dNTPs obtained from 
Fermentas Life Science (York U.K.).  
One unit of RiboLock RNase Inhibitor inhibits the activity of 5ng of RNaseA by 50%. 
One unit of the enzyme RevertAid H Minus M-MuLV Reverse Transcriptase 
incorporates 1nm of dTMP into a polynucleotide fraction (adsorbed on DE-81) in 10 
min at 37oC. Reactions were run on a Tetrad machine on the following programme: 
   25oC  10 mins  
   42oC  60 mins     
   70oC  10 mins 
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   4oC  Hold 
2.9 qRT-PCR 
Transcriptional expression of target mRNA transcripts were determined by PCR 
amplification, quantified by 5’-nuclease assay using fluorescent labelled TaqMan® 
probes and analysed using an ABI PRISM 7900HT Sequence Detection System 
thermal cycler (Applied Biosystems, Foster City, USA).  All primers/probes sets were 
purchased from Applied Biosystems.  The sets used and the probe label are shown in 
Table 2.2. 
Gene Product Code Probe Label 
18S Hs9999990_s1 VIC 
5’-nucleotidase, ecto (CD73) Hs01573922_m1 FAM 
Cyp24a1 Hs00167999_m1 FAM 
Ectonucleoside triphosphate 
diphosphohydrolase 1 (CD39) 
Hs00969559_m1 FAM 
FoxP3 Hs00203958_m1 FAM 
IL-2 Hs00174114_m1 FAM 
IL-10 Hs00174086_m1 FAM 
TGFβ1 Hs99999918_m1 FAM 
TGFβ2 Hs00234244_m1 FAM 
TGFβ3 Hs01086000_m1 FAM 
Table 2-2 A Table showing the probes used for qRT-PCR analysis 
86 | P a g e  
 
Reactions were performed in triplicate in 1 X TaqMan® Universal PCR MasterMix 
(Applied Biosystems) with typically 10ng reverse transcribed RNA, 0.5x gene specific 
primer/probe set and 0.25x 18S primer/probe set in a total volume of 10μl.  Cycle 
parameters used:  
 
2.9.1 qRT-PCR analysis 
For each sample assayed, the Threshold Cycle (Ct) were determined for both the 
target gene and the 18S endogenous control, from the corresponding amplification plot 
according to guidelines from Applied Biosystems, using SDS software version 2.1 
(Applied Biosystems). The Ct value for each reaction is the cycle number at the point 
where the amplification curve crosses the threshold of detection.  
The data is expressed as arbitrary units. This is calculated by first normalising the data, 
subtracting the Ct value of the endogenous control from the target gene Ct (δCt), then 
the δCt of the reference or control sample was subtracted from the δCt of the other 
samples to give the δδCt.  Finally, mRNA relative quantity of target genes was 
calculated using the equation: 2-(δδCt), which is expressed as RQ. 
 
2.10 Flow Cytometric and Statistical Analysis 
Flow data obtained from clinical trial samples and associated healthy donors were 
analysed using CellQuest Pro (BD Biosciences), samples acquired on a BD Canto or 
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BD Fortessa were analysed using FlowJo (Treestar Inc.).  Data analysis was 
performed in Graphpad Prism version 5.00 for Windows obtained from Graphpad 
Software Inc. (San Diego, U.S.A.) using statistical tests detailed in the figure legend. To 
determine exact p values for ANOVA tests, statistics was also performed using SPSS 
Statistics Version 17.0 obtained from IBM SPSS Inc., (Portsmouth, U.K.).  
  





3. Ex vivo phenotyping of Steroid 
Sensitive and Steroid Resistant 
Asthma 
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3.1 Introduction 
3.1.1 Severe asthma 
Severe asthma has been defined by the W.H.O. as uncontrolled asthma, with frequent 
severe exacerbations (or death) and/or failure to respond to medications and/or chronic 
morbidity [351] . Even with the treatment with high-dose of inhaled and/or oral steroids 
severe asthmatics have night and day symptoms, and low baseline lung function 
(<80% predicted FEV1) which limit their daily activities [167,351].  
 
3.1.2 Steroid Resistant (SR) Asthma 
Within the severe asthma spectrum there is a group of asthmatics who are Steroid 
Resistant (SR), believed to be around 5-10% of asthmatics.  These patients fail to 
show an improvement in lung function after treatment with a dose of oral steroids, 
unlike Steroid Sensitive (SS) asthmatics. 
 
Figure 3-1 Representative lung function data of Steroid Sensitive and Steroid 
Refractory asthmatics after 2-weeks of Prednisolone 
Representative lung function assessed in SS and SR asthmatics. Both SS and SR asthmatics 
were outside their predicted range as indicated by dotted lines. In the SS asthmatics a 2 weeks 
course of prednisolone restored their lung function to the predicted range, this was not observed 
in the SR asthmatics. 
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The first report of steroid resistant asthma was in 1968, where no reduction in 
peripheral eosinophilia after a course of oral glucocorticoids was reported [352]. 
Subsequently there has been a large body of research in the area of SR asthma and a 
number of mechanisms that contribute to SR asthma have been proposed including 
[183,353]: 
 Reduced Histone Deacetylase (HDAC) expression and activity in SR 
asthmatics (HDAC together with glucocorticoid bound to the GR inhibits 
inflammatory gene transcription) [354-356]. 
 Mutations in the glucocorticoid receptor (GR) thus reducing the ability of the 
GRα to bind to target genes [357-359].  
 Overexpression of GRβ; a dominant negative inhibitor of GR-α [360,361]. 
 Polymorphisms in the IL-10 gene resulting in reduced synthesis the anti-
inflammatory cytokine IL-10 [222-226].  
 NFκB and AP-1 is upregulated in environments high in oxidative stress (often 
seen in severe asthmatics and cigarette smokers). Components of AP-1 have 
been shown to suppress GRα function [353,362-364]. 
 Th2-associated cytokines as well as IL-2 (which are often seen overexpressed 
in Bronchioalveloar Lavage (BAL) of severe asthma patients) have been shown 
to be inhibitory of glucocorticoid action [365-368]. 
 A lack of steroidal induction of TIMP-1, resulting in a higher ratio of MMP:TIMP-
1 thus enhanced tissue remodelling in the lung [369]. 
Phenotypically SR asthmatics have been shown to have a Th2-low disease.  Instead 
severe asthma and steroid resistant disease has been proposed to be associated with 
an increase in Th17-associated cytokines (as will be discussed in the next chapter) 
[191,370,371]. Within the SR population there is an overrepresentation of smokers and 
people of black origin [183,189]. There is also epidemiological evidence associating 
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lower levels of serum 25(OH)D with a poor response to steroid treatment 
[302,305,372,373].  
 
3.1.3 Steroid Enhancement by Vitamin D 
Early studies from the host lab found that glucocorticoids increased production of the 
immunomodulatory cytokine IL-10 from CD4+ and CD8+ T cells in culture [185,187]. It 
is believed that inhibition of Th2 cytokines and particularly the induction of IL-10 
contribute to the efficacy of steroids in Steroid Sensitive (SS) patients as the induction 
of IL-10 in response to glucocorticoids is impaired by comparison in Steroid refractory 
(SR) patients in vitro [349]. Further work demonstrated that the active form of vitamin 
D, 1,25(OH)2D3 (also known as calcitriol) when used in conjunction with the steroid, 
dexamethasone (Dex) induced a large population of IL-10-producing regulatory cells 
which showed increased and more sustained IL-10 production and were highly 
inhibitory in both an animal model of Experimental Autoimmune Encephalomyelitis 
(EAE) and in human in vitro suppression assays [347]. Following these results a proof 
of concept study was established of 4 healthy volunteers and 3 SR patients who were 
administered Calcitriol (active from of Vitamin D; 1,25(OH)2D3) orally at 2.5ng twice 
daily according to British National Formulary (BNF) guidelines. Blood was taken at 
days 1, 3 and 7 after ingestion and cultured in vitro. Calcitriol treatment restored or 
enhanced responsiveness to dexamethasone in SR asthmatics for induction of IL-10 
production in vitro [350]. These results have led to the development of a clinical trial 
that began in April 2009. The aim of the clinical trial is to identify whether the capacity 
of calcitriol to restore steroid-induced IL-10 production in cultures of cells for SR 
asthma patients, correlates with clinical benefit, specifically improvement in lung 
function in SR asthma patients. The primary endpoint of the study is change of FEV1 at 
baseline compared to the end of the treatment period. This clinical study hypothesizes 
that 1,25(OH)2D3 will enhance clinical responsiveness to systemic glucocorticoid 
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therapy in the SR patient group and was performed by Dr Alexandra Nanzer a clinical 
research training fellow in the lab.  
 
We hypothesized that differences exist in lymphocyte and dendritic cell populations in 
the peripheral blood of SS versus SR asthmatics. The work presented in this chapter 
utilises the unique opportunity offered by this clinical trial to compare the frequency as 
well as total numbers of immune cell populations in the peripheral blood from SS and 
SR patients via performing directly ex vivo flow cytometric staining, focussing on 
lymphocyte populations including B cells, CD4+ and CD8+ T cells and Foxp3+ T cells, 
as well as dendritic cell phenotyping. The effects of 2-weeks of oral prednisolone 
treatment on these parameters were determined. Information on vitamin D status of the 
patients, assessed as serum 25(OH)D levels by Dr Peter Timms at the Homerton 
Hospital, London, allowed further analyses of the associations between Vitamin D 
status and immune cell frequency and phenotype.  
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3.2 Results: 
A flow diagram of the design of the clinical trial can be seen below (Figure 3-2). Full 
information on design and patient entry criteria of the trial are presented in Appendix I.  
 
Figure 3-2 Schematic showing the Clinical Trial protocol 
Severe asthmatics were recruited as described in Appendix 1. Briefly severe asthmatics were 
given prednisolone at Screening Visit 1 and returned two weeks later at Screening Visit 2, SS 
asthmatics were excluded from the trial and SR asthmatics were retained. After a four week 
wash out period the SR began the clinical trial where at Treatment Visit 1 the patient s were 
given either calcitriol (1,25(OH)2D3) or placebo, at Treatment Visit 2 the patients were given 
Prednisolone and then they returned two weeks later for Treatment Visit 3. At each visit Lung 
function was performed and peripheral blood was isolated to perform immunological 
assessments. The red box around Screening Visit 1 and 2 highlights the focus of this chapter 
which is immunological assessments on SS and SR asthmatics pre- and post-steroids. 
 
Due to the clinical trial being blinded at the time of writing, the focus of this chapter is 
comparison of SS and SR asthmatics pre- and post-steroids (as highlighted by the red 
box in Figure 3-2). 
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3.2.1 Patient characteristics. 



























Age (years) 41 (30-61) 48.5 (21-64) 53.3 (20-72) 
Sex ratio (F/M) 3/7 8/4 11/14 
FEV1 (L) 
* FEV1 (L) post steroids 




FEV1 (% predicted) 
* FEV1 (%) post steroids 




FeNo  31.6 (18-73) 26.5 (12-70) 

















Average ICS dose (BDP 
equivalent) mcg 
 1133 (800-2000) 1200 (800-2000) 
Table 3-1 Patient Characteristics – taken from Alexandra Nanzer’s PhD thesis 
Data shown for the severe asthmatics was from Screening Visit 1 (pre-steroids). 
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The table above gives an overview of the healthy controls and the severe asthma 
patients defined as either SS or SR. SR was defined as having less than 10% 
improvement in their lung function post a 2-week course of prednisolone as identified 
clinically by FEV1. SS asthmatics (those who had >10% improvement in FEV1) were 
excluded from the clinical trial (Treatment Visits 1 - 3). The asthma patients were 
recruited for screening for the clinical trial (Screening visits 1 and 2), of whom 12 were 
clinically defined to be SS and 25 were SR.  There was no significant difference 
between age, race, sex ratio, atopic status and inhaled steroid dose between the SS 
versus the SR group. The only significant difference observed between the two cohort 
of patients was their lung function post 2-weeks of prednisolone, where SS had a 
significant improvement in their lung function (56% pre-steroids; 71% post-steroids) 
whereas SR did not (62% pre-steroids; 61% post-steroids) (post steroid FEV1  SR vs 
SS p<0.001  95% CI 10.405-21.451, ANCOVA). 
 
3.2.2 Healthy and Severe asthma donors had similar frequencies of 
lymphocytes. 
As this was a unique opportunity to assess lymphocyte populations directly ex vivo in 
SS and SR asthmatics pre- and post-steroids, flow cytometry was performed. As part 
of the frequency of T and B cells (CD3+ and CD19+ respectively) were assessed in the 
peripheral blood, additionally CD4 and CD8 were used to differentiate the helper and 
cytotoxic T cell populations (within the CD3+ population). Additionally as DCs are 
known to be important for initiating or tolerising an immune response the frequency of 
pDCs and mDCs (as defined as being Lineage cocktail negative [CD3, CD14, CD16, 
CD19, CD20, CD56] and HLA-DR, and either BDCA-4 and CD11c respectively) was 
assessed whether there is different frequency of DC subsets in SS versus SR asthma. 
Additonally Foxp3+ Tregs were assessed through the following staining panel (CD3, 
CD25, CD127 and [intranuclear] Foxp3) as Foxp3 frequency and number has been 
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strongly associated with asthma severity and glucocortiocid treatment [172-
174,176,178,188].  
 
Figure 3-3 Example gating performed during ex vivo analysis of lymphocyte, 
dendritic cell and Foxp3+ populations 
A, Representative dot plots showing lymphocyte gating based on forward and side scatter plots.  
CD3+ and CD19+ cells were identified within the lymphocyte population (highlighted in red), 
CD4+ and CD8+ cells were identified from within the CD3+ gate. B, Representative dot plots 
showing Dendritic cell gating, where DCs were identified as being lineage negative (Lin-)HLA-
DR+. BDCA-4 and CD11c were used to identify plasmacytoid DCs and myeloid DCs 
respectively C, Representative dot plots showing CD4+Foxp3+ T cell gating. Foxp3+ expression 
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was assessed in the CD3+CD4+ lymphocyte gate, based on isotype control staining. Values 
shown represent the frequency of events in the quadrant. 
The frequency of B cells (CD19+), T cells (CD3+), CD4+ T cells and CD8+ T cells and 
regulatory T cells (Foxp3+CD4+ T cells) were assessed by flow cytometry. Healthy 
non-asthmatic control donors were compared to the severe asthma patients, as seen 
below: 
 Healthy Severe Asthma p value 
CD19+ lymphocytes 7.32 (3.93-11.00) 8.68 (3.78-13.94) 0.30 
CD3+ Lymphocytes 63.63 (56.34-74.25) 59.41 (40.20-73.88) 0.27 
CD4+ T cells 62.15 (47.5-80.6) 64.96 (52.84-80.16) 0.48 
CD8+ T cells 29.91 (16.11-44.91) 30.14 (17.48-42.49) 0.95 
CD3+/CD19+ ratio 8.96 (4.48-18.81) 8.27 (4.12-14.22) 0.62 
CD4+/CD8+ ratio 2.38 (1.08-5.07) 2.65 (1.25-4.59) 0.61 
Foxp3+ Tregs 7.99 (6.76-10.11) 7.4 (4.96-10.8) 0.46 
 n =10 n =37  
Table 3-2 Table showing the Frequency of Lymphocytes in the peripheral blood 
of healthy (non-asthmatic) donors and severe asthma donors. 
CD19+, CD3+, CD4+ T cells, CD8+ T cells and Foxp3+ Tregs were gated as described in 
Figure3-3. Data shown as Mean ± 10-90% Percentiles, comparison between healthy and severe 
asthma assessed by unpaired t-test. Data shown for the severe asthmatics was from Screening 
Visit 1. 
As can be seen above in Table 3-2, there was no significant difference in the frequency 
of B cells (CD19+), T cells (CD3+), CD4+ T cells and CD8+ T cells in the peripheral 
blood of healthy and severe asthma donors. Equally there was no significant difference 
between the ratio of B cells to T cells or the CD8+ to CD4+ T cells. 
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3.2.3 Severe asthmatics have an increased frequency of myeloid DC as 
compared to healthy donors. 
DCs were identified as being Lineage negative (CD3, CD14, CD16, CD19, CD20 and 
CD56) HLA-DR+ cells. DCs were further characterised as myeloid and plasmacytoid on 
the basis of CD11c and BDCA-4 respectively. The frequency of the DC populations 
was assessed in healthy (non-asthmatic) donors and severe asthmatic donors: 
 
Figure 3-4 The frequency of Myeloid and Plasmacytoid DC in healthy and severe 
asthma donors 
A, Frequency of CD11c+ and BDCA-4+ cells within the DC gate (Lin-HLA-DR+) B, Ratio of 
CD11c+ to BDCA-4+ DCs in healthy (n=10) and severe asthma donors (n=33). B, Healthy 
versus severe asthma assessed by unpaired t-test. Data shown from severe asthma patients 
was from Screening Visit 1. 
As can been seen from Figure 3-4 above, there is significantly more CD11c+ (myeloid) 
DC in the peripheral blood of severe asthmatics as compared to healthy donors, 
whereas there is no significant difference between BDCA-4+ (plasmacytoid) DCs. In 
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Figure B there is a trend towards an increased ratio of CD11c+/BDCA-4+ cells in the 
severe asthma patients as compared to healthy controls.  
 
3.2.4 Comparison between healthy and severe asthmatics after 2-weeks of 
steroids 
To determine if a two-week course of steroids changes the frequency of lymphocytes 
and DCs from healthy donors, a comparison between healthy donors and severe 
asthmatics post-steroids was performed: 
 Healthy Severe Asthma p value 
CD19+ lymphocytes 7.32 (3.93-11.00) 11.77 (4.41-19.11) 0.01 
CD3+ Lymphocytes 63.63 (56.34-74.25) 51.11 (26.0-76.2) 0.20 
CD4+ T cells 62.15 (47.5-80.6) 66.60 (53.0-79.26) 0.21 
CD8+ T cells 29.91 (16.11-44.91) 28.65 (16.54-39.51) 0.70 
CD3+/CD19+ ratio 8.96 (4.48-18.81) 5.05 (2.55-9.03) 0.002 
CD4+/CD8+ ratio 2.38 (1.08-5.07) 2.71 (1.39-4.85) 0.49 
Foxp3+ CD4+ T cells 7.99 (6.76-10.11) 5.69 (2.67-8.84) 0.004 
 n =10 n =37  
Table 3-3 Frequency of lymphocytes in healthy and severe asthmatics post-
steroids. 
Data shown as Mean ± 10-90% Percentiles. Lymphocyte frequencies in healthy versus severe 
asthmatics assessed by an unpaired t-test. Severe asthmatic data shown was from Screening 
Screening Visit 2 (post-steroids). 
As can be seen from the table above there was no significant differences in the 
frequency of CD3+, CD4+ and CD8+ T cells  or in the ratio of CD4+ to CD8+ T cells in 
healthy and severe asthmatics post-steroids. There were significantly more B cells in 
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severe asthmatics post-steroids as compared to healthy donors, which resulted in a 
significant difference in the ratio of CD3+ T cell to CD19+ cells. There were significantly 
less Foxp3+ Tregs in severe asthmatics post-steroids as compared to healthy controls. 
These significantly changes are due to steroid usage as there were no significant 
differences in these lymphocyte populations pre-steroids. 
 
3.2.5 Steroid Sensitive patients had a similar frequency and number of 
lymphocytes as compared to Steroid Refractory asthmatics at Baseline. 
The impact of steroid treatment in vivo. 
As there was no difference between healthy and severe asthmatics the next aim was to 
identify if there were any significant differences between SS and SR asthmatics. The 
frequency of B cells (CD19+), T cells (CD3+), CD4+ T cells and CD8+ T cells were 
assessed by flow cytometry. The gating strategy shown in Figure 3-3A was used and 
lymphocyte populations were compared between SS and SR asthma as seen below in 
Table 3-3: 
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  Pre-steroids   Post-steroids  
 SS SR p 
value 
SS SR p 
value 
CD19+ lymphocytes 9.10 (4.89-14.05) 8.46 (3.56-15.12) 0.64 11.55 (2.93-20.90) 11.93 (4.60-19.03) 0.84 
CD3+ Lymphocytes 58.57 (42.88-72.91) 59.86 (38.53-75.78) 0.74 53.37 (16.70-77.99) 49.94 (26.28-74.28) 0.62 
CD4+ T cells 66.60 (55.85-81.79) 64.00 (48.10-79.45) 0.51 68.26 (53.98-82.10) 65.62 (50.05-79.29) 0.46 
CD8+ T cells 28.90 (16.68-38.94) 30.87 (15.6-47.94) 0.60 27.38 (16.33-38.76) 29.40 (15.81-40.50) 0.52 
CD3+/CD19+ ratio 7.386 (4.10-12.79) 8.74 (4.12-14.9) 0.30 5.40 (2.5-11.33) 5.12 (2.09-9.67) 0.81 
CD4+/CD8+ ratio 2.58 (1.46-4.97) 2.688 (1.00-5.144) 0.84 2.83 (1.40-5.17) 2.61 (1.24-4.96) 0.65 
 n = 13 n = 24  n = 12 n = 22  
Table 3-4 Frequency of Lymphocyte populations in SS and SR asthmatics was not different pre- and post-steroids 
Data shown as Mean ± 10-90% Percentiles. Lymphocyte frequencies in SS versus SR asthmatics assessed by an unpaired t-test pre- and post-
steroids. Data shown was from Screening Visit 1 (pre-steroids) and Screening Visit 2 (post-steroids).
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There was no significant difference in the frequency of CD19+ or CD3+ cells pre-
steroid treatment or after 2-weeks of prednisolone between SS versus SR asthma 
patients (Table 3-3). The same was also seen with the frequency of CD4+ and CD8+ T 
cells. The ratio of CD3+/CD19+ and CD4+/CD8+ cells was not significantly different 
between SS versus SR asthmatics at Screening Visit 1 or 2 (Table 3-3).  
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  Steroid 
Sensitive 
  Steroid 
Resistant 
 
 Pre-steroids Post-steroids p 
value 
Pre-steroids Post-steroids p 
value 
CD19+ lymphocytes 9.34 (4.84-14.08) 12.11 (2.69-21.15) 0.09 8.08 (3.50-13.73) 11.58 (4.56-18.42) 0.003 
CD3+ Lymphocytes 57.32 (42.2-70.60) 51.47 (14.56-78.15) 0.41 58.96 (37.64-76.25) 50.62 (25.39-74.49) 0.04 
CD4+ T cells 67.30 (55.81-82.09) 68.26 (53.98-82.10) 0.54 63.41 (47.21-79.87) 65.79 (49.37-79.60) 0.31 
CD8+ T cells 28.17 (16.32-38.97) 27.38 (16.33-38.76) 0.55 31.4 (14.39-49.06) 29.31 (15.57-40.58) 0.30 
CD4+/CD8+ Ratio 2.58 (1.46-4.97) 2.827 (1.40-5.17) 0.34 2.64 (0.96-5.54) 2.64 (1.22-5.00) 0.49 
Table 3-5 Frequency of Lymphocyte populations in SS and SR asthmatics pre- and post-steroids 
Data shown as Mean ± 10-90% Percentiles (SS n=12; SR n=21). Differences in lymphocyte populations in SS and SR pre- and post-steroids were 
assessed by paired t-test. Data shown was from Screening Visit 1 (pre-steroids) and Screening Visit 2 (post-steroids).
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There was no significant difference in the frequency of CD3+CD4+ or CD3+CD8+ T 
cells in SS or SR asthmatics post-steroids. There was no significant difference in SS 
asthmatics post-steroids, but there was a significant reduction in the frequency of SR 
CD3+ cells (SS p=0.41; SR p=0.04). There was a significant increase in the mean 
frequency of CD19+ cells post steroid treatment in both SS and SR asthmatics (SS p = 
0.09; SR p = 0.003). Thus due to the increase in the frequency of CD19+ cells in both 
SS and SR asthmatics post-prednisolone the ratio of CD3+ cells to CD19+ cells was 
also significantly changed post-steroids (Figure 3.5). 
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Figure 3-5 The ratio of CD3+ to CD19+ cells in the peripheral blood of severe 
asthmatics pre- and post- steroids 
A, representative CD3 and CD19 staining in the lymphocyte population pre-steroids (right) and 
post-steroids (left) in SS (top) and SR (bottom) B, The ratio of CD3+ to CD19+ cells in the 
peripheral blood of SS (open shapes) and SR (closed shapes) pre- and post-steroids. B, 
CD3+CD19+ ratio in SS and SR asthma pre- and post-steroids assessed by paired t-test. Data 
shown was from Screening Visit 1 (pre-steroids) and Screening Visit 2 (post-steroids). 
There is a significant decrease in the ratio of CD3+ to CD19+ cells in the peripheral 
blood of severe asthmatics (Figure 3-5B), the lower ratio meaning that there were more 
CD19+ cells as compared to CD3+ cells post 2-week course of Prednisolone. This is 
most likely due to the increase in the frequency of CD19+ lymphocytes post-steroids as 
shown above in Table 3-4. 
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3.2.6 CD19+ lymphocyte numbers significantly increase post-prednisolone in 
both SS and SR asthmatics; CD3+ numbers decrease in SS asthmatic 
donors only. 
Full blood counts were obtained at each time point in the clinical trial and this data was 
used in conjunction with the flow cytometric data to calculate the number of each 
population of lymphocytes in the peripheral blood of the severe asthma cohort, as seen 
below: 
 SS SR p value 
CD19+ lymphocytes 1.58 (0.71-2.85) 1.53 (0.51-3.07) 0.90 
CD3+ Lymphocytes 10.41 (5.30-14.76) 11.38 (6.49-18.93) 0.57 
CD4+ T cells 6.94 (3.63-11.13) 7.07 (2.51-14.58) 0.91 
CD8+ T cells 2.98 (1.31-4.64) 3.23 (1.20-5.18) 0.71 
 n =13 n = 22  
Table 3-6 Lymphocyte numbers in SS and SR asthmatics pre-steroids. 
Data shown as Mean ± 10-90% Percentiles. Lymphocyte numbers in SS and SR asthma 
assessed by paired t-test pre-steroids. assessed by unpaired t-test. Data shown was from 
Screening Visit 1. 
There was no significance difference in B cell (CD19+), T cell (CD3+) lymphocyte 
numbers between SS and SR asthmatics (Table 3-5). The same was also true with 
CD8+ and CD4+ T cells with no significant difference seen at baseline in SS versus 
SR.  
The numbers of lymphocytes and also B cells, T cells and CD4+ and CD8+ T cells 
were compared in SS and SR asthmatics pre- and post-prednisolone. 
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Figure 3-6 The number of lymphocytes in the peripheral blood of severe 
asthmatics pre- and post-steroids 
A, The number of lymphocytes in the peripheral blood of severe asthmatics pre- and post-
steroids B, The number of CD19+ (B cells), CD3+ (T cells), CD4+ T cells and CD8+ T cells in 
the peripheral blood of SS (open shapes, n=9) and SR (closed shapes, n=18) pre- and post-
steroids. A, Differences in lymphocyte numbers in SS and SR asthmatics assessed by unpaired 
t-test pre- and post-steroids and B, differences in lymphocyte numbers pre- and post-steroids 
assessed by paired t-test in SS and SR patients. Data shown was from Screening Visit 1 (pre-
steroids) and Screening Visit 2 (post-steroids). 
There was no significant difference in the total number of lymphocytes in the peripheral 
blood of SS and SR asthmatics as determined by full blood count performed as part of 
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clinical assessment pre- and post-steroids (Figure 3-6A). In contrast the number of 
CD19+ lymphocytes was significantly increased in SR post 2-weeks of prednisolone 
(p=0.02), and a similar trend was seen in the SS asthmatics (p = 0.10) (Figure 3-6B). 
There was no significant difference in the number of CD3+ T cells pre- and post-
steroids in both SS and SR asthmatics. There was a significant reduction in the number 
of CD4+ T cells in the peripheral blood of SS asthmatics post 2-weeks of prednisolone 
(p=0.001), whereas there was no significant difference seen in SR asthmatics. There 
was no significant difference in the number of CD8+ T cells in SS or SR (Figure 3-6B). 
 
3.2.7 SR asthmatics have a higher frequency of myeloid DC as compared to 
SS at baseline. 
As well as lymphocyte populations DC frequency was assessed. As described before 
in Figure 3-3B, DCs were identified as being Lineage negative (CD3, CD14, CD16, 
CD19, CD20 and CD56) HLA-DR+ cells and were further characterised by the cell 
surface expression of CD11c (myeloid; mDC) and BDCA-4 (plasmacytoid; pDC) on the 
DCs:
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Figure 3-7 The Frequency of mDCs and pDCs in SS versus SR severe 
asthmatics. 
DCs (lineage cocktail-HLA-DR+) were gated as shown in Fig 3-3. A. The frequency (%) of 
CD11c+ (mDCs) and BDCA-4+ (pDCs) B, the ratio of CD11c+/BDCA-4+ in peripheral blood of 
SS (n=13) and SR (n=21) asthmatics.  A, differences in frequency of DCs in SS versus SR 
assessed by unpaired t-test. Values shown represent the frequency of events in the 
quadrant/gate. Data shown was from Screening Visit 1. 
The SR asthmatics had a significantly higher frequency of CD11c+ DCs in the 
peripheral blood as compared to SS (p=0.028) (Figure 3-7A). There was no significant 
difference in the frequency of pDCs. There was a trend suggesting that there were 
more mDCs to pDCs in SR asthmatics as compared to SS as shown by the higher ratio 
of CD11c+/BDCA-4+ DCs in SR asthmatics (Figure 3-7B). Further phenotypic analysis 
of the CD11c and BDCA-4 DCs was performed by assessing the cell surface 
expression of CD86, ILT3 and HLA-DR. ILT3 is an inhibitory receptor expressed on 
DCs, and expression of ILT3 has been shown to be important for induction of Foxp3+ 
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Tregs  [334,374]. ILT3 was investigated on DC populations because it had been shown 
to be modulated by 1,25(OH)2D3, and that ILT3 expression was important in 
ameliorating disease in patients who had psoriasis [334,337]. 
 
Figure 3-8 mDCs have higher expression of CD86 and HLA-DR but lower ILT3 as 
compared to pDCs. 
DCs defined as being (lineage cocktail-HLA-DR+) were further characterised as CD11c+ 
(mDCs) and BDCA-4+ (pDCs) as shown above in Figure 3-4A A, Representative histograms of 
CD86 (left) ILT3 (middle) and HLA-DR (right) on mDCs (blue) and pDCs (red) as compared to 
FMO control staining (grey) B, cumulative data (severe asthmatics n=36). B, Expression of cell 
surface molecules on DCs in mDCs versus pDCs in all severe asthmatics assessed by unpaired 
t-test. Data shown was from Screening Visit 1.
Myeloid DCs, as defined by CD11c+ expression had significantly higher expression of 
CD86 and HLA-DR and lower expression of ILT3 as compared to pDCs. (Figure3-8). 
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3.2.8 The phenotype of mDCs and pDCs is the same at baseline (pre steroid) 
in SS and SR asthma patients 
The expression of ILT-3, CD86 and HLA-DR on the surface of pDCs and mDCs was 
compared in SS and SR asthmatics. 
  pDCs   mDCs  
 SS SR 
p 






























 n=14 n = 22  n=14 n = 22  
Table 3-7 Expression of HLA-DR, ILT3 and CD86 on pDCs and mDCs of 
peripheral blood obtained from SS and SR. 
Data shown as Mean ± 10-90% Percentiles. Expression of HLA-DR, ILT3 and CD86 on pDCs or 
mDcs in SS versus SR assessed by unpaired t-test Data shown was from Screening Visit 1. 
There was no significant difference between the expression of ILT3, CD86 and HLA-
DR on pDCs and mDCs between SS and SR asthmatics at baseline (Table 3-6). 
 
3.2.9 The frequency of total DCs and pDC significantly decreases post-
prednisolone. 
The effect of a 2-week course of prednisolone on DC frequency was investigated. 
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Figure 3-9 Dendritic cell frequencies significantly decrease post-steroids 




) in the peripheral blood of all severe 
asthmatics pre- and post-steroids (n=31) B, The frequency of CD11c+ and BDCA-4+ DCs in the 
peripheral blood of SS (open shapes, n=12) and SR (closed shapes, n=19) pre- and post-
steroids. A, frequency of DCs in all severe asthmatics pre- and post-steroids assessed by a 
paired t-test and B, differences in frequency of mDCs or pDC pre- and post-steroids assessed 
by paired t-test in SS and SR patients.  
Data shown was from Screening Visit 1 (pre-steroids) and Screening Visit 2 (post-steroids). 
A significant reduction in the frequency of all DC (defined as Lineage cocktail negative, 
HLA-DR+) was observed from the peripheral blood of severe asthmatics post-steroids 
(pre-steroids mean = 0.412 (0.146-0.815); post-steroids mean = 0.094 (0.04-0.23) 
p=0.0001) (Figure 3-9A). The frequency of DC subsets was also investigated post-
steroid treatment, and in SS asthmatics there was a significant increase in the 
frequency of mDCs (pre-steroids 52.06 (17.13-69.63); post-steroids 63.74 (31.49-
78.87)), whilst conversely there was a significant reduction in the frequency of pDCs 
post steroids (pre-steroids 27.08 (14.80-46.50); post-steroids 10.97 (1.88-20.61)). In 
contrast in the SR asthmatics, there was a significant reduction in both mDCs (pre-
steroids 64.75 (49.40-82.33); post-steroids 52.11 (30.40-80.49)) and pDCs (pre-
steroids 21.00 (3.81-39.17); post-steroids 9.87 (2.53-19.28)) (Figure 3-9B).  
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3.2.10 The expression of HLA-DR and ILT3 on pDCs, and CD86 and HLA-DR on 
mDCs from SS asthmatics is significantly decreased post-steroids. 
The expression of the markers CD86, Immunoglobulin-like transcript 3 (ILT3) and HLA-
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Figure 3-10 Expression of ILT3, CD86 and HLA-DR on pDCs in peripheral blood 
of SS and SR asthmatics pre- and post-steroids 
A, representative histograms of ILT3 (left), CD86 (middle) and HLA-DR (right) expression on 
pDCs in SS (top) and SR (bottom) as compared to FMO control (grey) B, cumulative data of SS 
(open shapes, n=13) and SR (closed shapes, n=22) pre- and post-steroids.  B, Expression of 
ILT3, CD86 and HLA-DR on pDCs pre and post-steroids assessed by paired t-test in SS and 
SR asthmatics. Data shown was from Screening Visit 1 (pre-steroids) and Screening Visit 2 
(post-steroids). 
Although the data is limited by the low frequency of DCs observed post-steroids (Figure 
3-9A) a significant reduction in the expression of ILT3 and HLA-DR on pDCs from both 
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SS and SR asthmatics post steroid treatment was observed. In contrast there was no 
significant difference in the expression of CD86 on pDCs post a 2-week course of 
prednisolone (Figure 3-10). ILT3, CD86 and HLA-DR expression was also assessed on 
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Figure 3-11 Expression of ILT3, CD86 and HLA-DR on mDCs in peripheral blood 
of SS and SR asthmatics pre- and post-steroids 
A, representative histograms of ILT3 (left), CD86 (middle) and HLA-DR (right) expression on 
mDCs in SS (top) and SR (bottom)  as compared to FMO control (grey) and B, cumulative data 
of SS (open shapes, n=13) and SR (closed shapes, n=22) pre- and post-steroids. B, Expression 
of ILT3, CD86 and HLA-DR on mDCs pre and post-steroids assessed by paired t-test in SS and 
SR asthmatics. Data shown is from Screening Visit 1 (pre-steroids) and Screening Visit 2 (post-
steroids). 
There was no significant difference in the expression of ILT3 on mDCs post-steroids. 
There was a trend for reduction in the expression of CD86 and HLA-DR on the surface 
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of CD11c+ DCs post-steroids in SS; this was not significant in SR asthmatics (Figure 3-
11). 
 
3.2.11 The frequency and number of Foxp3+ Tregs is lower in SR as compared 
to SS asthmatics pre- and post-prednisolone. 
The frequency of Tregs, defined by expression of the transcription factor Foxp3, was 
investigated on CD3+CD4+ T cells as shown in Figure 3-3C. The cell surface markers 
CD127 and CD25 were also assessed to better indicate that the cells represented 
Foxp3+ Treg cells and to distinguish them from activated effector T cells.  
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Figure 3-12 The frequency of Foxp3+ Tregs is lower in SR as compared to SS 
asthmatics pre- and post-steroids 
A, Representative dots plots showing gating strategy for identifying Foxp3+ T cells (CD3+CD4+ 
lymphocytes) B, representative dot plots showing CD25 and CD127 staining within the Foxp3+ 
and Foxp3- population C, Correlation between frequency of Foxp3+ CD4+T cells and 
CD127loCD25hi CD4+ T cells D, Frequency of Foxp3+CD4+ T cells in SS (n=14) and SR 
(n=22) asthmatics Pre- and Post-steroids. C, correlation between % Foxp3+CD4+ T cells and % 
CD127loCD25hi CD4+ T cells assessed by Pearsons correlation test D, frequency of Foxp3+ 
CD4+ T cells in SS versus SR assessed by an unpaired t-test pre-steroids (left) and post-
steroids (right). A and B, Values shown represent the frequency of events in the relevant 
quadrant. Data shown was from Screening Visit 1 (pre-steroids) and Screening Visit 2 (post-
steroids).
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Foxp3+ Tregs were identified within the CD3+CD4+ lymphocyte population and 
Foxp3+ gating was based on isotype control staining (Figure 3-12A). To confirm that 
the gating strategy did contain ‘real’ Tregs, in sixteen of the severe asthma patients the 
cell surface markers CD127 and CD25 were used, as these markers had previously 
been identified to distinguish Foxp3+ Tregs from effector T cells [92]. Around 90% of 
the Foxp3+ CD4+ T cells were CD25hiCD127lo, whereas in the Foxp3- this was only 
2.9% of the CD4+ T cell population (Figure 3-12B). The frequency of Foxp3+ Tregs 
positively correlated with the frequency of CD25hiCD127lo CD4+ T cells (Figure 3-
12C). There was a significantly lower frequency of Foxp3+ Tregs in the peripheral 
blood of SR as compared to the SS asthmatics. This was also true after 2-weeks of 
prednisolone (Figure 3-12D).  
The impact of Prednisolone on Foxp3+ Tregs frequency was assessed in SS and SR 
asthmatics. 
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Figure 3-13 The frequency of Foxp3+ Tregs decreases post-steroids 
A, representative dot plots from SS (top) and SR (bottom) donors, isotype control (left), pre- 
(middle) and post-steroids (right) B, Cumulative data showing the frequency of Foxp3+ Tregs 
pre- and post-steroids in SS (open shapes, n=14) and SR (closed shapes, n=22) asthmatics. B, 
differences in the frequency of Foxp3+ CD4+ T cells pre- and post-steroids was assessed by 
paired t-test in SS (left) and SR) right. Data shown was from Screening Visit 1 (pre-steroids) and 
Screening Visit 2 (post-steroids). 
In both SS and SR asthmatics there was a significant reduction in the frequency of 
Foxp3+ Tregs in the peripheral blood after 2-weeks of prednisolone (SS p=0.014; SR 
p=0.006) (Figure 3-13). The data from Figure 3-13 was used to calculate the numbers 
of Foxp3+ Tregs in the peripheral blood of the severe asthma patients, as seen below: 
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Figure 3-14 Foxp3+ Tregs pre- and post-steroids 
A, The total number of Foxp3+ Tregs in the peripheral blood of SS (n=10) and SR (n=17) 
asthmatics pre-prednisolone (top left) and after prednisolone (middle) B, The total number of 
Foxp3+ CD4+T cells in the peripheral blood of SS (open shapes) and SR (closed shapes) pre- 
and post-steroids. A, number of Foxp3+ CD4+ T cells in SS versus SR assessed by unpaired t-
test pre-steroids (left) and post-steroids (right) and B, number of Foxp3+CD4+ T cells pre- and 
post-steroids assessed by paired t-test in SS and SR. Data shown was from Screening Visit 1 
(pre-steroids) and Screening Visit 2 (post-steroids). 
At Screening Visit 1 before prednisolone, there were significantly lower numbers of 
Foxp3+ Tregs in the peripheral blood of SR as compared to SS (p=0.035), but post-
prednisolone there was no statistical difference in the number of these cells between 
the 2 asthma cohorts (Figure 3-14A). The number of Foxp3+ Tregs in the peripheral 
blood of SS, but not SR, asthmatics was significantly reduced post-steroids (Figure 3-
14B).  
 
3.2.12 Severe asthmatics had significantly lower levels of serum 25(OH)D as 
compared to non-asthmatics. 
The serum 25(OH)D levels (measurement of vitamin D status) was assessed at 
baseline (Screening visit 1) in the severe asthmatics and compared to the non-
asthmatic donors. 
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Figure 3-15 Serum levels of 25(OH)D changed with season and Severe 
asthmatics had significantly lower levels of serum 25(OH)D as compared to 
healthy controls. 
A, Serum 25(OH)D levels in severe asthmatics throughout the year (Winter – Dec-Feb (n=10); 
Spring Mar-May (n=8); Summer – Jun-Aug (n=8); Autumn – Sept-Nov (n=10)) B, Serum 
25(OH)D levels in Healthy (n=6) SS (n=12) and SR (n=23). A, differences in serum 25(OH)D 
through the seasons assessed by one-way ANOVA with Tukeys post-hoc test and B, 
differences in serum 25(OH)D in healthy versus SS versus SR assessed by one-way ANOVA 
with Tukeys post-hoc test. * p≤0.05 ** p≤0.01 *** p≤0.001. Data shown for severe asthmatics 
was from Screening Visit 1. 
Even though the severe asthmatics were recruited all year round only two of the 
patients recruited had sufficient levels of vitamin D, defined as >75nmol/L 25(OH)D. 
Hence the majority of the severe asthma cohort were vitamin D insufficient (between 
50-75nmol/L) or deficient (<50nmol/L) all year round. The patients recruited in Summer 
and Autumn had significantly higher levels of serum 25(OH)D as compared to Winter 
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and Spring (Figure 3-15A). Such seasonal variation was not seen in the few healthy 
donors that we have serum samples from (Figure 3-15C). There were significantly 
lower levels of serum 25(OH)D in the SS and the SR asthmatics as compared to 
healthy controls (Figure 3-15B).  
 
3.2.13 Serum 25(OH)D positively correlated with the number of Foxp3+ Tregs. 
To ascertain whether serum 25(OH)D had any influence on lymphocyte numbers, total 
lymphocyte numbers were assessed for correlation with serum 25(OH)D.  No 
statistically significant correlations were observed (r=0.098; p=0.586). Also no 
correlation was observed between CD19+ cells (r=0.136; 0.4429), CD3+ cells (0.208; 
p=0.239), CD4+ T cells (r=-0.027; p=0.879) or CD8+ T cells (r=-0.063; p=0.722) with 
serum 25(OH)D. Foxp3+ Tregs numbers were also assessed for correlation with serum 
25(OH)D. 
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Figure 3-16 Positive correlation between serum 25(OH)D and Foxp3+ Tregs 
numbers in severe asthmatics. 
Correlation between Serum 25(OH)D and number of Foxp3+ CD4+ T cells assessed by 
Pearsons correlation statistical test. SS asthmatics – open circles SR asthmatics – closed 
squares. Data shown was from Screening Visit 1. 
Serum 25(OH)D positively correlated with the number of Foxp3+ Tregs in the 
peripheral blood of the severe asthma cohort. The individuals with the lowest number 
of Foxp3+ Tregs had the lowest serum 25(OH)D, and the converse was also true 
(Figure 3-16). 
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3.3 Discussion 
The clinical trial provided a unique opportunity to directly assess ex vivo flow cytometry 
data comparing lymphocyte and dendritic cell populations in healthy subjects versus 
severe asthma patients, and also in SS versus SR. The main findings were (i) 
increased frequency of CD19 and associated CD19:CD3 ratios in severe asthmatics 
post-steroids; (ii) increased frequency of mDCs and (iii) decreased frequency of 
Foxp3+ Tregs in SR as compared to SS asthmatics and finally (iv) a significant positive 
correlation between the number of Foxp3+ Tregs and serum 25(OH)D. Summary of the 
SS versus SR asthma observations below: 
 SS  SR  
 Frequency Number Frequency Number 
CD19+  = = = = 
CD3+  = = = = 
CD4+ T cells = = = = 
CD8+ T cells = = = = 
mDCs - nd + nd 
pDCs = nd = nd 
Foxp3+ Treg  + + - - 
Table 3-8 A summary Table showing the similarities and differences between SS 
and SR asthmatics 
= means there is no significant difference; + means there is significantly more;  – means there is 
significantly less between SS versus SR. nd = no data. 
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The effects of a 2-week course of prednisolone on the frequency and number of 
lymphocytes and dendritic cells from the peripheral blood of severe asthmatics are 
summarised below: 
 SS  SR  
 Frequency Number Frequency Number 
CD19+  + = + + 
CD3+  = = - = 
CD4+ T cells = - = = 
CD8+ T cells = = = = 
mDCs + nd - nd 
pDCs - nd - nd 
Foxp3+ Treg  - - - = 
Table 3-9 A summary Table showing the impact of 2-weeks of Prednisolone on 
lymphocyte and dendritic cell numbers in severe asthmatics 
= means there is no significant difference; + means there is significantly more;  – means there is 
significantly less after 2-weeks of prednisolone. nd = no data. 
There was no significant difference in the frequency of B cells and T cells in the 
peripheral blood of healthy subjects versus severe asthmatics at the start of the study 
and in severe asthmatics no significant difference in lymphocyte numbers pre and post 
steroids. Nevertheless after 2-weeks of steroids there was a significant increase in the 
frequency and total numbers of CD19+ cells in the peripheral blood of both SS and SR 
asthmatics. This resulted in a significantly lower frequency of CD3+ to CD19+ cells 
(CD3+/CD19+ ratio) in the severe asthma cohort after 2-weeks of steroids.  With 
hindsight it would have been  interesting to further investigate the phenotype of the 
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CD19+ T cells using cell surface markers such as CD5, CD24, CD27 and CD38 which 
are markers of B regulatory cells (Bregs) [61,375]. The increase in the frequency of 
CD19+ cell post-steroids has been observed previously [376].There were no significant 
changes in the numbers of CD3+ and CD8+ T cells post-steroids. Interestingly there 
was only a significant reduction in the number of CD4+ T cells in the peripheral blood 
of SS asthmatics and not SR. This data implies that a potential reason why the SR 
patients did not respond to steroids was due to the lack of effect on CD4+ T cell 
numbers. However due to the nature of the clinical trial it is not possible to determine if 
it is a defect in the patients response to steroids or due to a lifetimes use of steroids. In 
an independent study on healthy donors it was found that after a 2-week course of 
prednisolone there was no significant differences in the frequency of CD3+, CD4+ and 
CD8+ T cells [377], however a significant increase in all lymphocyte numbers (Total, 
CD3+, CD4 and CD8+ T cells) post-prednisolone was observed.  This was believed to 
be due to leukocytosis, which is a well-known side-effect of glucocorticoids [377-379]. 
However, an increase in the number of lymphocyte populations was not seen in the 
severe asthma patients studied in this work. However, there was a significant increase 
in the neutrophil population post-steroids (data not shown; taken from Alexandra 
Nanzer’s PhD thesis), suggesting that in this severe asthma cohort, leukocytosis only 
occurred within the neutrophil population. 
A second major observation arising from this study was that there were significantly 
more mDCs in the peripheral blood of SR as compared to SS; this resulted in an 
increase in the ratio of mDC/pDC. Overall pDCs were found to have higher expression 
of ILT3 and lower expression of CD86 and HLA-DR as compared to mDCs. This data 
suggests that mDCs are more activated and are more ready to initiate immune 
responses, whereas pDCs due to the high expression of ILT3 and lower activation 
markers more tolerogenic. This supports a number of studies that have demonstrated 
that pDCs have regulatory capacity as they have been shown to be key in T-cell-
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independent oral tolerance as well as prolonging graft survival in a mouse model of 
transplantation [380-382].  
No difference was observed in the expression of ILT3, CD86 or HLA-DR on pDC and 
mDCs in SS versus SR. However due to the higher frequency of mDCs seen in SR 
asthmatics this suggests there are more DCs ready to initiate immune responses. The 
differential expression of ILT3 on pDCs versus mDCs is in contrast to work performed 
by Penna et al, where it was shown that both populations of DCs had similar levels of 
expression of ILT3 [334]. However in their study they isolated the DCs from a buffy 
coat first and then cell surface stained, and this isolation could have affected the 
expression of ILT3 and for this reason we stained directly ex vivo. In their study Penna 
et al used slightly different cell surface markers to differentiate mDCs and pDCs 
(BDCA-1 [CD1c] and BDCA-2 [CD303] respectively), and although these markers are 
supposedly redundant this may account for differences. 
After 2-weeks of prednisolone there was a significant reduction in the frequency of all 
DCs, as well as pDCs, in the peripheral blood of severe asthmatics. This corresponds 
with other studies in autoimmune disease patients where prednisolone treatment 
caused a reduction in the frequency of plasmacytoid DCs in the peripheral blood. This 
is believed to be due to the fact that pDCs are susceptible to glucocorticoid-induced 
death [376,383,384], although we cannot also exclude effects on DC homing. 
Interestingly prednisolone did not have any significant effects on the activation and 
antigen presentation markers on DCs (CD86 and HLA-DR), and actually significantly 
decreased the expression of the tolerogenic marker ILT3 on pDCs. This is in contrast 
to earlier data which demonstrated in culture that steroids inhibit DC maturation and 
render them more tolerogenic. However those studies were performed on monocyte-
derived DCs and thus was not looking at DCs directly isolated from the peripheral 
blood [385,386].  Furthermore, our data are the first to address in vivo effects in 
humans in severe asthma. 
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A third observation of interest from this study was evidence of no significant difference 
in the frequency of Foxp3+ Tregs in the peripheral blood of healthy donors as 
compared to severe asthmatics. This contradicts earlier findings which showed that 
mild asthmatics had a lower frequency of Foxp3+ Tregs as compared to healthy donors 
[172]. However, when the severe asthmatics were further characterised as being either 
SS or SR, there was a significantly increased frequency and number of Foxp3+ Tregs 
in the peripheral blood of SS as compared to SR asthmatics. Post-steroids there was 
still a significantly increased frequency of Foxp3+ Tregs in the peripheral blood of SS 
as compared to SR. However when total number of Foxp3+ Tregs was assessed there 
was no significant difference, which could be partially explained by the significantly 
lower number of CD4+T cells in the peripheral blood of SS as compared to SR. 
After 2-weeks of prednisolone there was a significant reduction in the frequency of 
Foxp3+ T cells in both SS and SR. This is a contentious area in the literature at the 
moment as there are a number of studies that show that glucocorticoids in humans 
increase mRNA and protein levels of Foxp3 within CD4+ T cell populations in vivo 
[188,387,388]. There is also a large body of evidence in mouse models of allergic 
asthma and EAE, that administration of dexamethasone increases the frequency of 
Foxp3+ T cells [389,390]. Conversely, in other studies in healthy individuals and a 
paediatric asthma cohort, the opposite was observed and glucocorticoids reportedly 
decreased Foxp3+ Treg populations [377,391]. What is clear is that none of these 
earlier asthma papers studied severe asthmatic patients, but rather mild/moderate 
asthmatics (asthma was under control with only a requirement for low-dose inhaled 
steroids) and these patients will have a very different phenotype (mild asthmatics with 
no requirement for inhaled steroids) of asthma then the cohort of patients studied here 
(severe asthmatics on high inhaled steroids with the requirement of oral steroids during 
asthma exacerbations) [172,188]. The reduced frequency of Foxp3+ Tregs in the 
peripheral blood of the severe asthmatics post-steroids could be due to cells being 
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recruited to the site of inflammation i.e. to the lung environment, as it has previously 
been seen that inhaled steroids increased the number of CD4+CD25hi T cells in the 
BAL of asthmatic children [174]. Although it would have been of interest to compare 
Foxp3+ Treg in both peripheral blood and the airways our study did not include this, not 
least because bronchoscoping severe asthma patients is difficult, and needs additional 
ethics approval from the clinical trial authority. Also it would have made recruitment to 
the trial much more difficult as it is an invasive procedure that would have taken 
additional time; hence we would have found it more difficult to recruit individuals. 
All but two of the severe asthma patients recruited had insufficient if not deficient levels 
of serum 25(OH)D (mean: SS - 40.29nmols/L; SR – 33.76nmols/L). This was 
significantly different to the healthy donors who had a mean of 71.5nmol/L. However, 
the healthy donors represent a group of young, active people, and this 25(OH)D level  
does not reflect the serum levels of 25(OH)D seen in the normal U.K. population  
[279,392,393]. Hence this represents a weakness with the data as the healthy controls 
were not age and vitamin D status matched, and if this clinical trial was performed 
again I would have tried to match the healthy donors with the asthmatic patients. This 
data confirms earlier findings, including our own [373], that have shown that low levels 
of serum 25(OH)D correlate with disease severity and poor responsiveness to steroids 
[302,305,307,372,373,394],  providing further evidence that vitamin D likely plays an 
important role in asthma control. A significant positive correlation seen between the 
number of Foxp3+ Tregs in the peripheral blood of the severe asthmatics and serum 
25(OH)D (r=515; p=0.003) supports earlier findings in our lab correlating the frequency 
of BAL (airway) Foxp3+ cells and serum 25(OH)D, and other reports published 
correlating Foxp3+ Treg frequency and function with serum 25(OH)D in other human 
immune-mediated diseases [342,395,396]. These data collectively demonstrate an 
important role of vitamin D in modulatingTreg number and function and support earlier 
in vitro findings in our lab [342].  
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Interesting although the SR asthmatics characterised in this trial do not respond 
clinically to steroids, as assessed by changes in lung function (FEV1), we are seeing 
immunological changes in the frequency of CD19+ and CD3+ cells as well as Foxp3+ 
Tregs. Thus suggesting that the immunological changes observed may not be 
important for the clinical response to steroids. However it also highlights that studying 
immune cell numbers and frequency in the airways would also be of considerable 
interest. 
There are several limitations to the results generated from this trial; primarily the data 
observed was from the peripheral blood of the severe asthmatics. To gain a full insight 
into what is happening in these patients it would have been more informative to have 
studied BAL samples as well as the peripheral blood, because then we would have had 
more information about the tissue of interest. However access to BAL was not possible 
and was out of the remit of the trial and hopefully future trials will involve BAL samples 
as this would be very informative. Also it would have been very interesting to study the 
function of the Foxp3+ Tregs in these severe asthma patients, to determine if there 
was functional abnormality as well as there being a reduced frequency. However due 
to the limitations of peripheral blood obtained this was not possible. 
This cross-sectional study demonstrates that the frequency of circulating Foxp3+ Tregs 
is significantly lower in steroid resistant than in SS asthmatic patients with comparable 
disease severity. The majority of patients with severe asthma had serum 
concentrations of 25(OH)D within the deficient range, and this strongly correlated with 
a paucity of Foxp3+ Tregs in the peripheral blood. These data suggest a strong 
functional correlation between vitamin D status, assessed as circulating 25(OH)D, 
circulating Foxp3+ Tregs numbers, and corticosteroid responsiveness in chronic 
asthma. They also provide important in vivo validation of in vitro studies with human 
cells and evidence from animal models suggesting that the vitamin D pathway plays an 
133 | P a g e  
 
important role in enhancing the frequency of the Foxp3+ Tregs compartment in 
humans. 
  




4. Severe asthmatics have enhanced 
IL-17A production which is 
ameliorated by 1,25(OH)2D3. 
Potential role for CD39. 
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4.1 Introduction 
Th17 cells have been demonstrated to be critical for defence against bacterial and 
fungal infections at mucosal surfaces [397]. Mice deficient in IL-17A or IL-17RA are 
highly susceptible to infection by mucosal pathogens such as Klebsiella pneumoniae, 
and Candida albicans [398,399]. It is believed that IL-17A is important for defence 
against pathogens through induction of inflammatory mediators such as IL-8 and G-
CSF from airway epithelium cells, and IL-1β and TNFα from macrophages [400,401]. 
IL-17A-mediated activation of the innate immune system and neutrophil influx can be 
protective against infection but can also lead to damage of the surrounding tissues 
associated with immune pathology [402,403].  
Originally Th17 cells and the associated cytokine IL-17A were implicated in steroid 
non-responsiveness in a murine model of allergic asthma [404]. It was shown in vitro 
and in vivo that transfer of Th17 or Th2 cells could both initiate airway 
hyperresponsiveness, and that only the Th2 cells could be inhibited with glucocorticoid 
[404]. Subsequently elevated IL-17A expression in human sputum or bronchial 
mucosal biopsies has been shown to correlate with bronchial hyperresponsiveness 
[405], granulocyte infiltration [406] and production of fibrogenic mediators by bronchial 
fibroblasts [407]. An elevated serum IL-17A concentration appears to be both a marker 
and an independent risk factor for severe asthma and steroid responsiveness 
[370,371,405-408].   
In human studies it was shown that Th17-associated cytokines upregulate GRβ, a non-
functional receptor for glucocorticoids, in human epithelial airway cells from severe 
asthmatics [409]. IL-22 another Th17-associated cytokine was also shown to have both 
protective functions with respect to airway infections, but also detrimental effects 
associated with immune pathology in the airways [410-412]. This was probably 
dependent at least in part on the location, cellular sources, cytokine milieu and timing 
of its expression [410-412]. It has been shown in an experimental model of allergic 
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asthma that IL-22 initiated allergic disease and that IL-22 enhances the inflammatory 
properties of IL-17A [56]. 
Several groups have pointed out striking links in population studies between vitamin D 
deficiency and increased asthma severity or poor responsiveness to anti-inflammatory 
medication [302,372,373,394]. In previous studies investigating the immunological 
basis of this relationship, we have shown that 1 α,25-dihydroxyvitamin D3 
(1,25(OH)2D3) exerts immunomodulatory effects on T cells from patients with SR 
asthma, enhancing the impaired steroid-induced IL-10 response in these individuals 
[350]. Others have highlighted the capacity of 1,25(OH)2D3 to inhibit Th17 proliferation 
and function in mouse models of autoimmunity and also in human keratinocytes and T 
cells in vitro [331,413-415]. Conversely in a VDR-/- mouse model, where there is an 
absence of Vitamin D signalling, there is overproduction of IL-17A [416]. 
Controlling chronic inflammation including Th17-mediated disease whilst maintaining 
respiratory health, is the ideal aim for treating respiratory disease such as severe 
asthma. Regulatory T cells, and molecules that induce these populations such as 
vitamin D, represent an exciting prospect for limiting Th17-mediated disease whilst not 
being detrimental to respiratory health through induction of anti-microbial pathways 
[316,317,417]. Certainly it is known that Foxp3+ Tregs are important for controlling 
Th17-mediated diseases, in particular CD39+Foxp3+ T cells [138,418]. However the 
role of additional regulatory cell populations in controlling Th17-mediated disease has 
not yet been fully investigated.  
In this chapter it was hypothesised that the severe asthma cohort secrete higher 
amount of Th17-associated cytokines as compared to healthy donors, and that 
1,25(OH)2D3 may play a role in controlling the production of these cytokines. To 
achieve this Th17-associated cytokine production from cells isolated from the 
peripheral blood of severe asthma and healthy controls were assessed. Further to this 
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the role of dexamethasone and 1,25(OH)2D3 in controlling Th17-associated cytokines 
were investigated in cells from healthy control subjects.   
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4.2 Results 
4.2.1 Comparison of IL-17A and IL-22 production by CD8-depleted PBMCs 
from Steroid Sensitive (SS) and Refractory (SR) asthma patients 
compared to healthy controls in vitro. 
Emerging epidemiological evidence suggests that SR asthmatics may make more IL-
17A then less severe asthmatics and healthy controls [370,371]. Since asthmatic 
disease is believed to be CD4+ T cells-mediated disease and samples were limited in 
the amount of peripheral blood received from each severe asthma patient, CD8-
depeleted PBMCs were utilised. CD8+ T cells were removed from the PBMC 
population as it has been historically used in the lab due to CD8+ T cells out competing 
CD4+ T cells when stimulated with anti-CD3 and IL-2 [185]. CD8-depleted PBMCs 
were isolated from the peripheral blood of healthy and severe asthma donors from the 
clinical trial and were investigated for Th17-cytokine production (patients characteristics 
can be found in Chapter 3 Table 3-1 and further information about the patient 
recruitment can be found in Appendix 1). Cells were cultured for 7 days with anti-CD3 
and IL-2 in the presence or absence of drugs, and at day 7 PMA and Ionomycin was 
added for 4 hours, with the final 2-hours containing Monensin. Intracellular cytokine 
production was assessed by flow cytometry. Cells were also recounted at Day 7 and 
re-cultured at 1x106/ml in the presence of anti-CD3 and IL-2 and in the absence of 
drugs for a further 48-hours to account for differential cell loss. Supernatants were 
collected and cytokine production was assessed by Cytometric Bead Array (CBA).  
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Figure 4-1 Severe asthma patients express higher levels of IL-17A and IL-22 
CD8-depleted PBMCs were stimulated for 7-days with anti-CD3 and IL-2. Control and asthmatic 
cultures were assessed for IL-17A and IL-22 production by intracellular flow cytometry and CBA. 
A, Representative dot plots. B, Cumulative data of cytokine positive cells (healthy n=8; SS n=8 
and SR n=14) and C, secreted cytokines (Healthy n=10; SS n=10 and SR n=14). B, and C, 
differences in the % of positive cells between healthy and severe asthmatics assessed by 
unpaired t-test, Severe asthma patients were from Screening Visit 1. * p<0.05; ** p<0.001. Open 
circles SS; closed squares SR; and closed triangles healthy controls.  
This data is a combination of Dr Alexandra Nanzer’s and my work. All healthy data is 
predominantly my work and the severe asthma data is predominantly Dr Nanzer’s, however due 
to the nature and duration of the clinical trial there is a significant element of crossover. 
 
Significantly greater percentages of IL-17A+ and IL-22+ expressing cells were 
observed in cultures from asthma patients, as compared to healthy control subjects 
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(Figure 4-1A & B). When patients were subdivided based on clinical responsiveness to 
glucocorticoids only SR patients showed a significant difference in IL-17A 
immunoreactivity (SR p=0.003; SS p=0.142) and IL-22 immunoreactivity (SR p=0.037; 
SS p=0.701), compared to control subjects (Figure 4-1B). Cells co-expressing IL-17A 
and IL-22 [56], are proposed to represent the most pathogenic population, and were 
significantly increased in all asthmatics and SR asthmatics compared to healthy control 
subjects (all asthmatics p=0.029; SR p=0.009).  At seven days cells were also 
harvested and re-cultured at equal cell densities for 48 hours with anti-CD3 and IL-2 
alone. Culture supernatants from asthma patients contained significantly higher 
quantities of secreted IL-17A and IL-22 as compared to healthy controls (Figure 4-1C). 
Production of IL-17A and IL-22 was significantly increased in all severe asthmatics as 
compared to controls (IL-17A: p=0.009; IL-22: p=0.036). Supernatants from SR had 
significantly more IL-17A as compared to SS (p=0.016), whereas culture supernatants 
from SS and SR patients contained comparable levels of IL-22. 
 
4.2.2 Dexamethsone fails to inhibit whereas 1,25(OH)2D3 decreases IL-17A 
production. 
The severe asthma patients who secreted large amount of IL-17A in culture were on 
high doses of inhaled steroids (Table 3-3) and also had very low levels of serum 
25(OH)D. In comparison the healthy controls had significantly higher levels of serum 
25(OH)D and were not using inhaled steroids (Figure 3-14). This data implied that 
either/or the dose of steroids or the vitamin D insufficiency of the severe asthmatics 
may have influenced the high level of Th17-associated cytokine production. Hence the 
impact of steroids (dexamethasone) and 1,25(OH)2D3 was assessed in CD8-depleted 
PBMCs from healthy controls in vitro to assess what impact these drugs had on Th17-
associated cytokines. Cells were isolated from the peripheral blood of healthy donors 
and were investigated for Th17-associated and Th1- and Th2-associated cytokine 
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production. Cells were cultured for 7 days with anti-CD3 and IL-2 in the presence or 
absence of drugs, and at day 7 intracellular cytokine production was assessed by flow 
cytometry. Cells were also recounted at Day 7 and re-cultured at 1x106/ml in the 
presence of anti-CD3 and IL-2 in the absence of drugs for further 48-hours, then 
supernatants were harvested and cytokine production was assessed by Cytometric 
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Figure 4-2 Dexamethasone enhances IL-17A conversely to 1,25(OH)2D3 
CD8-depleted PBMCs stimulated for 7-days with anti-CD3 and IL-2 (No drugs; - ) or additionally 
with the indicated concentration of 1,25(OH)2D3 (VitD3; 10xM) and/or dexamethasone (Dex; 
10xM), assessed for IL-17A and IL-22 production by intracellular flow cytometry and CBA. A, 
representative dot plots B, cumulative data of intracellular staining of cytokines IL-17A (n=5) 
and IL-22 (n=3) C, cumulative cytokine secretion data from CD8-depleted cells (n=7). B, and C, 
cytokine production assessed by repeated-measures one-way ANOVA with Tukey’s multiple 
comparison post-test * p ≤ 0.05, **p ≤ 0.01 ***p ≤ 0.001. 
Dexamethasone was used at 10-7M as determined by extensive earlier studies in the 
lab; found that this concentration had the optimum induction of IL-17A and other 
cytokines [185,187,349]. There was a significant increase in the frequency of IL-17A+ 
cells in cultures containing 10-7M dexamethasone and there is a similar trend observed 
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in IL-22+ cells (Figure 4-2A and B). When 10-7M 1,25(OH)2D3 is present in the cultures 
there was a significant decrease in the frequency of IL-17+ and IL-22+ cells as 
compared to dexamethasone. Inhibition of IL-17A by 1,25(OH)2D3 occurred 
independently of whether dexamethasone was present or not. There was a trend 
towards increase in the amount of IL-17A secreted in culture in the presence of 
dexamethasone (p = 0.12) which was significantly decreased with the presence of 
1,25(OH)2D3. The drugs dexamethasone and 1,25(OH)2D3 still had the predicted 
effects on Th1 and Th2-associated cytokines with a reduction in IFNγ and IL-5, whilst 
significantly increasing IL-10 production when both drugs were present (Figure 4-2C). 
 
4.2.3 Dexamethsone significantly inhibits proliferation, whereas 1,25(OH)2D3 does not 
in culture. 
As asthma is proposed to predominantly be a CD4+ T cell-mediated disease, and it is 
predicted that the majority of the Th17-associated cytokines come from CD4+ T cells 
both CD8-depeleted PBMCs and CD4+ T cells were investigated. To determine if the 
inhibition of IL-17A by 1,25(OH)2D3 was due to inhibition of proliferation, CD8-depleted 
PBMCs and CD4+ T cells were labeled at Day 0 with CellTrace Violet and cultured for 
7-days with anti-CD3 and IL-2. Intracellular cytokine production and proliferation were 
assessed by flow cytometry on Day 7.  
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Figure 4-3 Dexamethasone inhibits proliferation whereas 1,25(OH)2D3 does not 
CD8-depleted PBMCs or CD4+ T Cells stimulated for 7-days with anti-CD3 and IL-2 (No drugs; 
- ) or additionally with 1,25(OH)2D3 (VitD3; 10
-7
M) and/or dexamethasone (Dex; 10
-7
M). 
Intracellular cytokine expression was assessed at Day 7 post 4 hour incubation with PMA and 
Ionomycin with the final 2hours containing Monensin. Proliferation was assessed by loss of 
fluorescence of CellTrace violet at Day 7.  A, representative histograms of (i) CD8-depleted 
PBMCs and (ii) CD4+ T cells B, Cumulative data of division index of CD8-depleted PBMCs 
(n=4; left) and CD4+ T cells (n=5; right) C, Cumulative data of intracellular IL-17A staining of 
CD8-depleted PBMCs (n=4; left) and CD4+ T cells (n=3; right). B, and C, proliferation and % 
positive cells respectively assessed by repeated-measures one-way ANOVA with Tukey’s 
multiple comparison post-test * p ≤ 0.05, **p ≤ 0.01 ***p ≤ 0.001. 
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Dexamethasone significantly inhibited proliferation of CD8-depleted and CD4+ T cells 
independent of whether 1,25(OH)2D3 was present or not. However, in both CD8-
depleted and CD4+ cell cultures the majority of IL-17A is being produced by cells that 
had proliferated (Figure 4-3). 
 
4.2.4 Comparison of CD39 and CD73 expression ex vivo in severe asthma and 
healthy control peripheral blood. 
CD39 is an ecotnucleotidase expressed on the cell surface of Foxp3+ Tregs and 
memory CD4+ T cells [136,418,419]; it breaks down proinflammatory extracellular ATP 
to AMP. This generated AMP is rapidly converted by CD73, to the immunomodulatory 
molecule Adenosine [137,139,418], as can be seen below in Figure 4-2: 
 
Figure 4-4 Schematic of the CD39/CD73 pathway.  
Extracellular ATP acts as a Danger associated molecular pattern (DAMP), however ATP is 
broken down into AMP by CD39 and this is further catalysed to adenosine by CD73. Taken from 
[420] 
What is becoming increasingly clear is that CD39+Foxp3+ T cells play an important 
role in ameliorating Th17-mediated disease, as it was shown that only CD39+Foxp3+ T 
cells and not CD39-Foxp3+ T cells could control Th17 cytokine production in vitro 
[138]. 
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Multiple Sclerosis (MS) is an autoinflammatory condition assumed to be driven at least 
in part by an inappropriate Th17 immune response. MS patients were assessed and 
found to have reduced frequency and function of CD39+Foxp3+ CD4+ T cells [138]. 
This has subsequently been confirmed by other groups showing that CD39+ T cells are 
important for controlling Th17 cells [140,418]. 
The severe asthma patients assessed had significantly higher levels of IL-17A and IL-
22 in culture, therefore as CD39 has been implicated as being important for controlling 
Th17 cells the frequency of CD39 and CD73 cells were investigated ex vivo. Peripheral 
blood of severe asthmatics and healthy controls were stained for CD39, CD73, CD3, 
CD25 and Foxp3, and the gating strategy to assess CD39+ and CD73+ populations 
can be found below in Figure 4-5. 
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Figure 4-5 Representative staining showing the gating strategy for CD39 and 
CD73 ex vivo analysis 
Direct ex vivo flow cytometric analysis of whole peripheral blood obtained from a representative 
healthy donor A, gating strategy for CD3+, then within the CD3+ gate Foxp3+ and Foxp3- gates 
based on isotype control staining B, representative staining of CD39 (left) and CD73 (right) in 
CD3+ T cells (top), Foxp3+CD3+ T cells (middle) and Foxp3-CD3+ T cells (bottom). 
CD39 and CD73 expression was assessed on all CD3+ T cells as well as Foxp3+ 
CD3+T cells and Foxp3-CD3+T cells (Figure 4-5). The cumulative results can be found 
below (Figure 4-6): 
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Figure 4-6 Increased frequency of CD39+ T cells in the peripheral blood of 
healthy donors as compared to severe asthmatics 
Direct ex vivo flow cytometric analysis of peripheral blood obtained from healthy and severe 
asthma donors A, cumulative data of CD39  expression on CD3+ T cells (left), Foxp3+ T cells 
(middle) and Foxp3-  T cells (right) in healthy (n=8) and severe asthma (n=23) B, cumulative 
data of CD73  expression on CD3+ T cells (left), Foxp3+  T cells (middle) and ), Foxp3- T cells 
(right) in healthy (n=8) and severe asthma (n=23) A, and B % of positive cells were in healthy 
versus severe asthmatics were assessed by unpaired t-test. Data shown for the severe 
asthmatics was from Screening Visit 1.  
There was no significant difference in the frequency of CD39+ or CD73+ CD3+T cells 
(p = 0.25 and p = 0.70 respectively) in the peripheral blood of SS versus SR asthmatics 
(data not shown). However, when comparing healthy and severe asthmatics there was 
a significant increased frequency of CD39+CD3+ cells in healthy donors as compared 
to severe asthmatics. As CD39 has predominantly been associated with being 
expressed in Foxp3+ T cells, Foxp3 was costained with CD39. There were significantly 
more CD39+Foxp3+ T cells in the peripheral blood of healthy as compared to severe 
asthma donors. However, not all CD39+ cells were Foxp3+ and when Foxp3-
CD3+CD39+ cells were assessed there was equally a significant difference between 
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healthy and severe asthmatics. There was no significant difference between the 
frequency of CD73+CD3+, CD73+Foxp3+ or CD73+Foxp3- cells in healthy and severe 
asthma.  
As the severe asthma cohort had lower levels of serum 25(OH)D, the data was 
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Figure 4-7 Serum 25(OH)D moderately correlated with CD39+ but not CD73+ T 
cell frequencies 
Direct ex vivo flow cytometric analysis of peripheral blood obtained from healthy and severe 
asthma donors was carried out as described in Figure 4-5 A, correlation between serum 
25(OH)D and CD39+ (right) and CD73+ (left) T cell frequencies B, correlation between serum 
25(OH)D and CD39+Foxp3+ (right) and CD73+Foxp3+ (left) T cell frequencies. A, and B 
correlations between serum 25(OH)D and frequency of cells was assessed by Pearsons 
correlation test. SR closed circles, SS closed squares and Healthy open triangles. Data shown 
for the severe asthmatics was from Screening Visit 1 
There was a significant moderate positive correlation between the frequency of CD39+ T cells 
and serum 25(OH)D (r = 0.42; p = 0.027) (Figure 4-7A). Also there was a trend towards a 
moderate positive correlation between the frequency of Foxp3+CD3+ T cells and serum 
25(OH)D (r = 0.339; p = 0.084). There was no correlation observed between the frequency of 
CD73+ and CD73+Foxp3+ T cells and serum 25(OH)D (Figure 4-7A and B). 
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4.2.5 1,25(OH)2D3 increases CD39 and CD73 expression on CD4+ T cells in vitro 
As 1,25(OH)2D3 has the capacity to inhibit IL-17A production as well as there being a 
moderate positive correlation between frequency of CD39+ T cells and serum 
25(OH)D3, it was next investigated if 1,25(OH)2D3 had any effect on CD39 and CD73 
expression on CD4+ T cells in culture. CD4+ T cells were isolated by positive selection 
from the peripheral blood of healthy donors, and cultured for 7-days with anti-CD3 and 
IL-2 in the presence or absence of drugs as indicated. The effects of 1,25(OH)2D3 on 
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Figure 4-8 1,25(OH)2D3 increased the frequency and expression of CD39 and 
CD73 on healthy CD4+ T cells in vitro. 
CD4+ T Cells stimulated for 7-days with anti-CD3 and IL-2 (No drugs; - ) or additionally with the 
indicated concentration of 1,25(OH)2D3 (VitD3; 10
x
M) A, cumulative data of relative mRNA 
expression of CD39 and CD73 gene expression (n=7) B, representative histograms based on 
isotype control (grey) and C, Cumulative data of cell surface expression of CD39 (n=6) (% of 
cells (left); MFI of positive cells (right)) D, representative histograms based on isotype control 
(grey) and E, Cumulative data of cell surface expression of CD73 (n=6) (% of cells (left); MFI of 
positive cells (right). A, comparison between relative mRNA expression assessed by Freidman 
test with Dunn’s multiple comparison post-test and C, and E, differences in frequencies of cells 
cultured with or without 1,25(OH)2D3 was assessed by paired t-test. * p ≤ 0.05, **p ≤ 0.01. 
1,25(OH)2D3 significantly increased the gene expression of CD39 (Ectonucleoside 
triphosphate diphosphohydrolase 1 – gene name) and CD73 (5’-nucleotidase, ecto – 
gene name) in CD4+ T cells cultured in vitro for 7 days as compared to the no drug 
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condition (Figure 4-8A).  To assess whether a similar pattern was seen at the protein 
level, cell surface flow cytometry was performed. There was a trend for 1,25(OH)2D3 to 
increase the frequency of CD39+ CD4+ T cells (p=0.19), however there was a 
significant increase in the expression of CD39 on the CD39+ cells as determined by 
MFI expression (Figure 4-8B and C). 1,25(OH)2D3 also significantly increased the 
frequency CD73+ CD4+ T cells as compared to no drug conditions. In conjunction with 
this 1,25(OH)2D3 also significantly increased the expression of CD73 on CD73+ cells 
(Figure 4-8D and E). 
To further phenotype 1,25(OH)2D3-induced CD39+ and CD73+ CD4+ T cells, 
costaining was performed with intranuclear Foxp3 staining, as CD39 and CD73 have 
predominantly been associated with being Foxp3+ Treg markers. 
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Figure 4-9 1,25(OH)2D3 increased the frequency and expression of CD39+CD73+ 
but not CD39+Foxp3+ or CD73+ Foxp3+  CD4+ T cells in vitro. 
CD4+ T Cells stimulated for 7-days with anti-CD3 and IL-2 (No drugs; - ) or additionally with 
1,25(OH)2D3 (VitD3; 10
-7
M) A, representative dot plots B, cumulative data of the frequency of 
CD39+CD73+ CD4+ T cells (n=6) C, representative dot plots D, cumulative data of the 
frequency of CD73+Foxp3+ (left) and CD73+Foxp3- CD4+ T cells (n=6) E, representative dot 
plots F, cumulative data of the frequency of CD39+Foxp3+ (left) and CD39+Foxp3- CD4+ T 
cells (n=6) B, and D, and F, differences in the frequency of Foxp3+ CD4+ T cells when cultured 
with or without 1,25(OH)2D3  was assessed by paired t-test. * p ≤ 0.05, **p ≤ 0.01. 
1,25(OH)2D3 significantly increased the co-expression of CD39 and CD73 on CD4+ T 
cells as compared to the no drug condition (Figure 4-9A and B). There was no 
significant difference in the frequency of CD73+Foxp3+ or CD39+Foxp3+ cells cultured 
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with or without 1,25(OH)2D3. However, 1,25(OH)2D3 significantly increased the 
frequency of CD73+ on Foxp3- cells (Figures 4-9C-F). 
 
4.2.6 Inhibition of CD39 enzymatic activity with POM-1 
To assess the role of 1,25(OH)2D3-induced CD39 in inhibition of IL-17A production, a 
CD39 inhibitor was used, POM-1, which inhibits the enzymatic activity of CD39. As the 
original observations about 1,25(OH)2D3 inhibition of IL-17A production were observed 
in CD8-depleted PBMCs, CD8-depleted PBMCs were cultured in the presence or 
absence of 1,25(OH)2D3 and POM-1. Cells were recounted at Day 7 and re-cultured at 
1x106/ml in the presence of anti-CD3 and IL-2 in the absence of drugs for a further 48-
hours when supernatants were collected and cytokine production was assessed by 
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Figure 4-10 Inhibition of CD39 by POM-1 partially abrogates the inhibition of IL-
17A by 1,25(OH)2D3 
CD8-depleted PBMCs were cultured for 7-days with anti-CD3 and IL-2 (No drugs) or additionally 
with 1,25(OH)2D3 (VitD3; 10
-7
M) and/or POM-1 (10μM) A, cumulative data of cytokine 
production as measured by CBA (n=7) B, cumulative cytokine data normalised to the no drug 
condition (1 = no drug level of cytokine production) (n=7). B, differences in cytokine production 
assessed by paired t-test.  
As expected when cells were cultured in the presence of 1,25(OH)2D3 there was 
enhancement of IL-10 production and inhibition of IFNγ and IL-17A. The addition of 
POM-1 into culture had no significant effect on IL-10, IL-5 or IFNγ cytokine production 
in the presence or absence of 1,25(OH)2D3 (Figure 4-10A). However the addition of 
POM-1 to 1,25(OH)2D3 cultures enhanced IL-17A production, and nearly restored it 
back to no drugs levels. Due to the large donor variation this did not reach significance, 
however when the data was analysed as a ratio to the no drug condition as seen in 
Figure 4-10B, there was a significant increase in IL-17A when POM-1 was added to 
1,25(OH)2D3 cultures. There was no significant difference seen with IL-10, IL-5 or IFNγ 
(Figure 4-10A and B). 
  
157 | P a g e  
 
4.3 Discussion 
The data in this chapter demonstrates that the production of IL-17A and IL-22 by 
human peripheral blood cells is elevated in severe asthma. The glucocorticoid 
dexamethasone enhanced the frequency of IL-17A positive cells and IL-17A production 
in non-asthmatic control cultures. In contrast the active form of vitamin D reduced both 
cytokines directly and also when dexamethasone was present in culture. 1,25(OH)2D3 
increased expression of CD39 and CD73, and also significantly increased 
CD39+CD73+ CD4+ T cells. However unexpectedly the population of CD39+ and 
CD73+ CD4+ T cells induced by 1,25(OH)2D3 are not Foxp3+ but Foxp3- T cells. 
Together with data using the CD39 inhibitor POM-1, this work suggests a role for the 
ectonucleotidase CD39 in 1,25(OH)2D3 mediated inhibition of the IL-17A response. 
This work leads us to propose the following model: 
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4-11 Schematic representation of our proposed role for glucocorticoids and 
1,25(OH)2D3 in IL-17A-mediated severe asthma 
Asthma is treated with glucocorticoids, and although they have broad anti-inflmamatory 
properties, we propose that they also enhance production of IL-17A. IL-17A has been previously 
linked with increased steroid resistance as well as increasing inflammation and enhancing the 
asthmatic disease. We propose that 1,25(OH)2D3 inhibits IL-17A production from CD4+ T cells 
through increase in IL-10 production as well as increase in surface expression of CD39 and 
CD73. 
This work extends earlier observations from a number of groups showing an 
association between elevated IL-17A production and severe asthma [370,371]. 
However this study was novel as the severe asthmatics were further characterised as 
being SS and SR, based on their clinical response to steroids. While cells from all 
asthmatics demonstrated elevated IL-17A and IL-22 synthesis, the most striking 
difference was in the levels of secreted IL-17A where there was 7-fold more IL-17A 
produced in the SR as compared to SS. This data is the first human study to highlight 
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the higher expression of IL-17A in clinically-defined SR asthmatics. It extends earlier 
findings that showed that Th17- rather than Th2-mediated inflammation in an allergic 
mouse model of asthma was not inhibited by steroids [404]. In contrast there was no 
difference in levels of IL-22 produced between SS versus SR. This is interesting as IL-
22 and IL-17A are both proposed to be expressed by Th17 cells, and earlier data 
suggests that IL-22 enhances IL-17A inflammation, thus differences in IL-17A are more 
important with regards to Th17-driven inflammation then IL-22 [56]. In OVA-driven 
allergic mouse models of asthma it was identified that high expression of IL-22 can 
prevent allergic inflammation [55,410]. So what is really interesting is that there were a 
significantly higher proportion of IL-17A+ IL-22+ double positive cells in severe 
asthmatics as compared to healthy non-asthmatic controls. These data support earlier 
reports highlighting that double positive conventional T cells are proposed to represent 
the more pathogenic population with studies showing that as both IL-17A and IL-22 
enhances the pro-inflammatory properties of each other [56].  
There is a single study suggesting that IL-17A initiates disease, however that it also 
plays a role in controlling established allergen-driven inflammation [421]. However 
whether these experimental models accurately reflect the complex disease that is 
human SR asthma, particularly airway remodelling a defining characteristic of asthma 
is unclear. The majority of publications provide evidence that Th17 cytokines play a 
mechanistic role in increasing asthma severity and reducing corticosteroid sensitivity 
[405,406] and a number of human studies have shown association between IL-17A 
levels with asthma severity [370,371,407]. Nevertheless, we cannot completely exclude 
the possibility that elevated IL-17A production by severe asthma is associated with 
inhaled corticosteroid administration since all of the severe asthma patients recruited 
were on high-dose of inhaled steroids for the duration of the study (Table 3-1), and we 
observed that a positive correlation exists between the dose of inhaled steroids and 
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amounts of blood PBMC IL-17A released in vitro (Pearson correlation r=0.459; 
p=0.014) (Alexandra Nanzer and ESC, unpublished observations). 
Dexamethasone significantly increased the frequency of IL-17A+ cells and IL-17A 
secretion in cells isolated from the peripheral blood of healthy subjects. Conversely 
1,25(OH)2D3 significantly inhibited IL-17A production in a dexamethasone-independent 
mechanism. Additional issues with high IL-17A is the reported upregulation of GRβ, 
which is an inhibitory receptor for GRα (the functional receptor) for glucocorticoids and 
this may worsen disease and also prevent clinical response to treatment [360,409]. 
These data imply a complex and potentially detrimental relationship between IL-17A, 
steroid treatment and responsiveness in severe asthma, on which vitamin D may have 
a positive impact. It is interesting to note that we and others have shown that both 
1,25(OH)2D3 and dexamethasone increase the expression of the anti-inflammatory 
cytokine IL-10 in vitro, and IL-10 has been shown to inhibit IL-17A production 
[186,347,349,350,422-424]. So it is interesting that only 1,25(OH)2D3 inhibits IL-17A 
production, and this could be due to additional mechanisms shown in this report such 
as CD39 or due to differential effects on Th1- and Th2-associated cytokine production. 
Dexamethasone was shown to be more inhibitory on Th2-associated cytokine 
production then 1,25(OH)2D3, and this is good in the context of Th2-associated disease 
associated with milder and allergic forms of asthma. However Th2-associated 
cytokines have also been shown to play an important role in inhibiting IL-17A cytokine 
production [422,425]. Thus blocking Th2 responses by dexamethasone may allow the 
Th17 response to develop. This could represent a potential mechanism through which 
dexamethasone is less inhibitory on Th17 cytokines, and perhaps suggests a 
contributory mechanism through which steroids may enhance Th17 disease. 
With hindsight it would have been informative to have included IL-17F in the staining 
and CBA protocol as the cytokine IL-17F has been associated with IL-17A production 
as well as severe asthma [371,426]. IL17F and other Th17-associated cytokines can 
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also be assessed in stored sera from these patients in the future. Also it would be very 
informative to investigate the expression of GRα/β in our severe asthma cohort and 
compare this to healthy controls to determine if there is any correlation with cytokine 
response.  
As CD39+Foxp3+ T cells have been implicated in controlling Th17-mediated disease 
[138,140], CD39 and its associated marker CD73 were investigated directly ex vivo by 
flow cytometric analysis. What was interesting was that there was a significantly 
increased frequency of CD39+ T cells in the peripheral blood of healthy donors as 
compared to severe asthmatics. When this was further analysed based on Foxp3 
expression, there was significantly higher frequency of Foxp3+CD39+ T cells as well 
Foxp3-CD39+ T cells in the peripheral blood of healthy controls as compared to severe 
asthmatics. There was no significant difference in the frequency of CD73+ T cells of the 
peripheral blood of healthy and severe asthmatics. This is perhaps not surprising as in 
the CD39-CD73 pathway converting ATP to Adenosine CD39 is considered the rate 
limiting step and actually the conversion of AMP to Adenosine by CD73 happens 
almost instantly [137]. Some Healthy donors were further characterised by cell surface 
staining to identify whether the CD3+ T cells were CD4+ or CD8+ T cells. It was found 
that CD39 was predominantly expressed on the surface of CD4+ T cells, whereas 
CD73 was expressed on CD8+ and CD4+ cells (data not shown).  
As 1,25(OH)2D3 was efficient at inhibiting IL-17A production, modulation of CD39 and 
CD73 on CD4+ T cells was investigated. As expected activation in culture itself 
upregulated CD39 expression [427], however when the level of expression of CD39 
was investigated further it was found that 1,25(OH)2D3 increased the expression of 
CD39 on the CD39+ T cells i.e. there was no difference in frequency but a significant 
increase in MFI values. Also 1,25(OH)2D3 significantly enhanced CD73  number and 
expression of cells. The modulation of CD73 on CD4+ T cells by 1,25(OH)2D3  in vitro 
was a surprise as in vivo there was no correlation between serum 25(OH)D and CD73+ 
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T cells, however it does suggest that in a local microenvironment i.e. within the lung 
1,25(OH)2D3 may have the capacity to modulate CD73 expression. This would require 
further investigation perhaps by analysing BAL levels of 25(OH)D, although this still 
represents a technical challenge,  and CD73 expression on T cells where you predict 
there may be a correlation. There was also a significant increase in the frequency of 
CD39+CD73+ cells present in 1,25(OH)2D3 cultures. Whether these cells are the most 
regulatory is yet to be investigated. The CD39+ and CD73+ cells induced by 
1,25(OH)2D3 are predominantly Foxp3-, as there is no significant difference in 
CD39+Foxp3+ or CD73+Foxp3+ cells in the presence or absence of 1,25(OH)2D3 . 
This is somewhat surprising as the majority of reports have stated that CD39 and CD73 
are Foxp3+ Treg markers. However, perhaps these cells induced by 1,25(OH)2D3 are 
a different population of Treg, especially as the concentration of 1,25(OH)2D3  used 10
-
7M, is known to induce IL-10+ Tregs rather than Foxp3+ [342] (and work presented in 
the next chapter) . Future work on this project will involve performing suppression 
assays to determine if CD39+ or CD73+ T cells are suppressive of CD4+ T cell 
proliferation and also IL-17A production. It will also be interesting to measure the levels 
of ATP and Adenosine in the supernatants of the samples to assess the function of 
CD39 and CD73.  
In the context of other Th17-mediated inflammatory diseases, expansion of 
CD39+Foxp3+ in patients with Multiple Sclerosis (MS) has been shown to correlate 
with remission [428]. Conversely a reduction in CD39+ Treg function correlates with 
disease progression, and certainly it has been shown that the expansion of 
CD39+Tregs is required for control of the Th17-mediated inflammation 
[136,138,428,429]. CD39 has been shown to be expressed on memory Th17 cells in a 
mouse model of transplantation [430]. CD73 has also recently been identified as a 
memory Th17 marker, in a study where peripheral blood CD73+CD4+ T cells were 
shown to correlate with active Inflammatory Bowel Disease, which is suggested to be a 
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predominantly Th17-mediated disease [431]. One could speculate that these CD39+ or 
CD73+ Th17 cells perhaps have a regulatory capacity, similar to what is seen in Th2-
mediated inflammation where Foxp3+ Tregs need to co-express the Th2-specific 
transcription factor IRF4, to control Th2-mediated inflammation [95], suggesting that 
Tregs use components involved in T helper CD4+ cell differentiation pathway to control 
the respective inflammation [95].  
To further elucidate the role of CD39 in 1,25(OH)2D3  cultures the inhibitor POM-1 was 
used in CD8-depleted cultures containing 1,25(OH)2D3 to inhibit CD39 function. POM-1 
partially abrogated the inhibition of IL-17A responses by 1,25(OH)2D3, suggesting that 
CD39 plays a role in 1,25(OH)2D3-inhibition of IL-17A. It would have been interesting to 
observe if full restoration of IL-17A would have been observed if a combination of 
POM-1 and αIL-10R (IL-10R blocking antibody) was used, as it is already known Th17-
cells express the IL-10R and IL-17A production is inhibited by IL-10 [422-424]. Also 
1,25(OH)2D3 can strongly induce IL-10, my and earlier data from the lab show 
[342,347,350].  
There are many ways in which IL-17A may drive asthmatic disease including bronchial 
smooth muscle hypertrophy and hyperplasia, and subepithelial fibrosis [432]. We and 
others have previously demonstrated a negative association between 25(OH)D status 
and airways smooth muscle mass [373,433]. Certainly the asthma patients we 
assessed had very low levels of serum 25-hydroxyvitamin D (25(OH)D) (as shown in 
Figure 3-14), and this may have reduced their responsiveness to corticosteroids and 
enhanced their IL-17A production [372,394]. Manipulation of vitamin D status for 
therapeutic benefit in asthma and other respiratory conditions is currently highly topical. 
Understanding the various mechanisms by which vitamin D controls respiratory health 
and steroid responsiveness is central in targeting this pathway therapeutically and 
these results provide support for an additional beneficial effect. We believe that 
evidence of 1,25(OH)2D3 down regulating pro-inflammatory cytokines such as IL-17A 
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and IL-22, its capacity to enhance anti-microbial pathways, regulatory T cells and other 
homeostatic mechanisms such as CD200 [434], are all likely to contribute to promoting 
homeostasis in the airway and lung health.   






5. In vitro induction of 1,25(OH)2D3-
induced T regulatory Cells: role of 
cytokine milieu. 
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5.1 Introduction 
1,25(OH)2D3 has been shown to increase Foxp3+ Treg frequency in several different 
experimental models. It was shown first in mouse models of autoimmune diseases that 
1,25(OH)2D3 increases the frequency of CD4+CD25+ Treg populations [339,340,435]. 
Subsequently in humans 1,25(OH)2D3 has been shown to induce Foxp3+ Tregs from 
human CD4+ T cells in vitro in the presence of IL-2, and these Tregs express CTLA-4 
[341]. It has also been shown that 1,25(OH)2D3 increases the suppressive capacity 
and function of human Foxp3+Tregs in culture [436].1,25(OH)2D3 is also reported to 
indirectly enhance Foxp3+Treg populations by preventing maturation of DCs and 
upregulating inhibitory receptors such as ILT3 [334-337].  
We have previously reported that 1,25(OH)2D3 enhances IL-10+ Tregs in vitro and in 
vivo [350,437]. Subsequent analysis demonstrated that the induced cells do not co-
express IL-10 and Foxp3, and that the concentration of 1,25(OH)2D3 is important in 
determining whether IL-10+ or Foxp3+ Tregs are induced (Figure 5-1). 
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Figure 5-1 1,25(OH)2D3 can increase the frequency of Foxp3+ and IL-10+ Treg 
populations.  
Human CD4+ T cells were stimulated for two 7-day cycles with anti-CD3, IL-2 and IL-4 (No 
VitD3) or additionally with the indicated concentration of 1,25(OH)2D3 (VitD3; 10
x
M). A, At day 
14, cells were re-stimulated for 16 hours with anti-CD3 and IL-2. IL-10+ cells were identified 
using an IL-10 secretion assay kit. FoxP3+ cells were assessed by intranuclear staining. Values 
represent % of gated live CD4+ cells. Data from several (6-10 per group) healthy donors are 
depicted. B, Cells were co-stained for expression of both IL-10 and FoxP3 in the presence of 
10
-7
M 1,25(OH)2D3. Two representative FACS plots from different donors are shown. Note the 
absence of FoxP3+IL-10+ cells. C, Data from the co-staining experiments depicted in a 
correlation analysis. Each symbol represents a different donors; closed symbols = 10
-6
M 
1,25(OH)2D3, open symbols = 10
-7
M 1,25(OH)2D3. *=p<0.05, **=p<0.01 as determined by the 
Mann Whitney rank sum test. Taken from [342] 
 
As can be seen from Figure 5-1 at the high doses of 1,25(OH)2D3 (10
-6M) there is an 
increased frequency of Foxp3+ Tregs and no induction of IL-10+ Tregs, whereas 
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conversely at the lower doses of 1,25(OH)2D3 (10
-7M) there is increased frequency of 
IL-10+ but not Foxp3+ Tregs. Also when co-staining was performed there was little if 
no co-expression of Foxp3 and IL-10, suggesting that these are distinct regulatory 
populations. 
Further evidence suggesting a role for 1,25(OH)2D3  in Foxp3+ Treg induction exists. 
We and others have demonstrated clear in vivo correlates showing that serum 
25(OH)D levels correlate with Foxp3+ Tregs frequency and numbers in the periphery 
and in the airways (Chapter 3 Figure 3-15) [312,342,395]. Vitamin D status has also 
been linked to functionality of Tregs, as it was demonstrated in Multiple Sclerosis 
patients that low serum 25(OH)D status was associated with reduced suppressive 
capacity of CD25+CD4+CD127lo Tregs [396].  
In this chapter I hypothesized that the cytokine milieu, as well as the concentration of 
1,25(OH)2D3, influences Foxp3+ Treg induction by 1,25(OH)2D3. Hence the aim of this 
chapter is to build on earlier work from the lab, in particular to identify the potential 
mechanisms by which 1,25(OH)2D3 at a high concentration (10
-6M) increases the 
frequencies of Foxp3+ Tregs, and also to identify the effects of cytokine milieu on 
Foxp3+ Treg induction by lower, potentially more physiologically relevant 
concentrations of 1,25(OH)2D3. 
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5.2 Results 
5.2.1 High dose 1,25(OH)2D3 (10
-6M) exerts greater inhibition of Foxp3- T cell 
proliferation than Foxp3+ T cell proliferation 
To build on previous observations from the lab showing that 1,25(OH)2D3 at 10
-6M 
increases the frequency of Foxp3+ CD4+ T cells in culture, my work involved 
assessing potential mechanisms through which high dose 1,25(OH)2D3 exerts its 
effect.  In initial experiments proliferation of CD4+ T cells cultured in the presence or 
absence of different concentrations of 1,25(OH)2D3, was assessed at Day 7 and Day 
14. CD4+ T cells were labeled at Day 0 with CellTrace Violet and cultured for one or 
two rounds of 7-day culture with anti-CD3 and IL-2. Proliferation was assessed by loss 
of fluorescence of CellTrace. 
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Figure 5-2 High dose 1,25(OH)2D3 (10
-6M) inhibits proliferation of CD4+ T cells in 
vitro  
CD4+ T Cells and then labeled at Day 0 with CellTrace Violet. Cells were stimulated for one or 
two 7-day cycles with anti-CD3 and IL-2 (No drugs; - ) or additionally with the indicated 
concentration of 1,25(OH)2D3 (VitD3; 10-xM). Proliferation was assessed by loss in 
fluorescence. A, representative dot plots B, cumulative data of division index C, Cumulative 
data percent of original population divided after 7 days (top) and 14 days (bottom) B, and C, 
differences in proliferation assessed by a repeated-measures one-way ANOVA with Tukey’s 
post-test. * p ≤ 0.05, **p ≤ 0.01, *** p ≤ 0.001, ****p ≤ 0.0001 
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1,25(OH)2D3 at 10
-6M significantly inhibited CD4+ T cell proliferation at Day 7 and Day 
14. This was assessed in two ways, firstly by % of the original population of cells that 
had divided (Figure 5-2C) and secondly by Division index which is a ratio that 
calculates how many cells have undergone division (% divided) multiplied by the 
number of rounds of division (proliferation index) (Figure 5-2B).  
To further elucidate the mechanism of 10-6M 1,25(OH)2D3 effect on Foxp3+ T cells co-
staining of CellTrace with Foxp3 was performed to investigate the proliferation of 
Foxp3+ versus Foxp3- cells. CD4+ T cells were labeled at Day 0 with CellTrace and 
cultured for 7-days or 14-days with anti-CD3 and IL-2 in the presence or absence of 
1,25(OH)2D3 at the concentrations indicated, proliferation was assessed by loss of 
fluorescence of CellTrace. At Day 7 and Day 14 intranuclear Foxp3 staining was 
performed. 
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Figure 5-3 1,25(OH)2D3 is less inhibitory on Foxp3+ as compared to Foxp3- CD4+ 
T cell proliferation 
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CD4+ T Cells stimulated for one or two 7-day cycles with anti-CD3 and IL-2 (No drugs; - ) or 
additionally with the indicated concentration of 1,25(OH)2D3 (VitD3; 10-xM). Cells were labeled 
at Day 0 with CellTrace Violet and proliferation was assessed by loss in fluorescence  A, 
representative dot plots B, representative histograms of Foxp3- (red) versus Foxp3+ (blue) 
proliferation with or without 1,25(OH)D3 after 7 days (top) or 14 days (bottom) of culture C, 
cumulative data of division index of Foxp3- (white) versus Foxp3+ (grey). C, differences in 
Foxp3+ and Foxp3- proliferation under different culture conditions were assessed by a paired t-
test. * p ≤ 0.05 
As previously seen in Figure 5-2, 10-6M 1,25(OH)2D3 inhibited proliferation of CD4+ T 
cells at Day 7 and Day 14 as compared to other conditions. Cells were gated based on 
whether they were Foxp3+ or Foxp3-. There was significantly less inhibition of Foxp3+ 
proliferation as compared to Foxp3-  CD4+ T cells when 10-6M 1,25(OH)2D3 was 
present (Figure 5-3 B and C). Also 10-7M 1,25(OH)2D3 was significantly less inhibitory 
on Foxp3+ as compared to Foxp3- CD4+ T cell proliferation. There was no significant 
difference in Foxp3+ versus Foxp3- CD4+ T cell proliferation in the no drug condition. 
 
5.2.2 1,25(OH)2D3 is less inhibitory on Treg as compared to T effector cell 
proliferation 
Foxp3 has been identified as an early activation marker, as low levels of expression of 
Foxp3 are seen post-stimulation in CD4+ T cells [97]. To establish  the effects of 
1,25(OH)2D3 on existing Foxp3+ Tregs versus effects on conversion of effector T cells 
to Foxp3+ cells, Tregs and T effector CD4+ T cells were isolated from the peripheral 
blood by a cell sorter method (Figure 5-4).  
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Figure 5-4 Sorting strategy to isolate Tregs and Teffectors 
CD4+ cells were negatively selected from peripheral blood, and were subsequently cell surface 
stained with CD127 and CD25.  A, Teffector cells (CD127hiCD25low) and Tregs 
(CD127loCD25hi) were FACs sorted based on their CD127 and CD25 expression, Teffector 
cells and Tregs were subsequently stained for Foxp3 (right). B, representative plots of cells 
cultured with anti-CD3 and IL-2 for 7-days in the presence of 10
-6
M 1,25(OH)2D3, either the 
Tregs (right) or Teffectors (left) were labeled with CellTrace to assess proliferation in the 
respective populations of cells. 
 
Tregs were sorted based on CD127loCD25hi expression, and Teffector cells were 
identified as being CD127hiCD25lo/-. Typically 87% of the Tregs isolated were Foxp3+, 
whereas <1% of the T effector cells were Foxp3+ (Figure 5-4A). To establish the effect 
of 1,25(OH)2D3 on Treg versus Teffector proliferation, either the Treg population or the 
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T effector population were labelled with CellTrace violet and then the two cell 
populations were reconstituted and cells were reconstituted at a 1 Treg to 9 T effector 
ratio (Figure 5-4B). Cells were cultured for 7-days with anti-CD3 and IL-2 in the 
presence or absence of 1,25(OH)2D3 at concentrations indicated, proliferation was 
assessed by loss of fluorescence of CellTrace. At Day 7 intranuclear Foxp3 staining 
was performed. 
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Figure 5-5 1,25(OH)2D3 is less inhibitory on Treg as compared to T effector cell 
proliferation 
CD4+ T Cells were isolated by negative selection then were further sorted based on CD25 and 
CD127 cell surface staining for Tregs (CD127loCD25hi) and T effectors (CD127hiCd25lo/-). 
177 | P a g e  
 
Either Tregs or Teffectors were labelled with CellTrace violet and were cultured together at the 
ratio 1:9 (Treg:Teffectors) and stimulated for 7-days with anti-CD3 and IL-2 (No drugs; - ) or 
additionally with the indicated concentration of 1,25(OH)2D3 (VitD3; 10
-x
M). Proliferation was 
assessed  by  CellTrace loss in fluorescence  A, representative histograms of Teffector cells 
(CD127hiCD25low; red) versus Treg (CD127lowCD25+; blue)  B, cumulative data of division 
index of Teffectors (white) versus Tregs(grey) (n=3)  C, representative histograms of Teffector 
cells (CD127hiCD25low; red) when cultured alone D, cumulative data (n=4) with effectors 
cultured in the presence (white) or absence (black) of Tregs (n=4) E, frequency of Tregs post 7-
days of culture cumulative data (n=4). E, differences in Treg frequencies under different culture 
conditions were assessed by repeated measures one-way ANOVA with Tukey’s post-test. * p ≤ 
0.05, **p ≤ 0.01. 
 
1,25(OH)2D3 promoted Treg proliferation over T effector proliferation at both 10
-7M and 
10-6M (Figure 5-5A-B). However only three experiments were performed and although 
all demonstrated the same pattern significance was not achieved. Interestingly when 
effector cells were cultured in the absence of Tregs, 1,25(OH)2D3  seemed to be less 
inhibitory of effector proliferation (Figure 5-5C-D). Also of interest when the frequency 
of Tregs was assessed at Day 7, even though 10% Tregs were put in the system only 
around 5% were seen in the No drug and 10-7M 1,25(OH)2D3 conditions. Whereas 10
-
6M 1,25(OH)2D3  had significantly more Tregs as defined by CellTrace labelling as 
compared to the other conditions (Figure 5-5E). This could be due to the inhibitory 
effect of 10-6M 1,25(OH)2D3  on T effectors, and/or due to additional mechanism(s) that 
prevents death and/or maintains Treg cells. 
 
5.2.3 10-6M 1,25(OH)2D3  increases the frequency of IL-2+ CD4+ T cells 
IL-2 was originally described as a T cell growth factor. However IL-2 knockout mice 
have been shown to develop a lethal lymphoproliferative disease suggesting a lack of 
regulatory pathways in these mice [438,439]. Foxp3+ Tregs express high levels of the 
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CD25 receptor, the high-affinity form of the IL-2R [440-442]. High concentrations of IL-2 
are require to expand Foxp3+ Tregs in culture [443]. However Foxp3+ Tregs are 
known to have an inability to make IL-2 themselves and hence rely on IL-2 production 
from other T effector cells [151]. As 10-6M 1,25(OH)2D3 has been shown to be less 
inhibitory of Tregs as compared to T effectors,  the question arose what role does IL-2 
play in this effect. In initial experiments to address this IL-2 production was investigated 
by intracellular cytokine staining and CBA.  
Cells were cultured for 3, 7 or 14 days with anti-CD3 and IL-2 in the presence or 
absence of drugs. At day 3, 7 or 14 PMA and Ionomycin was added for 4 hours, with 
the final 2-hours containing Monensin. Intracellular cytokine production was assessed 
by flow cytometry. Cumulative supernatants were collected at Day 7 and IL-2 
production was assessed by Cytometric Bead Array (CBA). 
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Figure 5-6 A high concentration of 1,25(OH)2D3 (10
-6M)  increases the frequency 
of IL-2+ CD4+ T cells 
CD4+ T Cells stimulated for 3, 7 or 14 days with anti-CD3 and IL-2 (No drugs; - ) or additionally 
with the indicated concentration of 1,25(OH)2D3 (VitD3; 10
-x
M). Intracellular cytokine staining 
was performed following 4 hours stimulation with PMA/Ionomycin with the final 2 hours 
containing Monensin. A, representative dot plots from Day 7 B, cumulative data of frequency of 
IL-2+ cells at day 3 (n=4), day 7 (n=5) and day 14 (n=3)  C, Cumulative data of IL-2 as detected 
by CBA of supernatants collected post 7-days of culture. B, and C, differences in IL-2 
production under different culture conditions assessed by a repeated measures one-way 
ANOVA with Tukey’s post-test. * p ≤ 0.05, **p ≤ 0.01. 
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10-6M 1,25(OH)2D3 significantly increased the frequency of IL-2+ CD4+ T cells at Day 
3 and Day 7 as compared to the no drug condition (Figure 5-6A-B). By Day 14 there 
was no significant difference in the frequency of IL-2+ CD4+ T cells between the 
conditions. Also there was an increased amount of IL-2 in the Day 7 supernatants as 
assessed by CBA in cultured that contained 10-6M 1,25(OH)2D3 (Figure 5-6C). Since 
exogenous IL-2 was added to the cultures the CBA data are difficult to interpret, 
however all values are above the 50IU added at the start of culture (Figure 5-6C). 
 
5.2.4 IL-2 signalling predominantly occurs in Foxp3+ Tregs over Foxp3- T 
effector cells in cultures containing 10-6M 1,25(OH)2D3   
The increase in IL-2 seen at 10-6M 1,25(OH)2D3 corresponds with the increased 
frequency of Foxp3+ Tregs (Figure 5-1 and 5-6) suggesting that IL-2 is a requirement 
of Foxp3+ Tregs. To further understand which cells were utilising the IL-2 in the 10-6M 
1,25(OH)2D3 cultures, cell surface staining for CD25 (the high affinity receptor for IL-2) 
was performed. Total CD4+ cells (Figure 5-7A), or co-culture of Tregs plus Teffectors 
[at 1:9 ratio respectively] (Figure 5-7B) were cultured for 7 days with anti-CD3 and IL-2 
in the presence or absence of drugs. At Day 7 cell surface staining for CD25 was 
performed with intranuclear Foxp3 staining.  
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Figure 5-7 CD25 expression is significantly inhibited by 1,25(OH)2D3 at 10
-6M  on 
Foxp3- CD4+ T cells but not Foxp3+ CD4+ T cells 
Figure 5-7A total CD4+ T Cells stimulated for one 7-day cycle; Figure 5-7B either Tregs or 
Teffectors were labelled with CellTrace violet. Cells were cultured at the ratio 1:9 
(Treg:Teffectors) with either Treg or Teffector cells labeled with CellTrace violet as described in 
Figure 5-4. Cells were cultured for 7-days with anti-CD3 and IL-2 (No drugs; - ) or additionally 
with the indicated concentration of 1,25(OH)2D3 (VitD3; 10
-x
M).  A, Cumulative data of CD25 
expression on (i) Total CD4+ Cells or (ii) Foxp3+ or Foxp3- cells CD4+ T cells  B, representative 
histograms (of n=2) of T effectors (red) or Teffectors (blue) cultured as described in Figure 5-4 
A, differences in CD25 expression under different culture conditions were assessed by a 
repeated measures one-way ANOVA with Tukey’s post-test. * p ≤ 0.05, **p ≤ 0.01. 
 
There were significantly lower levels of CD25 on CD4+ T cells cultured in the presence 
of 10-6M 1,25(OH)2D3 as compared to 10
-7M 1,25(OH)2D3 (Figure 5-7Ai). When the 
cells were assessed according to their Foxp3 expression, there was significantly lower 
expression of CD25 in the Foxp3- CD4+ T cell population in the presence of 10-6M 
1,25(OH)2D3 as compared to 10
-7M 1,25(OH)2D3 and no drug condition. In contrast 
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there was no significant difference in CD25 expression on Foxp3+ CD4+ T cells under 
all experimental conditions (Figure 5-7Aii). To confirm that the Foxp3+ cells seen in 
Figure5-7A were Tregs, CD25 expression was assessed on Tregs and T effectors 
individually labelled (isolated and cultured as described in Figure 5-4). 10-6M 
1,25(OH)2D3 seemed to prevent the upregulation of CD25 on T effector cells in culture 
as compared to no drug and 10-7M 1,25(OH)2D3 conditions, whereas the expression of 
CD25 on Tregs seemed to be similar in all culture conditions (Figure 5-7B). 
To confirm that the IL-2 was being preferentially used by the Tregs in cultures 
containing 10-6M 1,25(OH)2D3 and not the T effectors cells, phosphorylation of STAT5 
as a marker of IL-2 signalling was assessed. Downstream of IL-2 ligation of CD25 there 
is phosphorylation of tyrosine at site 694, which is a prerequisite for STAT5 activation 
[444-446]. Treg or T effector cells were labelled with CellTrace (Figure 5-4B) and were 
cultured at a 1 Treg to 9 Teffector ratio. Cells were cultured for 7-days with anti-CD3 
and IL-2 in the presence or absence of 1,25(OH)2D3 at concentrations indicated. At 
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Figure 5-8 IL-2 signaling predominantly occurs in Tregs in cultures containing 
10-6M 1,25(OH)2D3 
CD4+ T Cells  were isolated by negative selection then were further sorted based on CD25 and 
CD127 cell surface staining for Tregs (CD127loCD25hi) and T effectors (CD127hiCD25low) (as 
described in Figure 5-4). Either Tregs or Teffectors were labelled with CellTrace violet and were 
cultured at the ratio 1:9 (Treg:Teffectors) and stimulated for 7-days with anti-CD3 and IL-2 (No 
drugs; - ) or additionally with the indicated concentration of 1,25(OH)2D3 (VitD3; 10
-x
M). A, 
histograms of two donors showing phospo-STAT5 (p-STAT5) staining in Teffectors (red) and 
Tregs (blue) and unstained (grey) B, frequency of phospo-STAT5+ (p-STAT5+) cells (gating 
based on unstained cells) Teffectors (white) and Tregs (grey) post 7-days of culture. 
 
In all conditions there was more IL-2 signalling, as determined by phosphorylation of 
STAT5, in the Tregs as compared to Teffectors. However in cultures containing 10-6M 
1,25(OH)2D3 there was much more phosphorylation of STAT5 in Tregs and less in 
Teffectors as compared to the no drug and 10-7M 1,25(OH)2D3 conditions (Figure 5-8). 
This data suggests that the lack of upregulation of CD25 seen in Figure 5-7 in cultures 
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containing 10-6M 1,25(OH)2D3 results in the  IL-2 being preferentially consumed by the 
Tregs. 
 
5.2.5 1,25(OH)2D3 increases TGFβ expression in CD4+ T cell cultures 
TGFβ has been shown to be an important factor for induction of Foxp3+Tregs, in 
particular for iTregs [178]. Earlier data in the lab showed that the addition of anti-TGFβ 
in 10-6M 1,25(OH)2D3 containing cultures reduced the frequency of Foxp3+ CD4+ T 
cells [342]. The next aim was to further investigate the role of TGFβ in 1,25(OH)2D3-
induced Treg induction, and the capacity of vitamin D to modulate TGFβ levels.  
Attempts were made to detect TGFβ protein by ELISA and CBA but we were not 
satisfied with the data generated from the assays (data not shown). So two surrogate 
markers of TGFβ expression were used Latency Associated Protein (LAP) and 
Glycoprotein A repetitions predominate (GARP) to assess protein production of TGFβ 
[447].   TGFβ is synthesised as a propeptide, it is further activated through cleavage of 
the N-terminal pro-peptide from the TGFβ by the protein FURIN, and this N-terminal 
propeptide is LAP [448-450]. Subsequently, LAP non-covalently binds to the active 
TGFβ and it is co-expressed on the surface of cells. LAP prevents the binding of TGFβ 
to its target receptor [450]. GARP is a transmembrane protein expressed on the 
surface of cells and is a receptor for LAP bound to TGFβ. GARP has been proposed to 
play a role in anchoring LAP-TGFβ onto the cell surface as well as activating TGFβ 
itself [447,451,452]. Both LAP and GARP have been shown to be specifically 
expressed on Foxp3+ Tregs [451-453]. 
TGFβ gene expression as well as cell surface LAP and GARP expression was 
assessed in CD4+ T cell cultures. CD4+ cells were cultured for either one or two 7-day 
rounds of culture with anti-CD3 and IL-2 in the presence or absence of 1,25(OH)2D3. At 
Day 7 and Day 14 cell pellets were obtained and gene expression of TGFβ was 
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assessed by qRT-PCR. Also at Day 7 and Day 14 cell surface expression of LAP and 
GARP was assessed. 
 
Figure 5-9 1,25(OH)2D3 upregulates TGFβ gene and protein expression 
CD4+ T Cells stimulated for one or two 7-day cycles with anti-CD3 and IL-2 (No drugs; - ) or 
additionally with the indicated concentration of 1,25(OH)2D3 (VitD3; 10
-x
M). A, cumulative data 
of relative mRNA expression of TGFβ1 and TGFβ1 gene expression Day 7 (top; n=5) and Day 
14 (bottom; n=4) B, representative dot plots of CD4+ cells cell surface stained for LAP and 
GARP at Day 14 C, Cumulative data of GARP and LAP expression at Day 7 (top; n=5) and Day 
14 (bottom; n=4). B, differences in mRNA gene expression under different culture conditions 
were assessed by Freidman test with Dunn’s multiple comparison post-test C, differences in 
LAP and GARP expression under different culture conditions was assessed by a repeated 
measures one-way ANOVA with Tukey’s post-test. * p ≤ 0.05, **p ≤ 0.01. 
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There are three isoforms of TGFβ; TGFβ1, TGFβ2, and TGFβ3 with TGFβ1 being the 
most common and dominant isoform in the immune system [454,455]. The majority of 
research on the role of TGFβ in the immune system has focussed on the predominant 
isoform TGFβ1 [159,178]. TGFβ2 was not detected in CD4+ T cells at any time-points 
sampled (data not shown). 1,25(OH)2D3 at 10
-6M significantly increased the expression 
of TGFβ3 at Day 7 and a similar trend was seen at Day 14. Conversely, TGFβ1 was 
not significantly altered by 1,25(OH)2D3 at day 7, whereas by Day 14 there was a 
significant increase in TGFβ1 gene expression as compared to the no drug condition 
(Figure 5-9A). Cell surface expression of LAP and GARP were used as surrogate 
markers for TGFβ expression. 1,25(OH)2D3 significantly increased the expression of 
LAP and GARP on CD4+ T cells after 14 days of culture (Figure 5-9B and C). The 
optimum concentration for increasing LAP and GARP expression was 10-7M 
1,25(OH)2D3, and there was a significant increase in GARP expression at Day 7  as 
well as Day 14 along with LAP (Figure 5-9C). 
To further characterise these LAP and GARP populations Foxp3 intranuclear staining 
was also performed. At Day 7 and Day 14 cell surface expression of LAP and GARP 
was assessed with intranuclear Foxp3 staining. 
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Figure 5-10 1,25(OH)2D3 predominantly upregulates LAP and GARP in Foxp3- 
CD4+ T cells 
CD4+ T Cells stimulated for two 7-day cycles with anti-CD3 and IL-2 (No drugs) or additionally 
with the indicated concentration of 1,25(OH)2D3 (VitD3; 10
-x
M). A, representative dot plots and 
B, Cumulative data of GARP expression in Foxp3- (white) and Foxp3+ (grey) populations (n=3) 
C, representative dot plots and D, Cumulative data of LAP expression in Foxp3- (white) and 
Foxp3+ (grey) populations (n=3).  
 
In the no drug condition there is no significant difference in GARP and LAP expression 
between Foxp3+ CD4+ T cells and Foxp3- CD4+ T cells. The addition of 10-7M 
1,25(OH)2D3 into culture resulted in a trend towards an increase in expression of LAP 
and GARP (p = 0.079 and p = 0.133 respectively) on the surface of Foxp3- CD4+ T 
cells as compared to Foxp3+ CD4+ T cells. The addition of 1,25(OH)2D3 resulted in 
increased expression of LAP and GARP on Foxp3+ and Foxp3- cells,  the majority of 
the upregulation is occurring in the Foxp3- CD4+ population (Figure 5-10). 
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5.2.6 TGFβ increases the frequency of Foxp3+ CD4+ T cells in culture in the 
presence of a lower concentration of 1,25(OH)2D3 
Although 10-6M 1,25(OH)2D3 may be applicable in some environments as 
physiological, emerging data suggests that 10-7M 1,25(OH)2D3 may be more 
physiological [272,273]. It was shown that human monocyte-derived Dendritic cells had 
the capacity to generate 1,25(OH)2D3 from 25(OH)D at concentrations ranging from 10
-
9M to 10-8M in culture [272,273]. As the optimum induction of LAP and GARP occurs at 
10-7M 1,25(OH)2D, thus the question remains - what is the function of TGFβ, and does 
it play a role in Treg induction? To answer this, TGFβ was added to culture with the 
lower concentration of 1,25(OH)2D3 to establish the effects of TGFβ on Foxp3+ Treg 
frequencies.  
CD4+ cells were stimulated with anti-CD3 and IL-2 in the presence or absence of drugs 
(1,25(OH)2D 10
-7M; TGFβ 2ng/ml). At Day 7 and Day 14 cells were stained for 
intranuclear Foxp3 expression. 
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Figure 5-11 1,25(OH)2D3 and TGFβ increase the frequency of Foxp3+ CD4+ T 
cells 
CD4+ T Cells stimulated for two 7-day cycles with anti-CD3 and IL-2 (No drugs; - ) or 
additionally with the indicated concentration of 1,25(OH)2D3 (VitD3; 10
-x
M) and/or TGFβ 
(2ng/ml) .  A, representative dot plots of Foxp3 expression in CD4+ T cells cultured in the 
presence or absence of 1,25(OH)2D3 and/or TGFβ as compared to isotype control B,  
Cumulative data of CD4+ T cells cultured in the presence of 1,25(OH)2D3 (VitD3 10-7M)  in the 
absence (white) or presence (grey) of TGFβ (n=4). C, cumulative data of relative mRNA 
expression of Foxp3 and IL-10 gene expression at Day 7 (n=4). B, differences in the frequency 
of Foxp3+ CD4+ T cells under different culture conditions was assessed by paired t-test and C, 
differences in mRNA expression under different culture conditions was assessed by a repeated 
measures two-way ANOVA with Sidak’s multiple comparison test.* p ≤ 0.05, **p ≤ 0.01, ***p ≤ 
0.001. 
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As previously reported 10-7M 1,25(OH)2D does not significantly increase the frequency 
of Foxp3+ CD4+ T cells at either Day 7 or Day 14 as compared to no drug. When 
TGFβ is present in culture there is a significant increase in the frequency of Foxp3+ T 
cells, as has been reported previously. The addition of TGFβ to 10-7M 1,25(OH)2D 
containing cultures significantly increased the frequency of Foxp3+ T cells at Day 7 and 
Day 14 (Figure 5-11A and B). When the gene expression was assessed TGFβ had a 
significant effect of the expression on Foxp3, there was no additional synergistic effect 
of the combination of TGFβ and 10-7M 1,25(OH)2D (Figure 5-11C). As expected 10
-7M 
1,25(OH)2D but not TGFβ significantly increased the gene expression of IL-10 from 
CD4+ T cells.  
To try and establish the mechanism behind the increased frequency of Foxp3+ T cells 
in culture in the presence of 10-7M 1,25(OH)2D and TGFβ, proliferation was assessed 
in Foxp3+ and Foxp3- populations. CD4+ T cells were labeled at Day 0 with CellTrace 
and cultured for one or two 7-day rounds of stimulation with anti-CD3 and IL-2 in the 
presence or absence of drugs (1,25(OH)2D 10
-7M) and TGFβ (2ng/ml). Proliferation 
was assessed by loss of fluorescence of CellTrace. At Day 14 intranuclear Foxp3 
staining was performed and samples were assessed by flow cytometry. 
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Figure 5-12 A combination of TGFβ and 10-7M 1,25(OH)2D3 is less inhibitory on 
proliferation of  Foxp3+ as compared to Foxp3- CD4+ T cells 
CD4+ T Cells stimulated for two 7-day cycles with anti-CD3 and IL-2 (No drugs; - ) or 
additionally with the indicated concentration of 1,25(OH)2D3 (VitD3; 10
-x
M) and/or TGFβ 
(2ng/ml) . Cells were labeled at Day 0 with CellTrace Violet and proliferation was assessed by 
loss in fluorescence. A, representative histograms of CellTrace expression in Foxp3- (red) and 
Foxp3+ (blue). B,  Cumulative data of the percent of original population divided in Foxp3- 
(white) and Foxp3+ (n=4). B, differences in Foxp3+ and Foxp3- proliferation under different 
culture conditions were assessed by paired t-test * p ≤ 0.05, **p ≤ 0.01.  
 
Although the effect is modest there is significantly more proliferation in the Foxp3+ 
population as compared to the Foxp3- in cultures containing a combination of 10-7M 
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1,25(OH)2D and TGFβ. There was a similar trend seen in cultures that contained only 
TGFβ or 10-7M 1,25(OH)2D (Figure 5-12).  
 
5.2.7 A combination of 10-7M 1,25(OH)2D3 and TGFβ  greatly increases the 
frequency of IL-2+ CD4+ T cells in culture. 
IL-2 was shown to be increased at the higher doses of 1,25(OH)2D which coincided 
with an increased frequency of Foxp3+ T cells (Figure 5-6). IL-2 secretion was 
assessed in cultures containing TGFβ and 10-7M 1,25(OH)2D to investigate whether IL-
2 production also coincides with increased Foxp3 expression in cultures containing 
TGFβ. CD4+ T cells were cultured for 3, 7 days with anti-CD3 and IL-2 in the presence 
or absence of 1,25(OH)2D at 10
-7M and  TGFβ at 2ng/ml). At day 3 and 7 PMA and 
Ionomycin was added for the final 4 hours of culture, with the last 2-hours containing 
Monensin. Intracellular cytokine production was assessed by flow cytometry. 
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Figure 5-13 A combination of TGFβ and 10-7M 1,25(OH)2D3 increase the 
frequency of IL-2+ CD4+ T cells 
CD4+ T Cells stimulated with anti-CD3 and IL-2 (50 IU/ml) for 3 or 7 days (No drugs) or 
additionally with the indicated concentration of 1,25(OH)2D3 (VitD3; 10
-x
M) and/or TGFβ 
(2ng/ml). Cells were stimulated for 4 hours with PMA/Ion with the final 2 hours containing 
monensin.  A, representative dot plots of intracellular cytokine staining for IL-10 and IL-2 at Day 
7 B, Cumulative data of IL-2+ cells in the absence (white) or presence (black) of TGFβ (n=4). B, 
differences in mRNA expression under different culture conditions was assessed by a repeated 
measures two-way ANOVA with Sidak’s multiple comparison test. 
 
10-7M 1,25(OH)2D alone significantly inhibited IL-2 at Day 3 but not Day 7 as compared 
to the no drug condition. Whereas TGFβ significantly increased IL-2 at Day 3 with a 
similar trend seen at Day 7 as compared to the no drug condition. There was no 
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synergy seen with the combination of 10-7M 1,25(OH)2D and TGFβ on IL-2+ cells, 
although considerably variability between donors was seen (Figure 5-13). 
 
5.2.8 IL-10 inhibits the increase in frequency of Foxp3+ CD4+ Cells in cultures 
containing 1,25(OH)2D 
It has previously been shown that the addition of anti-IL-10R in cultures containing 10-
7M 1,25(OH)2D increases the frequency of Foxp3+ CD4+ T cells in culture [342]. To 
assess whether the reverse could be true, IL-10 was added to cultures containing 10-
6M 1,25(OH)2D and Foxp3+ CD4+ T cells were assessed. CD4+ cells were cultured for 
either one or two 7-day rounds of culture with anti-CD3 and IL-2 in the presence or 
absence of drugs (1,25(OH)2D 10
-6M; IL-10 5ng/ml). At Day 7 gene expression was 
assessed by qRT-PCR and at Day 14 cells were stained for intranuclear Foxp3 
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Figure 5-14 The addition of IL-10 in culture reduced the frequency of 1,25(OH)2D3 
(10-6M)–induced Foxp3+ Tregs 
CD4+ T Cells stimulated with anti-CD3 and IL-2 (50 IU/ml) for two 7-day cycles (No drugs; - ) or 
additionally with the indicated concentration of 1,25(OH)2D3 (VitD3; 10
-x
M) and/or IL-10 
(5ng/ml). A, cumulative data of relative mRNA expression of IL-10 and Foxp3 at day 7 (n=4) B, 
representative dot plots and C, cumulative data (n=5) of the frequency Foxp3+ CD4+ T cells at 
Day 14. C, differences in the % of Foxp3+ CD4+ T cells under different culture conditions was 
assessed by a paired t-test. * p ≤ 0.05, **p ≤ 0.01. Dotted line indicated the levels of gene 
expression seen in CD4+ T cell cultures with no drugs present. 
The addition of IL-10 in cultures containing 10-6M 1,25(OH)2D increased IL-10 and decreased 
Foxp3 gene expression back to similar levels to those of CD4+ T cells cultured in the presence 
of no drug (Figure 5-14A). There were significantly less Foxp3+ T cells in 10-6M 1,25(OH)2D 
cultures that contained IL-10 (Figure 5-14B and C).  
Blockade of IL-10 signalling with anti-IL-10R blocking antibody has been shown 
previously in our lab to increase the frequency of Foxp3+ T cells [342], and effects on 
proliferation of Foxp3+ and Foxp3- CD4+ T cells was assessed. CD4+ T cells were 
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labeled at Day 0 with CellTrace and cultured for 7-days with anti-CD3 and IL-2 in the 
presence or absence of 1,25(OH)2D at 10
-7M, in the presence or absence of anti-IL-
10R  or control antibody both at 5 g/ml. Proliferation was assessed by loss of 
fluorescence of CellTrace. At Day 7 intranuclear Foxp3 staining was performed and 
samples were assessed by flow cytometry. 
 
Figure 5-15 Anti IL-10R antibody increases the frequency of 1,25(OH)2D3 (10
-7M)-
induced Foxp3+ T cells by promoting the proliferation of  Foxp3+ over Foxp3- 
CD4+T cells 
CD4+ T Cells stimulated with anti-CD3 and IL-2 (50 IU/ml) for 7-days or additionally with the 
indicated concentration of 1,25(OH)2D3 (VitD3; 10
-x
M) and/or aIL-10-R antibody (5 g/ml) and/or 
IgG control antibody (5 g/ml). Cells were labeled at Day 0 with CellTrace Violet and proliferation 
was assessed by loss in fluorescence. A, cumulative data of Foxp3+ cells at day 7 (n=5) B, 
representative histograms of CellTrace labelling in Foxp3- (red) and Foxp3+ (blue) populations 
C, cumulative data (n=5) cells cultured with 1,25(OH)2D3 10
-7
M in Foxp3- (left) and Foxp3+ 
(right) in the absence (white) or presence (black) of anti-IL-10R.  A, differences in % Foxp3+ 
CD4+ T cells under different culture conditions was assessed by a paired t-test and C, 
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differences in Foxp3+ and Foxp3- proliferation under different culture conditions were assessed 
by a paired t-test. * p ≤ 0.05, **p ≤ 0.01. 
In confirmation of earlier findings, the addition of anti-IL-10R into cultures containing 10-
7M 1,25(OH)2D3 significantly increased the frequency of Foxp3+ CD4+ T cells at Day 7 
(Figure 5-15A). Anti-IL-10R increased proliferation of Foxp3+ CD4+ T cells in 10-7M 
1,25(OH)2D3 containing cultures (Figure 5-15B and C). 
 
5.2.9 The combination of anti-IL-10R antibody, TGFβ and 10-7M 1,25(OH)2D3 
increases the frequency of Foxp3+ CD4+ T cells 
As the addition of either anti-IL-10R or TGFβ in the presence of 10-7M 1,25(OH)2D3 
modestly but significantly enhanced the frequency of Foxp3+ CD4+ T cells, a 
combination of all was investigated. CD4+ T cells were labeled at Day 0 with CellTrace 
and cultured for one or two rounds of 7-day culture with anti-CD3 and IL-2 in the 
presence or absence of 1,25(OH)2D at 10
-7M; anti IL-10R 5 g/ml; control antibody 
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Figure 5-16 Combination of TGFβ and anti-IL-10R greatly increases the frequency 
of Foxp3+ Tregs at lower concentrations of 1,25(OH)2D3 
CD4+ T Cells stimulated with anti-CD3 and IL-2 for one or two 7-day cycles or additionally with 
the indicated concentration of 1,25(OH)2D3 (VitD3; 10
-x
M) and/or anti-IL-10-R antibody (5 g/ml) 
and/or IgG control antibody (5 g/ml) and/or TGFβ (5ng/ml). Cells were labeled at Day 0 with 
CellTrace Violet and proliferation was assessed by loss in fluorescence. A, representative dot 
plots  B, cumulative data of  Foxp3+ expression in cells at day 7 (top; n=5) and day 14 (bottom; 
n=3) C, representative histograms of CellTrace labelling in Foxp3- (red) and Foxp3+ (blue) 
populations D, cumulative data day 7 (top; n=5) and day 14 (bottom; n=3). A, differences in % 
Foxp3+ CD4+ T cells under different culture conditions was assessed by a paired t-test and C, 
differences in Foxp3+ and Foxp3- proliferation under different culture conditions were assessed 
by a paired t-test. * p ≤ 0.05, **p ≤ 0.01. 
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There is a significant increase in the frequency of Foxp3+ CD4+ T cells in cultures 
containing the combination of anti-IL-10R, TGFβ and 10-7M 1,25(OH)2D3 at Day 7 and 
a similar trend is seen at Day 14 (Figure 5-16A and B). There was significantly more 
proliferation in the Foxp3+ versus the Foxp3- CD4+ cells after 7 and 14 Days of culture 
under these conditions. 
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5.3 Discussion 
The data in this chapter demonstrate that high dose 1,25(OH)2D3 (10
-6M) significantly 
increases the frequency of Foxp3+ CD4+ T cells in culture and this is associated with 
less inhibition of Foxp3+ CD4+ T cell proliferation as compared to Foxp3- T cells. The 
lower concentration of 1,25(OH)2D3 (10
-7M), can increase the frequency of Foxp3+ T 
cells when it is in an environment high in TGFβ and/or low IL-10. Interestingly 
conditions that increased the frequency of Foxp3+ T cells i.e. 10-6M 1,25(OH)2D3 or 10
-
7M 1,25(OH)2D3 plus TGFβ, also had significantly more IL-2+ CD4+ T cells. There was 
enhanced phosphorylation of STAT5 in Foxp3+ Tregs in cultures containing 10-6M 
1,25(OH)2D3 as compared to T effectors. Evidence for increased IL-2, CD25 and 
phosphorylation of STAT5, all point towards a mechanism where the Foxp3+ CD4+ T 
cells population may be better able to compete for available growth factor. A novel 
finding from this work was that 1,25(OH)2D3 enhanced the gene expression of TGFβ 
as well as enhanced expression of LAP and GARP on the cell surface of CD4+ T cell in 
culture. 
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Figure 5-17 Proposed model for 1,25(OH)2D3 Treg generation 
High concentrations of 1,25(OH)2D3 (10
-6
M) in an environment low in IL-10 and high in IL-2 





M) increase the frequency of IL-10+ Tregs. The cytokine milieu can also modulate Treg 




M) in combination with an 
environment  low in IL-10 and high in IL-2 and TGFβ increases the frequency of Foxp3+ Tregs. 
 
In this model low concentrations of 1,25(OH)2D3 (10
-7M – 10-9M) increase the 
frequency of IL-10+ Tregs as reported from earlier studies from the lab [347,350,437], 
whereas high concentrations of 1,25(OH)2D3 (10
-6M) increase the frequency of Foxp3+ 
Tregs. Additionally the cytokine milieu can play an important role in the development of 
Tregs, as a high IL-10 environment inhibits Foxp3+ Treg development and promotes 
IL-10+ Tregs [347,350]. However if the 1,25(OH)2D3 environment is high in TGFβ and 
low in IL-10 then this increases the frequency of Foxp3+ Tregs [342]. 
Historically it was believed that the active form of vitamin D, 1,25(OH)2D3, was 
metabolised in the kidney, from the circulating precursor 25(OH)D. However 
subsequent work has identified that a number of cell types have the capability to 
generate 1,25(OH)2D3 from 25(OH)D, a number of which are found in the lung 
including APCs and epithelium [271-274]. These findings have identified that 
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monocyte-derived DCs can metabolise 1,25(OH)2D3 to concentrations of 1x10
-9M to 
6x10-8M in culture [272,273,456]. Thus concentrations investigated in the work seem to 
be approaching physiologically relevant ones and certainly likely to represent 
concentrations potentially found in the lung, although it is still technically challenging to 
address this experimentally. It seems credible that concentrations of 1,25(OH)2D3  
required to increase IL-10 expression by CD4+ T cells can be achieved locally in the 
tissues, however whether the concentrations required to promote Foxp3 expression 
occur is less clear. However the role of 1,25(OH)2D3 in promoting Foxp3+ Tregs in 
cultures is supported by my ex vivo data (Chapter 3 3-16) as well as earlier findings 
from our lab and other independent studies. These have shown that serum 25(OH)D 
positively correlates with the frequency and number of Foxp3+ CD4+ T cells in the 
peripheral blood and importantly with the frequency of lung Foxp3+ CD4+ T cells 
[312,342,395]. 
 
The cytokine environment has been shown to play an important role in Foxp3+ CD4+ T 
cell generation and my data implies that the cytokines IL-2, IL-10 and TGFβ have key 
functions in 1,25(OH)2D3-induced Treg development. The addition of either anti-IL-10R 
or TGFβ in the presence of 10-7M 1,25(OH)2D3 modestly but significantly enhanced the 
frequency of Foxp3+ CD4+ T cells, however a combination of both was found to 
significantly increase the frequency of Foxp3+ CD4+ T cell in vitro. The proposed 
mechanism for the increase in Foxp3+ T cells was due to less profound inhibition of 
Foxp3+ CD4+ T cell proliferation by 1,25(OH)2D3 at high concentration, as compared 
to that of Foxp3- CD4+ T cells. Additionally there was increased frequency of IL-2+ 
cells in conditions that increased the frequency of Foxp3+ T cells i.e. 10-6M 
1,25(OH)2D3 or 10
-7M 1,25(OH)2D3 and TGFβ. The data suggests that the Foxp3+ T 
cells were more efficient at utilising available IL-2 as shown by the enhanced 
phosphorylation of STAT5 in Foxp3+ Tregs as compared to T effectors. Evidence that 
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the Foxp3+ Tregs were out competing T effector cells in culture for the growth factor IL-
2 was suggested since in the absence of Tregs there was more proliferation in the T 
effector cultures. Previously 1,25(OH)2D3 and TGFβ have been shown to inhibit  IL-2 
production from CD4+ T cells, in contrast to the data presented here where I see an 
enhancement of IL-2 [325,457]. However in those studies they investigated lower 
concentrations of 1,25(OH)2D3  and the TGFβ work was performed in a mouse model 
which may explain the differences observed.  Nevertheless my data does provide a 
potential mechanism Foxp3+ T cells are increased in the presence of 1,25(OH)2D3 
through production of  IL-2, an essential cytokine for Treg function, maintenance, 
survival and stability of Foxp3+ cells [81,82,341,440,458-460].  
Interestingly, 1,25(OH)2D3 was found to significantly increase the gene expression of 
TGFβ1 and TGFβ3, as well as cell surface expression of GARP and LAP (surrogate 
markers of TGFβ expression) [447]. The role of 1,25(OH)2D3 on TGFβ is contrasting as 
1,25(OH)2D3  has previously been shown to be important in increasing TGFβ 
expression from CD8+ and CD4+ T cells in vitro, whilst also locally controlling TGFβ 
expression within the skin [344,461,462]. A negative correlation between serum 
25(OH)D and circulating levels of TGFβ has been reported, however  6 month 
supplementation with 25(OH)D has been shown to increase the levels of TGFβ 
secreted from PBMCs [463-465]. However to date there have been no publications 
demonstrating the effects of 1,25(OH)2D3 on LAP and GARP expression on CD4+ T 
cells. 
The increased expression of LAP and GARP in the presence of 10-7M 1,25(OH)2D3 
predominantly occurred on the cell surface of Foxp3-. This was in contrast to earlier 
work which has shown that LAP and GARP were only expressed on the cell surface of 
Foxp3+ CD4+ T cells [451-453]. Since the optimum concentration for LAP and GARP 
induction was 10-7M 1,25(OH)2D3 perhaps these cells are actually IL-10+ Tregs, and 
LAP and GARP may represent cell surface markers for these Tregs. Interestingly when 
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exogenous TGFβ is added into culture there was no significant effect on IL-10 gene 
expression.  For optimum induction of Foxp3+ CD4+ T cells in cultures containing 10-
7M 1,25(OH)2D3 there was a requirement for exogenous, thus suggesting there may be 
additional functions of the 1,25(OH)2D3-induced TGFβ. TGFβ has been shown to be 
required for IL-10 production from human Tr1 cells  in vitro and addition of an anti-
TGFβ blocking antibody abrogated IL-10 production [466]. Clearly this is an area of 
work that would require additional research to fully comprehend what is the function of 
1,25(OH)2D3-induced TGFβ. 
Previous data by Jeffery et al found that 1,25(OH)2D3 had the capacity to convert naive 
CD4+ T cells into Foxp3+ Tregs in culture [341]. However previous work from our lab 
did not replicate this data, as the frequency of Foxp3+ T cells generated from naive 
CD4+ T cells was not increased in culture as compared to the no drug condition [342]. 
This is perhaps due to differences in signal strength in culture as Jeffery et al used a 
combination of anti-CD3 and CD28 coated beads, which provide a very robust 
stimulus,  whereas we just used anti-CD3 and IL-2 [341,342]. The type of stimulation of 
the T cells is important as T cells need to be activated to upregulate VDR expression 
[467]. Additionally VDR has been shown to play a role in T cell receptor signalling 
[468]. VDR signalling has been shown to increase PLC-γ1 and cells were more 
responsive to TCR stimulation, thus differences in stimulations could impact on 
different Vitamin D responses [468]. 
Together this work provides further evidence for an important role of 1,25(OH)2D3 as 
an immunomodulatory molecule, as all concentrations of 1,25(OH)2D3 can promote 
Foxp3+ Tregs depending on the cytokine milieu. This data suggests that the 
administration of supplementation with vitamin D may represent an attractive therapy 
for enhancing endogenous populations of Tregs. Supplementation with vitamin D as a 
therapy to increase endogenous Treg populations is potentially a more practical, safer 
and may prove to be a cheaper method then those currently under development such 
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as Treg adoptive transfer in order to improve outcomes in transplantation an certain 
autoimmune conditions. Nevertheless ensuring vitamin D sufficiency in patients who 
have received Treg cell transfer might provide a conditioning environment that 
improves outcomes.  
Therefore, 1,25(OH)2D3 remains an attractive approach for treatment of chronic 
inflammatory diseases such as asthma, and vitamin D supplementation would be 
relatively safe, acceptable to patients and cost effective, and worthy of further 
investigation.  
  





6. General Discussion 
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6.1 Conclusions 
Asthma is a chronic inflammatory disease, characterised by airway remodelling, airway 
hyperresponsiveness and mucus hyperplasia. Asthma was originally described as a 
predominantly Th2-associated cytokine mediated disease, through effects of IL-4, IL-5, 
IL-9 and IL-13 on Th2-skewing of eosinophil, mast cell and B cell activation and 
antibody class switching to IgE.  [165,166]. However asthma is in fact a heterogeneous 
disease and can present in many different phenotypes examples of which include: Th2-
high, Th2-low, severe, neutrophilic and allergic asthma. These different asthma 
phenotypes present with similar symptoms albeit with different disease severity, yet the 
mechanism behind asthma development and exacerbations are different [165,166]. 
The current cornerstone treatment for asthma is glucocorticosteroids (steroids) and 
these work best in mild to moderate Th2-mediated asthma; these patients are known 
as steroid sensitive (SS) asthmatics [184,191]. A number of therapies are being 
developed as alternatives to steroids, and this is essential for the asthmatic phenotypes 
where steroids do not work [183]. Examples of such therapies include Pitrakinra (a 
competitive inhibitor of the IL-4Rα receptor) and Omalizumab (a humanised murine 
monoclonal antibody specific to the FcεR1-binding domain of IgE), but these therapies 
are specifically targeted to allergic asthmatics which is only a proportion of the 
asthmatic population [196,201,202]. Another Th2-specific therapy is Lebrikizumab 
(anti-IL-13 antibody) yet it was shown to be efficacious only in a population of 
asthmatics that had high serum levels of periostatin prior to treatment [168]. Thus these 
treatments although they demonstrate some clinical efficacy, are, however, extremely 
limited to certain phenotypes of asthma. 
Severe asthma is defined as being uncontrolled asthma, with frequent severe 
exacerbations (or death) and/or failure to respond to medications and/or chronic 
morbidity [351] . Despite the treatment with high-dose of inhaled and/or oral steroids 
severe asthmatics have night and day symptoms, and low baseline lung function 
208 | P a g e  
 
(<80% predicted FEV1) which limit their daily activities [167,351]. These patients report 
poor quality of life, and pose a huge economic and social burden upon the health 
service. Our clinical trial provided the exciting and unique opportunity to assess the 
phenotype of moderate/severe SS and SR asthmatics pre- and post-prednisolone to 
identify similarities and differences in the immune cell populations and their function. 
Our lab has previously shown that CD4+ T cells from SR patients fail to produce IL-10 
in response to steroids, in contrast to SS and healthy CD4+ T cells in vitro [349]. We 
have now shown additional immune cell differences in SR as compared to SS 
asthmatics, in particular Foxp3+ CD4+ T cells and dendritic cell (DC) populations. 
There were significantly fewer Foxp3+ CD4+ T cells in the peripheral blood of SR 
asthmatics as compared to SS. This observation may be linked to the lack of steroid 
responsiveness clinically, as independent studies suggest steroids enhance Foxp3+ 
Treg function, therefore fewer Foxp3+ Tregs could theoretically decrease the 
effectiveness of steroids [469].  There were significantly more mDCs in the peripheral 
blood of SR as compared to SS. These two data sets may be linked at there was a 
trend towards an increase in the ratio of CD11c/BDCA-4 DCs, and it has been 
previously been reported that pDCs (as defined by BDCA-4 expression) are involved in 
Treg induction. ILT3 has been implicated in the capacity of DC to enhance Treg 
experimentally, and evidence that ILT3 was expressed at much higher levels on pDCs 
then mDCs. Myeloid DCs have been implicated as being important for initiation and 
driving immune responses, and this is supported by the data showing that mDCs 
expressed higher CD86 and HLA-DR molecules on the cell surface. The differences 
seen in mDC and Foxp3+ CD4+ T cell in SS versus SR asthma populations could 
potentially be used as biomarkers for steroid responsiveness in severe asthma in 
conjunction with IL-17A expression. 
The effect of a 2-week course of prednisolone on immune phenotype in SS and SR 
asthmatics was also investigated. There was a significant increase in the frequency 
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and number of CD19+ cells, which resulted in a significant change in the CD3+/CD19+ 
ratio. There was a significant reduction in the frequency of DCs, and a dramatic 
decrease in the pDC population. The reduction in pDCs post-steroids could have been 
due to a number of reasons including trafficking to the site of inflammation and/or that 
pDCs are susceptible to steroid-induced death [384]. A significant decrease in the 
frequency of Foxp3+ CD4+ T cells in the peripheral blood of SS and SR asthmatics 
post-steroids was also observed.  This data differs from the earlier studies discussed 
above, and although the reasons for this are still unclear this could be due to 
differences in asthma severity since those earlier studies looked in the peripheral blood 
of adult patients with mild disease; it might also be due to recruitment of Foxp3+ CD4+ 
T cells into the lungs, as in asthmatic children this is where an increased frequency of 
Tregs was observed following inhaled steroids [172,174,188].  Interestingly although 
both SS and SR asthmatics had a similar frequency of CD4+ T cells pre- and post-
steroids, there was a significant decrease in the number of CD4+ T cells in SS but not 
in SR. This is interesting as asthma is predominantly mediated by CD4+ T cells, thus a 
decrease in CD4+ T cell, which are potentially pathogenic, in SS asthmatics 
corresponds with clinical improvement in lung function. A big issue with asthma 
treatment is patient compliance, so a quick and informative way of measuring steroid 
compliance may be to look for a decrease in Foxp3+ CD4+ T cell and increase in 
CD19+ B cell frequency in the peripheral blood of asthmatics in combination with the 
current standard of measuring cortisol, although further studies are required to validate 
this. The aim of future transcriptional array analysis is to identify additional biomarkers 
of steroid compliance and response, which could be translated for use in the clinical to 
aid with diagnosis and treatment. 
More recent epidemiological evidence suggests that severe asthma is partially 
mediated by Th17 cells and their associated cytokines IL-17A and IL-22. An elevated 
serum and BAL level of IL-17A appears to be both a marker of severe asthma as well 
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as for poor steroid responsiveness [370,371,404-408,426]. Our data provides 
additional evidence for a role of Th17 cells in severe asthma, as there is elevated 
secretion of Th17-associated cytokines from PBMC cultures from severe asthma 
patients as compared to healthy controls. Additionally when the severe asthmatics 
were further analysed according to steroid responsiveness clinically, there was 7-fold 
higher production of IL-17A from blood-PBMCs in SR donors as compared to the SS, 
but no significant difference between IL-22 was observed. Interesting, dexamethasone 
did not inhibit the IL-17A production and if anything seemed to enhance IL-17A 
production. This has important implications in the clinical setting as if these patients are 
not responding to steroids clinically further steroid use in these patients may actually be 
detrimental to these patients and may exacerbate disease. This data together with 
earlier epidemiological studies, suggests that IL-17A would provide a novel and 
exciting therapeutic target for severe asthma, however IL-17A has also been implicated 
in the clearance of mucosal infections, and this additional risk would need to be 
addressed. A number of anti-IL-17A monoclonal antibodies such as Secukinumab, are 
currently undergoing clinical trials for autoimmune diseases such as rheumatoid 
arthritis, psoriasis and Crohn’s disease, and although the results to date have not all 
been positive they do provide an alternative potential therapy for severe asthma [470-
473]. Perhaps a more targeted delivery of the anti-IL-17A therapy, i.e. in inhaler form, 
or even as discussed below, alternative therapies such as vitamin D, may be more 
efficacious in severe asthma.  
Vitamin D sufficiency has been strongly associated with poor respiratory health 
[296,305]. There is increasing epidemiological evidence showing that Vitamin D 
insufficiency correlates with asthma development and severity [278,302]. Additionally 
low Vitamin D intake during pregnancy is associated with an increased incidence of 
wheeze, a surrogate marker for asthma in 2-5 year olds since asthma is generally not 
diagnosed before the age of six years [303,304].  Children and adults with low vitamin 
211 | P a g e  
 
D status are most likely to have severe asthma and are less likely to respond to asthma 
treatment [305-307]. The severe asthmatics in this clinical trial had much low levels of 
serum 25(OH)D as compared to healthy controls, and the SR patients had the lowest 
average levels of serum 25(OH)D. Even though these patients were recruited all year 
round there were only two patients out of the thirty-seven studied that had sufficient 
levels of serum 25(OH)D. The data observed in this clinical trial adds further support to 
accumulating evidence of the important link between Vitamin D insufficiency and 
asthma. The interest of our group lies in understanding immunological pathways that 
explain the link between low levels of serum 25(OH)D and immune mediated diseases 
with particular focus on asthma. 
The active form of vitamin D, 1,25(OH)2D3, increases production of the anti-
inflammatory cytokine IL-10 both directly and through enhancing glucocorticoid-induced 
IL-10 responses from CD4+ T cells in vitro [342,347,350,437]. IL-10 is an important 
anti-inflammatory cytokine in asthma, as polymorphisms in the IL-10 gene have been 
associated with asthma, resulting in lower production of IL-10 [223,226]. Additionally to 
the earlier data from our lab, 1,25(OH)2D3 has been shown to significantly decrease 
the expression of the pro-inflammatory cytokines IL-17A and IL-22, which we have 
shown are elevated in severe asthma. 1,25(OH)2D3-mediated inhibition of IL-17A is 
partially due to the increase in expression of the ectonucelotidase CD39, which has 
been shown previously to have the capacity to control Th17-mediated disease 
[138,140,419]. As discussed above targeting Th17/IL-17A directly in the airways and in 
asthma may be complicated by the fact that, based on data from animal models, it also 
plays an essential role in combating mucosal infections such as Klebsiella 
pneumoniae, and Candida albicans [398,399]. Concern exists, as an increased risk of 
infection has been observed with biologics targeting TNFα for other immune-mediated 
conditions [474,475]. Thus vitamin D, through its capacity to both inhibit IL-17A 
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production as well as enhance anti microbial pathways may offer a more attractive 
therapeutic strategy. 
We and other have shown that 1,25(OH)2D3 has the capacity to increase the frequency 
of Foxp3+ T regs and IL-10+ Tregs in vitro [341,342]. However 1,25(OH)2D3 also 
increases the expression of a number of immunomodulatory pathways including CTLA-
4, PD-1, CD200, CD39, CD73, LAP and GARP whilst downregulating GITR in CD4+ T 
cells in culture [341,342,434]. A body of evidence is emerging supporting this in vitro 
data, by showing a positive correlation in vivo in patients between serum 25(OH)D and 
the frequency or number of Foxp3+ T cells [312,395]. Additionally we have also shown 
that serum 25(OH)D, the accepted measure of vitamin D status, correlates with the 
frequency of Foxp3+ CD4+ T cells in the lungs of a cohort of paediatric severe asthma 
[342]. 
There is little co-expression of IL-10 and Foxp3 on the 1,25(OH)2D3-induced Tregs, 
and this is in contrast to earlier mouse models which have shown that Foxp3+ Tregs 
express IL-10 however these Tregs were induced and analysed at mucosal sites, 
something which is difficult to study in humans [424,476].  Foxp3+ Treg function in 
mouse models of mucosal inflammation is inhibited through specifically knocking out 
IL-10 signalling in Foxp3+ Tregs [424]. Yet we have shown the opposite where 
inhibiting IL-10 signalling through the use of a blocking IL-10R antibody, actually 
enhances the frequency of Foxp3+ T cells in vitro [342]. Both the IL-10+ and Foxp3+ 
Tregs have been shown to have suppressive capacity, however when 1,25(OH)2D3 is 
withdrawn from culture the Foxp3+ T cells are more stable than the IL-10+ T cells. Why 
1,25(OH)2D3 increases either IL-10+ or Foxp3+ is obviously instructed by the 
environment however it is assumed that they have different regulatory functions within 
the lung environment. It is likely that the phenotype of 1,25(OH)2D3-induced Treg is 
dependent on the cytokine milieu, and we propose that the cytokines IL-2, IL-10 and 
TGFβ play an important role. It is unclear what the explanation is for the differences 
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observed in human and mouse studies with respect to co-expression of IL-10 and 
Foxp3. This could relate to relates to species differences however this seems unlikely 
since at least one human study has reported that 18% of Foxp3+ T cells also co-
expressed IL-10 in the nasal mucosa following grass pollen allergen immunotherapy 
[477], thus co-expression can occur in humans at least at mucosal sites. Plasticity 
within T cell functional phenotypes and/or the transient mature of cytokine expression 
may also contribute, although further work is clearly required to provide a full 
understanding. 
1,25(OH)2D3-induced an increase in expression of LAP and GARP (surrogate markers 
of TGFβ) as well as CD39 and CD73 on Foxp3- and Foxp3+ CD4+ T cells. This was 
unexpected as LAP and GARP have been previously reported to only be expressed on 
Foxp3+ T cells [136-138,140,447,451,452], and this raises the possibility that these are 
markers of the IL-10+ Tregs. It would be extremely useful to have cells surface markers 
of IL-10+ Tregs, as IL-10 is difficult to detect in vivo without genetic manipulation of 
mice as well as directly ex vivo [478]. However, further work would need to be 
performed to identify if these cells are IL-10+ Tregs, and this would require sorting 
CD73/LAP+ versus CD73/LAP- populations and assesses the differences in IL-10 as 
well as total gene expression. 
 
To conclude insufficiency in Vitamin D has been associated with a number of immune 
mediated diseases including asthma. We started these studies demonstrating that 
vitamin D has steroid-enhancing or sparing functions, and these data went on to form 
the basis of the clinical trial on which much of the present studies were based. We now 
show that vitamin D itself has a number of immunomodulatory properties including 
reducing proinflammatory cytokines and mediators such as ATP (through CD39 
upregulation), IL-17A and IL-22; induction of anti-inflammatory cytokines and mediators 
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such as IL-10, TGFβ and Adenosine (through induction of CD39 and CD73) as well as 
directly inducing Foxp3+ Tregs. Together this provides further evidence to support 
further investigation of the use of vitamin D supplementation clinically, which we 
believe would enhance immunoregulatory pathways and would be particularly 
beneficial for the hard to treat therapy-resistant asthmatics. 
 
6.2 Future Perspectives 
6.2.1 SS versus SR gene arrays 
As part of the clinical trial a number of cell pellets were collected (PBMCs, CD4+, CD8+ 
and CD8-depleted PBMCs) as well as whole blood directly stored and collected in 
Tempus Tubes from SS and SR asthmatics. These pellets are untouched and will 
provide an exciting opportunity to assess gene expression and methylation patterns, 
and compare SS and SR asthmatics pre- and post-steroids. This will hopefully enable 
the identification of biomarkers that could predict steroid responsiveness in the severe 
asthma cohort, with the potential to prevent unnecessary treatment of SR with high-
dose steroids. 
 
6.2.2 Does active Vitamin D restore response to steroids? 
The main body of the clinical trial (Treatment Visits 1-3) is still blinded at the point of 
writing this report. Thus there is a massive body of data performed including direct ex 
vivo flow cytometry, 7-day culture in the presence or absence of drugs as well as the 
cell pellets stored at each clinical trial visit. With the unblinding of the clinical trial this 
will enable us to see primarily if there is an improvement in lung function of the SR 
asthmatics on calcitriol, in conjunction with analysing the immunological parameters as 
described before in Chapter 3 and 4. It will be very interesting to see what the effects of 
calcitriol are on Foxp3+ Treg populations, and particularly what happens to the 
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frequency of these cells post-steroids. Serum samples are also available at all time 
points. An important goal will be to identify biomarkers of disease status or phenotype 
as well as the likely response to treatment. 
 
6.2.3 Future Clinical Trials 
i. The current clinical trial was focussed on SR asthma, however there is 
emerging epidemiological evidence that vitamin D insufficiency is seen in all 
phenotypes of asthma, as highlighted by our own asthma patients. Additionally 
all moderate/severe patients would welcome the opportunity to reduce their 
steroid intake. Thus a clinical trial of vitamin D supplementation for all asthma 
patients would be of interest.  
ii. The form of vitamin D used for treatment is still debated. In our clinical trial we 
used calcitriol, however this is suggested to have some negative feedback loop 
on vitamin D metabolism through upregulation of Cyp24a1, as well as increased 
risk of hypercalcemia. However there are individuals who have a reduced 
capacity to synthesize the active form of Vitamin D due to mutations in 
Cyp27B1, and these patients would perhaps benefit from treatment with 
calcitriol [294,295]. Therefore it would be interesting to perform a 
supplementation trial to allow comparison of the effects of calcitriol versus 
vitamin D3. The latter is likely to form a cheaper, safer option that has a much 
longer half-life in vivo (6 weeks compared to approx. 3 days) and may be more 
acceptable to patients. 
iii. The lab is associated with other clinical trials including assessing the impact of 
vitamin D supplementation during pregnancy on development of wheeze in the 
offspring, and where parallel immunological analyses are in progress. A vitamin 
D supplementation trial in a cohort of severe therapy resistant paediatric 
asthma cohort is also planned. 
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6.2.4 Are CD73, LAP and GARP markers of IL-10+Tregs? 
A recent paper identified that TGFβ plays an important role in induction of CD73 [427], 
thus it would be very interesting to see if vitamin D upregulation of CD73 expression 
can be inhibited by anti-TGFβ. CD73, GARP and LAP are all upregulated on Foxp3- 
CD4+ T cells and they are optimally upregulated in the presence of 10-7M 
1,25(OH)2D3, which suggests that these molecules could be cell surface markers of IL-
10+ Tregs. This would need to be addressed by co-staining of CD73, LAP and GARP 
with intracellular IL-10. It would also be very informative to isolate the individual 
populations (CD73+LAP+) and to perform suppression assays as well as looking at the 
gene expression profiles of these cells. 
 
6.2.5 Application of these findings into other immune-mediated disease 
Steroid resistant disease is not restricted to asthmatic disease, as it has been shown in 
a number of autoimmune diseases including Inflammatory Bowel Disease, Multiple 
Sclerosis (MS) and Graft versus Host Disease [479,480]. MS would be a very 
interesting disease to investigate as there is a large body of evidence showing 
associations with Vitamin D insufficiency and MS development [289,290,294,295]. 
Although there are a number ongoing in MS with vitamin D supplementation 
(www.clinicaltrials.gov, accessed March 2013) there is not a trial focussed on 
supplementation of SR MS with Vitamin D, and I believe this would be extremely 
interesting. The overall aim of the MS trial would be to restore clinical response to 
steroids, through Vitamin D-dependent induction of Treg populations and decrease in 
inflammatory cytokine such as IL-17A, as we have seen experimentally and hope to 
confirm in our clinical trial.  
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Appendix I 
Moderate to severe asthmatics were recruited from specialist asthma clinics at 3 
different hospitals: Guys and St Thomas’ NHS Foundation Trust, Barts and The 
London NHS Trust and Homerton University NHS Foundation Trust under the following 
inclusion and exclusion criteria: 
Inclusion criteria: 
1. Male or Female adults aged between 18 to 75 years. 
2. Documented history and typical symptoms of asthma for ≥ 6 months prior to 
screening. 
3. Pre-bronchodilator FEV1 < 80% predicted and documented variability in airways 
obstruction of 12% or greater within the previous 5 years or diurnal Peak Flow 
variability of > 20%. 
4. Corticosteroid refractory asthma, as defined by a < 10% improvement in FEV1 
following a 14 day course of prednisolone 40mg/1.73m2/day29-31. 
5. Written informed consent received  
 
Exclusion criteria: 
1. Past or present disease, which, as judged by the investigator, may affect the 
study outcome (other than asthma, rhinitis or eczema). 
2. Serum corrected calcium >2.66mmol/L 
3. Clinically significant deviation from normal (physical examination or laboratory 
parameters) as judged by the investigator at the screening visit. 
4. Current smoker or an ex-smoker of less than 5 years with a greater than 5 pack 
year history. 
5. Pregnant or lactating females or those at risk of pregnancy (women of 
childbearing age may be offered a pregnancy test prior to recruitment). 
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6. History of a respiratory tract infection and/or exacerbation of asthma within 4 
weeks of the screening visit requiring oral corticosteroid tablets. 
7. Participation in a study involving an investigational medicinal product in the 
previous 3 months or blood donation within the last year. 
8. Current or previous allergen immunotherapy. 
9. Concomitant treatment with lithium carbonate or calcium supplements. 
10. Inability to understand or comply with the research protocol 
Subjects were withdrawn from investigational product treatment if they develop 
hypercalcaemia (corrected serum calcium >2.65 mmol/l confirmed on two samples) 
during the course of the trial. This was monitored at each follow-up time point.  
Patients requiring rescue medication for exacerbation of asthma in form of 
corticosteroids immediately before and during the trial were excluded or withdrawn 
from the trial (this included the four week wash out period).  
Throughout the study the participants were allowed to continue their usual asthma 
medication as prescribed by their doctor (for example short and long acting beta 
agonists (inhaled and oral form) including slow release, anticholinergica, inhaled 
corticosteroids, leukotriene receptor antagonists, theophyllines or antihistamines).  
The severe asthmatics were given a 2-week course of oral prednisolone at 
40mg/1.73m2/day (where m2 = Body Surface Area, BSA) at Screening Visit 1 and upon 
Screening Visit 2 they were assessed to identify Steroid Resistant Asthma. SR was 
defined as having less than 10% improvement in their lung function post a 2-week 
course of prednisolone as identified clinically by FEV1. SS asthmatics (those who had 
>10% improvement in FEV1) were excluded from the clinical trial (Treatment Visits 1 - 
3). SR asthmatics were selected to enter the clinical trial after going through a 4-week 
washout. Upon entering the clinical trial the SR asthmatics were randomly and blindly 
assigned to either placebo or 1,25(OH)2D3 at Treatment Visit 1. After 2-weeks the 
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patients were given a further 2-weeks course of oral of prednisolone at the same dose 
at Screening Visit 1. Treatment Visit 3 was the final visit post-prednisolone. At all visits 
FEV1 was assessed as the primary clinical readout. Furthermore exhaled Nitric Oxide 
was measured at Screening Visit 1 and 2 and Treatment visit 2 and 3 and Asthma 
Control Quality questionnaires were taken at Treatment visit 2 and Final visit to assess 
quality of life and asthma control. Along with this <100ml of peripheral blood was 
obtained to check for haematological and biochemical safety parameters throughout 
the study and cortisol levels to confirm compliance with prednisolone. 
 
  







221 | P a g e  
 
1. Wissinger E, Goulding J, Hussell T: Immune homeostasis in the respiratory tract and 
its impact on heterologous infection. Semin Immunol 2009, 21:147-155. 
2. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, Davies J, Ervine A, 
Poulter L, Pachter L, et al.: Disordered microbial communities in asthmatic airways. 
PLoS One 2010, 5:e8578. 
3. Roth MD, Golub SH: Human pulmonary macrophages utilize prostaglandins and 
transforming growth factor beta 1 to suppress lymphocyte activation. J Leukoc Biol 
1993, 53:366-371. 
4. Yang YC, Zhang N, Van Crombruggen K, Hu GH, Hong SL, Bachert C: 
Transforming growth factor-beta1 in inflammatory airway disease: a key for 
understanding inflammation and remodeling. Allergy 2012, 67:1193-1202. 
5. Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L, 
Gwyer E, Sedgwick JD, Barclay AN, Hussell T: A critical function for CD200 in lung 
immune homeostasis and the severity of influenza infection. Nat Immunol 2008, 
9:1074-1083. 
6. Lambrecht BN, Hammad H: The airway epithelium in asthma. Nat Med 2012, 
18:684-692. 
7. Ueno K, Koga T, Kato K, Golenbock DT, Gendler SJ, Kai H, Kim KC: MUC1 mucin is 
a negative regulator of toll-like receptor signaling. Am J Respir Cell Mol Biol 2008, 
38:263-268. 
8. Yamada C, Sano H, Shimizu T, Mitsuzawa H, Nishitani C, Himi T, Kuroki Y: 
Surfactant protein A directly interacts with TLR4 and MD-2 and regulates inflammatory 
cellular response. Importance of supratrimeric oligomerization. J Biol Chem 2006, 
281:21771-21780. 
222 | P a g e  
 
9. Henning LN, Azad AK, Parsa KV, Crowther JE, Tridandapani S, Schlesinger LS: 
Pulmonary surfactant protein A regulates TLR expression and activity in human 
macrophages. J Immunol 2008, 180:7847-7858. 
10. Akbari O, DeKruyff RH, Umetsu DT: Pulmonary dendritic cells producing IL-10 
mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001, 
2:725-731. 
11. Parker D, Prince A: Innate immunity in the respiratory epithelium. Am J Respir Cell 
Mol Biol 2011, 45:189-201. 
12. Gallo RL, Murakami M, Ohtake T, Zaiou M: Biology and clinical relevance of 
naturally occurring antimicrobial peptides. J Allergy Clin Immunol 2002, 110:823-831. 
13. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol 2003, 21:335-
376. 
14. Kaisho T, Akira S: Toll-like receptor function and signaling. J Allergy Clin Immunol 
2006, 117:979-987; quiz 988. 
15. Hardison SE, Brown GD: C-type lectin receptors orchestrate antifungal immunity. 
Nat Immunol 2012, 13:817-822. 
16. Geijtenbeek TB, Gringhuis SI: Signalling through C-type lectin receptors: shaping 
immune responses. Nat Rev Immunol 2009, 9:465-479. 
17. Kumar H, Kawai T, Akira S: Pathogen recognition by the innate immune system. Int 
Rev Immunol 2011, 30:16-34. 
18. Strober W, Murray PJ, Kitani A, Watanabe T: Signalling pathways and molecular 
interactions of NOD1 and NOD2. Nat Rev Immunol 2006, 6:9-20. 
19. Stone KD, Prussin C, Metcalfe DD: IgE, mast cells, basophils, and eosinophils. J 
Allergy Clin Immunol 2010, 125:S73-80. 
223 | P a g e  
 
20. Bogdan C, Rollinghoff M, Diefenbach A: Reactive oxygen and reactive nitrogen 
intermediates in innate and specific immunity. Curr Opin Immunol 2000, 12:64-76. 
21. Kaplan MJ, Radic M: Neutrophil extracellular traps: double-edged swords of innate 
immunity. J Immunol 2012, 189:2689-2695. 
22. Powers KA, Szaszi K, Khadaroo RG, Tawadros PS, Marshall JC, Kapus A, 
Rotstein OD: Oxidative stress generated by hemorrhagic shock recruits Toll-like 
receptor 4 to the plasma membrane in macrophages. J Exp Med 2006, 203:1951-1961. 
23. Fernandez S, Jose P, Avdiushko MG, Kaplan AM, Cohen DA: Inhibition of IL-10 
receptor function in alveolar macrophages by Toll-like receptor agonists. J Immunol 
2004, 172:2613-2620. 
24. Steinmuller C, Franke-Ullmann G, Lohmann-Matthes ML, Emmendorffer A: Local 
activation of nonspecific defense against a respiratory model infection by application of 
interferon-gamma: comparison between rat alveolar and interstitial lung macrophages. 
Am J Respir Cell Mol Biol 2000, 22:481-490. 
25. Lambrecht BN, Hammad H: Biology of lung dendritic cells at the origin of asthma. 
Immunity 2009, 31:412-424. 
26. Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, Lambeck AJ, 
Figdor CG, de Vries IJ: Human plasmacytoid dendritic cells efficiently cross-present 
exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell 
subsets. Blood 2013, 121:459-467. 
27. Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A, Koni PA, 
Iwashima M, Munn DH: Cutting edge: induced indoleamine 2,3 dioxygenase 
expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 
2003, 171:1652-1655. 
224 | P a g e  
 
28. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, 
Dunbar PR, Wadley RB, Jeet V, et al.: Human CD141+ (BDCA-3)+ dendritic cells 
(DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. 
J Exp Med 2010, 207:1247-1260. 
29. Chu CC, Ali N, Karagiannis P, Di Meglio P, Skowera A, Napolitano L, Barinaga G, 
Grys K, Sharif-Paghaleh E, Karagiannis SN, et al.: Resident CD141 (BDCA3)+ 
dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress 
skin inflammation. J Exp Med 2012, 209:935-945. 
30. Anguille S, Lion E, Tel J, de Vries IJ, Coudere K, Fromm PD, Van Tendeloo VF, 
Smits EL, Berneman ZN: Interleukin-15-induced CD56(+) myeloid dendritic cells 
combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One 
2012, 7:e51851. 
31. Visekruna A, Ritter J, Scholz T, Campos L, Guralnik A, Poncette L, Raifer H, 
Hagner S, Garn H, Staudt V, et al.: Tc9 cells, a new subset of CD8(+) T cells, support 
Th2-mediated airway inflammation. Eur J Immunol 2012. 
32. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of 
murine helper T cell clone. I. Definition according to profiles of lymphokine activities 
and secreted proteins. J Immunol 1986, 136:2348-2357. 
33. Zheng W, Flavell RA: The transcription factor GATA-3 is necessary and sufficient 
for Th2 cytokine gene expression in CD4 T cells. Cell 1997, 89:587-596. 
34. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH: 
Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 
and CD8 T cells. Science 2002, 295:338-342. 
225 | P a g e  
 
35. Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV, Livingston DM, Kung AL, 
Cereb N, Yao TP, Yang SY, et al.: Role of T-bet in commitment of TH1 cells before IL-
12-dependent selection. Science 2001, 292:1907-1910. 
36. Holgate ST: Innate and adaptive immune responses in asthma. Nat Med 2012, 
18:673-683. 
37. Zhou L, Chong MM, Littman DR: Plasticity of CD4+ T cell lineage differentiation. 
Immunity 2009, 30:646-655. 
38. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL: Interleukin-23 
promotes a distinct CD4 T cell activation state characterized by the production of 
interleukin-17. J Biol Chem 2003, 278:1910-1914. 
39. Harrington LE, Mangan PR, Weaver CT: Expanding the effector CD4 T-cell 
repertoire: the Th17 lineage. Curr Opin Immunol 2006, 18:349-356. 
40. Schraml BU, Hildner K, Ise W, Lee WL, Smith WA, Solomon B, Sahota G, Sim J, 
Mukasa R, Cemerski S, et al.: The AP-1 transcription factor Batf controls T(H)17 
differentiation. Nature 2009, 460:405-409. 
41. Huber M, Brustle A, Reinhard K, Guralnik A, Walter G, Mahiny A, von Low E, 
Lohoff M: IRF4 is essential for IL-21-mediated induction, amplification, and stabilization 
of the Th17 phenotype. Proc Natl Acad Sci U S A 2008, 105:20846-20851. 
42. Veldhoen M, Hirota K, Christensen J, O'Garra A, Stockinger B: Natural agonists for 
aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of 
Th17 T cells. J Exp Med 2009, 206:43-49. 
43. Nishihara M, Ogura H, Ueda N, Tsuruoka M, Kitabayashi C, Tsuji F, Aono H, 
Ishihara K, Huseby E, Betz UA, et al.: IL-6-gp130-STAT3 in T cells directs the 
226 | P a g e  
 
development of IL-17+ Th with a minimum effect on that of Treg in the steady state. Int 
Immunol 2007, 19:695-702. 
44. Biswas PS, Gupta S, Chang E, Song L, Stirzaker RA, Liao JK, Bhagat G, Pernis 
AB: Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the 
development of autoimmunity in mice. J Clin Invest 2010, 120:3280-3295. 
45. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, Martin 
B, Wilhelm C, Stockinger B: Transforming growth factor-beta 'reprograms' the 
differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat 
Immunol 2008, 9:1341-1346. 
46. Angkasekwinai P, Chang SH, Thapa M, Watarai H, Dong C: Regulation of IL-9 
expression by IL-25 signaling. Nat Immunol 2010, 11:250-256. 
47. Townsend JM, Fallon GP, Matthews JD, Smith P, Jolin EH, McKenzie NA: IL-9-
deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and 
goblet cell hyperplasia but not T cell development. Immunity 2000, 13:573-583. 
48. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfarani F, 
Odorisio T, Traidl-Hoffmann C, Behrendt H, et al.: Th22 cells represent a distinct 
human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 
2009, 119:3573-3585. 
49. Basu R, O'Quinn DB, Silberger DJ, Schoeb TR, Fouser L, Ouyang W, Hatton RD, 
Weaver CT: Th22 cells are an important source of IL-22 for host protection against 
enteropathogenic bacteria. Immunity 2012, 37:1061-1075. 
50. Kim CJ, Nazli A, Rojas OL, Chege D, Alidina Z, Huibner S, Mujib S, Benko E, 
Kovacs C, Shin LY, et al.: A role for mucosal IL-22 production and Th22 cells in HIV-
associated mucosal immunopathogenesis. Mucosal Immunol 2012, 5:670-680. 
227 | P a g e  
 
51. Ma CS, Deenick EK, Batten M, Tangye SG: The origins, function, and regulation of 
T follicular helper cells. J Exp Med 2012, 209:1241-1253. 
52. Walker JA, McKenzie A: Innate lymphoid cells in the airways. Eur J Immunol 2012, 
42:1368-1374. 
53. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, Bucks C, Kane CM, 
Fallon PG, Pannell R, et al.: Nuocytes represent a new innate effector leukocyte that 
mediates type-2 immunity. Nature 2010, 464:1367-1370. 
54. Barlow JL, Bellosi A, Hardman CS, Drynan LF, Wong SH, Cruickshank JP, 
McKenzie AN: Innate IL-13-producing nuocytes arise during allergic lung inflammation 
and contribute to airways hyperreactivity. J Allergy Clin Immunol 2012, 129:191-198 
e191-194. 
55. Schnyder B, Lima C, Schnyder-Candrian S: Interleukin-22 is a negative regulator of 
the allergic response. Cytokine 2010, 50:220-227. 
56. Besnard AG, Sabat R, Dumoutier L, Renauld JC, Willart M, Lambrecht B, Teixeira 
MM, Charron S, Fick L, Erard F, et al.: Dual Role of IL-22 in allergic airway 
inflammation and its cross-talk with IL-17A. Am J Respir Crit Care Med 2011, 
183:1153-1163. 
57. Ribot JC, deBarros A, Pang DJ, Neves JF, Peperzak V, Roberts SJ, Girardi M, 
Borst J, Hayday AC, Pennington DJ, et al.: CD27 is a thymic determinant of the 
balance between interferon-gamma- and interleukin 17-producing gammadelta T cell 
subsets. Nat Immunol 2009, 10:427-436. 
58. Michel ML, Pang DJ, Haque SF, Potocnik AJ, Pennington DJ, Hayday AC: 
Interleukin 7 (IL-7) selectively promotes mouse and human IL-17-producing 
gammadelta cells. Proc Natl Acad Sci U S A 2012, 109:17549-17554. 
228 | P a g e  
 
59. Murdoch JR, Lloyd CM: Resolution of allergic airway inflammation and airway 
hyperreactivity is mediated by IL-17-producing {gamma}{delta}T cells. Am J Respir Crit 
Care Med 2010, 182:464-476. 
60. Suryani S, Fulcher DA, Santner-Nanan B, Nanan R, Wong M, Shaw PJ, Gibson J, 
Williams A, Tangye SG: Differential expression of CD21 identifies developmentally and 
functionally distinct subsets of human transitional B cells. Blood 2010, 115:519-529. 
61. Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, 
Mauri C: CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy 
individuals but are functionally impaired in systemic Lupus Erythematosus patients. 
Immunity 2010, 32:129-140. 
62. Lund FE, Randall TD: Effector and regulatory B cells: modulators of CD4(+) T cell 
immunity. Nat Rev Immunol 2010, 10:236-247. 
63. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F: 
Competence and competition: the challenge of becoming a long-lived plasma cell. Nat 
Rev Immunol 2006, 6:741-750. 
64. Tarlinton D: B-cell memory: are subsets necessary? Nat Rev Immunol 2006, 6:785-
790. 
65. Sakaguchi S, Miyara M, Costantino CM, Hafler DA: FOXP3+ regulatory T cells in 
the human immune system. Nat Rev Immunol 2010, 10:490-500. 
66. Nishizuka Y, Sakakura T: Thymus and reproduction: sex-linked dysgenesia of the 
gonad after neonatal thymectomy in mice. Science 1969, 166:753-755. 
67. Shevach EM: Suppressor T cells: Rebirth, function and homeostasis. Curr Biol 
2000, 10:R572-575. 
229 | P a g e  
 
68. Gershon RK, Kondo K: Cell interactions in the induction of tolerance: the role of 
thymic lymphocytes. Immunology 1970, 18:723-737. 
69. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance 
maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). 
Breakdown of a single mechanism of self-tolerance causes various autoimmune 
diseases. J Immunol 1995, 155:1151-1164. 
70. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA: CD4+CD25high regulatory 
cells in human peripheral blood. J Immunol 2001, 167:1245-1253. 
71. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH: Identification 
and functional characterization of human CD4(+)CD25(+) T cells with regulatory 
properties isolated from peripheral blood. J Exp Med 2001, 193:1285-1294. 
72. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, Isaacs JD, 
Lechler RI: Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory 
T cells. Blood 2001, 98:2736-2744. 
73. Takahata Y, Nomura A, Takada H, Ohga S, Furuno K, Hikino S, Nakayama H, 
Sakaguchi S, Hara T: CD25+CD4+ T cells in human cord blood: an immunoregulatory 
subset with naive phenotype and specific expression of forkhead box p3 (Foxp3) gene. 
Exp Hematol 2004, 32:622-629. 
74. Stephens LA, Mottet C, Mason D, Powrie F: Human CD4(+)CD25(+) thymocytes 
and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 2001, 
31:1247-1254. 
75. Levings MK, Sangregorio R, Roncarolo MG: Human cd25(+)cd4(+) t regulatory 
cells suppress naive and memory T cell proliferation and can be expanded in vitro 
without loss of function. J Exp Med 2001, 193:1295-1302. 
230 | P a g e  
 
76. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, Shimizu J, 
Sakaguchi S: Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic 
and suppressive T cells: induction of autoimmune disease by breaking their 
anergic/suppressive state. Int Immunol 1998, 10:1969-1980. 
77. Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S: 
Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and 
suppressive T cells as a key function of the thymus in maintaining immunologic self-
tolerance. J Immunol 1999, 162:5317-5326. 
78. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN: Human 
anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-
prone population. Eur J Immunol 2001, 31:1122-1131. 
79. Thornton AM, Shevach EM: CD4+CD25+ immunoregulatory T cells suppress 
polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 
1998, 188:287-296. 
80. Piccirillo CA, Shevach EM: Cutting edge: control of CD8+ T cell activation by 
CD4+CD25+ immunoregulatory cells. J Immunol 2001, 167:1137-1140. 
81. Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ: Interleukin 2 
signaling is required for CD4(+) regulatory T cell function. J Exp Med 2002, 196:851-
857. 
82. Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C: Regulatory CD4 T 
cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 
dependency. Int Immunol 1998, 10:371-378. 
83. Asano M, Toda M, Sakaguchi N, Sakaguchi S: Autoimmune disease as a 
consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996, 
184:387-396. 
231 | P a g e  
 
84. Hsieh CS, Zheng Y, Liang Y, Fontenot JD, Rudensky AY: An intersection between 
the self-reactive regulatory and nonregulatory T cell receptor repertoires. Nat Immunol 
2006, 7:401-410. 
85. Pacholczyk R, Ignatowicz H, Kraj P, Ignatowicz L: Origin and T cell receptor 
diversity of Foxp3+CD4+CD25+ T cells. Immunity 2006, 25:249-259. 
86. Kuniyasu Y, Takahashi T, Itoh M, Shimizu J, Toda G, Sakaguchi S: Naturally 
anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically 
distinct immunoregulatory T cell subpopulation. Int Immunol 2000, 12:1145-1155. 
87. Torgerson TR, Ochs HD: Immune dysregulation, polyendocrinopathy, enteropathy, 
X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin 
Immunol 2007, 120:744-750; quiz 751-742. 
88. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly 
TE, Saulsbury FT, Chance PF, Ochs HD: The immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of 
FOXP3. Nat Genet 2001, 27:20-21. 
89. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson 
JE, Galas D, Ziegler SF, Ramsdell F: Disruption of a new forkhead/winged-helix 
protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat 
Genet 2001, 27:68-73. 
90. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the 
transcription factor Foxp3. Science 2003, 299:1057-1061. 
91. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and 
function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336. 
232 | P a g e  
 
92. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, 
Gingeras TR, Fazekas de St Groth B, et al.: CD127 expression inversely correlates 
with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 
203:1701-1711. 
93. Kleinewietfeld M, Starke M, Di Mitri D, Borsellino G, Battistini L, Rotzschke O, Falk 
K: CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating 
effector cells. Blood 2009, 113:827-836. 
94. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, 
Heike T, Valeyre D, et al.: Functional delineation and differentiation dynamics of human 
CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009, 30:899-911. 
95. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY: Role of 
conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. 
Nature 2010, 463:808-812. 
96. Huehn J, Polansky JK, Hamann A: Epigenetic control of FOXP3 expression: the 
key to a stable regulatory T-cell lineage? Nat Rev Immunol 2009, 9:83-89. 
97. Josefowicz SZ, Wilson CB, Rudensky AY: Cutting edge: TCR stimulation is 
sufficient for induction of Foxp3 expression in the absence of DNA methyltransferase 1. 
J Immunol 2009, 182:6648-6652. 
98. Polansky JK, Kretschmer K, Freyer J, Floess S, Garbe A, Baron U, Olek S, 
Hamann A, von Boehmer H, Huehn J: DNA methylation controls Foxp3 gene 
expression. Eur J Immunol 2008, 38:1654-1663. 
99. Samstein RM, Josefowicz SZ, Arvey A, Treuting PM, Rudensky AY: Extrathymic 
generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. 
Cell 2012, 150:29-38. 
233 | P a g e  
 
100. Josefowicz SZ, Niec RE, Kim HY, Treuting P, Chinen T, Zheng Y, Umetsu DT, 
Rudensky AY: Extrathymically generated regulatory T cells control mucosal TH2 
inflammation. Nature 2012, 482:395-399. 
101. Kanhere A, Hertweck A, Bhatia U, Gokmen MR, Perucha E, Jackson I, Lord GM, 
Jenner RG: T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-
specific targeting of distal regulatory elements. Nat Commun 2012, 3:1268. 
102. Zhang F, Meng G, Strober W: Interactions among the transcription factors Runx1, 
RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells. 
Nat Immunol 2008, 9:1297-1306. 
103. Rudra D, deRoos P, Chaudhry A, Niec RE, Arvey A, Samstein RM, Leslie C, 
Shaffer SA, Goodlett DR, Rudensky AY: Transcription factor Foxp3 and its protein 
partners form a complex regulatory network. Nat Immunol 2012, 13:1010-1019. 
104. Wilson CB, Rowell E, Sekimata M: Epigenetic control of T-helper-cell 
differentiation. Nat Rev Immunol 2009, 9:91-105. 
105. Ray A, Khare A, Krishnamoorthy N, Qi Z, Ray P: Regulatory T cells in many 
flavors control asthma. Mucosal Immunol 2010, 3:216-229. 
106. Curotto de Lafaille MA, Lafaille JJ: Natural and adaptive foxp3+ regulatory T cells: 
more of the same or a division of labor? Immunity 2009, 30:626-635. 
107. Curotto de Lafaille MA, Lino AC, Kutchukhidze N, Lafaille JJ: CD25- T cells 
generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J Immunol 2004, 
173:7259-7268. 
108. Gregg R, Smith CM, Clark FJ, Dunnion D, Khan N, Chakraverty R, Nayak L, Moss 
PA: The number of human peripheral blood CD4+ CD25high regulatory T cells 
increases with age. Clin Exp Immunol 2005, 140:540-546. 
234 | P a g e  
 
109. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von 
Boehmer H: Inducing and expanding regulatory T cell populations by foreign antigen. 
Nat Immunol 2005, 6:1219-1227. 
110. Apostolou I, von Boehmer H: In vivo instruction of suppressor commitment in 
naive T cells. J Exp Med 2004, 199:1401-1408. 
111. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM: 
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells 
by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-1886. 
112. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF: Cutting 
edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 
induction and down-regulation of Smad7. J Immunol 2004, 172:5149-5153. 
113. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang 
HD, Bopp T, Schmitt E, et al.: Epigenetic control of the foxp3 locus in regulatory T cells. 
PLoS Biol 2007, 5:e38. 
114. Hill JA, Hall JA, Sun CM, Cai Q, Ghyselinck N, Chambon P, Belkaid Y, Mathis D, 
Benoist C: Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from 
CD4+CD44hi Cells. Immunity 2008, 29:758-770. 
115. Wang J, Huizinga TW, Toes RE: De novo generation and enhanced suppression 
of human CD4+CD25+ regulatory T cells by retinoic acid. J Immunol 2009, 183:4119-
4126. 
116. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, Belkaid Y: Small 
intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells 
via retinoic acid. J Exp Med 2007, 204:1775-1785. 
235 | P a g e  
 
117. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, 
Powrie F: A functionally specialized population of mucosal CD103+ DCs induces 
Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J 
Exp Med 2007, 204:1757-1764. 
118. Round JL, Mazmanian SK: Inducible Foxp3+ regulatory T-cell development by a 
commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A 2010, 
107:12204-12209. 
119. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, 
Yamasaki S, Saito T, Ohba Y, et al.: Induction of colonic regulatory T cells by 
indigenous Clostridium species. Science 2011, 331:337-341. 
120. Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio CW, Santacruz N, Peterson DA, 
Stappenbeck TS, Hsieh CS: Peripheral education of the immune system by colonic 
commensal microbiota. Nature 2011, 478:250-254. 
121. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, Shevach 
EM: Expression of Helios, an Ikaros transcription factor family member, differentiates 
thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010, 
184:3433-3441. 
122. Verhagen J, Wraith DC: Comment on "Expression of Helios, an Ikaros 
transcription factor family member, differentiates thymic-derived from peripherally 
induced Foxp3+ T regulatory cells". J Immunol 2010, 185:7129; author reply 7130. 
123. Gottschalk RA, Corse E, Allison JP: Expression of Helios in peripherally induced 
Foxp3+ regulatory T cells. J Immunol 2012, 188:976-980. 
124. Serre K, Benezech C, Desanti G, Bobat S, Toellner KM, Bird R, Chan S, Kastner 
P, Cunningham AF, Maclennan IC, et al.: Helios is associated with CD4 T cells 
236 | P a g e  
 
differentiating to T helper 2 and follicular helper T cells in vivo independently of Foxp3 
expression. PLoS One 2011, 6:e20731. 
125. Akimova T, Beier UH, Wang L, Levine MH, Hancock WW: Helios expression is a 
marker of T cell activation and proliferation. PLoS One 2011, 6:e24226. 
126. Tordjman R, Lepelletier Y, Lemarchandel V, Cambot M, Gaulard P, Hermine O, 
Romeo PH: A neuronal receptor, neuropilin-1, is essential for the initiation of the 
primary immune response. Nat Immunol 2002, 3:477-482. 
127. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout 
S, Anthony BA, Sverdrup FM, Head R, Kuster DJ, et al.: Neuropilin-1 distinguishes 
natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp 
Med 2012, 209:1713-1722, S1711-1719. 
128. Weiss JM, Bilate AM, Gobert M, Ding Y, Curotto de Lafaille MA, Parkhurst CN, 
Xiong H, Dolpady J, Frey AB, Ruocco MG, et al.: Neuropilin 1 is expressed on thymus-
derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg 
cells. J Exp Med 2012, 209:1723-1742, S1721. 
129. Milpied P, Renand A, Bruneau J, Mendes-da-Cruz DA, Jacquelin S, Asnafi V, 
Rubio MT, MacIntyre E, Lepelletier Y, Hermine O: Neuropilin-1 is not a marker of 
human Foxp3+ Treg. Eur J Immunol 2009, 39:1466-1471. 
130. Bacchetta R, Bigler M, Touraine JL, Parkman R, Tovo PA, Abrams J, de Waal 
Malefyt R, de Vries JE, Roncarolo MG: High levels of interleukin 10 production in vivo 
are associated with tolerance in SCID patients transplanted with HLA mismatched 
hematopoietic stem cells. J Exp Med 1994, 179:493-502. 
131. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo 
MG: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents 
colitis. Nature 1997, 389:737-742. 
237 | P a g e  
 
132. Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG: 
Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not 
CD25+CD4+ Tr cells. Blood 2005, 105:1162-1169. 
133. Sundstedt A, O'Neill EJ, Nicolson KS, Wraith DC: Role for IL-10 in suppression 
mediated by peptide-induced regulatory T cells in vivo. J Immunol 2003, 170:1240-
1248. 
134. Gabrysova L, Wraith DC: Antigenic strength controls the generation of antigen-
specific IL-10-secreting T regulatory cells. Eur J Immunol 2010, 40:1386-1395. 
135. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP: Activation of 
human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 
2003, 421:388-392. 
136. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, 
Hopner S, Centonze D, Bernardi G, Dell'Acqua ML, et al.: Expression of 
ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and 
immune suppression. Blood 2007, 110:1225-1232. 
137. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, 
Linden J, Oukka M, et al.: Adenosine generation catalyzed by CD39 and CD73 
expressed on regulatory T cells mediates immune suppression. J Exp Med 2007, 
204:1257-1265. 
138. Fletcher JM, Lonergan R, Costelloe L, Kinsella K, Moran B, O'Farrelly C, Tubridy 
N, Mills KH: CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are 
impaired in multiple sclerosis. J Immunol 2009, 183:7602-7610. 
139. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, 
Lang S, Jackson EK, Gorelik E, Whiteside TL: Generation and accumulation of 
238 | P a g e  
 
immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J 
Biol Chem 2010, 285:7176-7186. 
140. Ye ZJ, Zhou Q, Zhang JC, Li X, Wu C, Qin SM, Xin JB, Shi HZ: CD39+ regulatory 
T cells suppress generation and differentiation of Th17 cells in human malignant 
pleural effusion via a LAP-dependent mechanism. Respir Res 2011, 12:77. 
141. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, 
Jeffery LE, Kaur S, Briggs Z, et al.: Trans-endocytosis of CD80 and CD86: a molecular 
basis for the cell-extrinsic function of CTLA-4. Science 2011, 332:600-603. 
142. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow 
DB, Hunter KM, Smith AN, Di Genova G, et al.: Association of the T-cell regulatory 
gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511. 
143. Zheng Y, Manzotti CN, Burke F, Dussably L, Qureshi O, Walker LS, Sansom DM: 
Acquisition of suppressive function by activated human CD4+ CD25- T cells is 
associated with the expression of CTLA-4 not FoxP3. J Immunol 2008, 181:1683-1691. 
144. Sansom DM, Walker LS: The role of CD28 and cytotoxic T-lymphocyte antigen-4 
(CTLA-4) in regulatory T-cell biology. Immunol Rev 2006, 212:131-148. 
145. Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB: Structural analysis 
of CTLA-4 function in vivo. J Immunol 2000, 164:5319-5327. 
146. Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, Baroja ML, 
Madrenas J: CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms 
depending on its level of cell surface expression. J Immunol 2000, 165:1352-1356. 
147. Kubach J, Lutter P, Bopp T, Stoll S, Becker C, Huter E, Richter C, Weingarten P, 
Warger T, Knop J, et al.: Human CD4+CD25+ regulatory T cells: proteome analysis 
239 | P a g e  
 
identifies galectin-10 as a novel marker essential for their anergy and suppressive 
function. Blood 2007, 110:1550-1558. 
148. Loebbermann J, Thornton H, Durant L, Sparwasser T, Webster KE, Sprent J, 
Culley FJ, Johansson C, Openshaw PJ: Regulatory T cells expressing granzyme B 
play a critical role in controlling lung inflammation during acute viral infection. Mucosal 
Immunol 2012, 5:161-172. 
149. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ: 
Granzyme B and perforin are important for regulatory T cell-mediated suppression of 
tumor clearance. Immunity 2007, 27:635-646. 
150. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ: Human 
T regulatory cells can use the perforin pathway to cause autologous target cell death. 
Immunity 2004, 21:589-601. 
151. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ: CD4+CD25+Foxp3+ 
regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T 
cells. Nat Immunol 2007, 8:1353-1362. 
152. Banchereau J, Pascual V, O'Garra A: From IL-2 to IL-37: the expanding spectrum 
of anti-inflammatory cytokines. Nat Immunol 2012, 13:925-931. 
153. Hawrylowicz CM, O'Garra A: Potential role of interleukin-10-secreting regulatory T 
cells in allergy and asthma. Nat Rev Immunol 2005, 5:271-283. 
154. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA: Mechanisms of immune 
suppression by interleukin-10 and transforming growth factor-beta: the role of T 
regulatory cells. Immunology 2006, 117:433-442. 
240 | P a g e  
 
155. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy 
D, Blumberg RS, Vignali DA: The inhibitory cytokine IL-35 contributes to regulatory T-
cell function. Nature 2007, 450:566-569. 
156. Okamura T, Fujio K, Shibuya M, Sumitomo S, Shoda H, Sakaguchi S, Yamamoto 
K: CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. 
Proc Natl Acad Sci U S A 2009, 106:13974-13979. 
157. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, 
Malenkovich N, Okazaki T, Byrne MC, et al.: Engagement of the PD-1 
immunoinhibitory receptor by a novel B7 family member leads to negative regulation of 
lymphocyte activation. J Exp Med 2000, 192:1027-1034. 
158. Francisco LM, Sage PT, Sharpe AH: The PD-1 pathway in tolerance and 
autoimmunity. Immunol Rev 2010, 236:219-242. 
159. Marie JC, Letterio JJ, Gavin M, Rudensky AY: TGF-beta1 maintains suppressor 
function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005, 
201:1061-1067. 
160. Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O'Shea JJ, Shevach 
EM: CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-
dependent manner. J Exp Med 2008, 205:1975-1981. 
161. Braman SS: The global burden of asthma. Chest 2006, 130:4S-12S. 
162. Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: executive 
summary of the GINA Dissemination Committee report. Allergy 2004, 59:469-478. 
163. Barnes PJ: Immunology of asthma and chronic obstructive pulmonary disease. 
Nat Rev Immunol 2008, 8:183-192. 
241 | P a g e  
 
164. Pascual RM, Peters SP: Airway remodeling contributes to the progressive loss of 
lung function in asthma: an overview. J Allergy Clin Immunol 2005, 116:477-486; quiz 
487. 
165. Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL: The 
microbiology of asthma. Nat Rev Microbiol 2012, 10:459-471. 
166. Wenzel SE: Asthma phenotypes: the evolution from clinical to molecular 
approaches. Nat Med 2012, 18:716-725. 
167. Wenzel S: Severe asthma: from characteristics to phenotypes to endotypes. Clin 
Exp Allergy 2012, 42:650-658. 
168. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris 
JM, Scheerens H, Wu LC, Su Z, et al.: Lebrikizumab treatment in adults with asthma. N 
Engl J Med 2011, 365:1088-1098. 
169. Maazi H, Shirinbak S, Willart M, Hammad HM, Cabanski M, Boon L, Ganesh V, 
Baru AM, Hansen G, Lambrecht BN, et al.: Contribution of regulatory T cells to 
alleviation of experimental allergic asthma after specific immunotherapy. Clin Exp 
Allergy 2012, 42:1519-1528. 
170. Burchell JT, Wikstrom ME, Stumbles PA, Sly PD, Turner DJ: Attenuation of 
allergen-induced airway hyperresponsiveness is mediated by airway regulatory T cells. 
Am J Physiol Lung Cell Mol Physiol 2009, 296:L307-319. 
171. Runyon RS, Cachola LM, Rajeshuni N, Hunter T, Garcia M, Ahn R, Lurmann F, 
Krasnow R, Jack LM, Miller RL, et al.: Asthma discordance in twins is linked to 
epigenetic modifications of T cells. PLoS One 2012, 7:e48796. 
242 | P a g e  
 
172. Provoost S, Maes T, van Durme YM, Gevaert P, Bachert C, Schmidt-Weber CB, 
Brusselle GG, Joos GF, Tournoy KG: Decreased FOXP3 protein expression in patients 
with asthma. Allergy 2009, 64:1539-1546. 
173. Vale-Pereira S, Todo-Bom A, Geraldes L, Schmidt-Weber C, Akdis CA, Mota-
Pinto A: FoxP3, GATA-3 and T-bet expression in elderly asthma. Clin Exp Allergy 
2011, 41:490-496. 
174. Hartl D, Koller B, Mehlhorn AT, Reinhardt D, Nicolai T, Schendel DJ, Griese M, 
Krauss-Etschmann S: Quantitative and functional impairment of pulmonary 
CD4+CD25hi regulatory T cells in pediatric asthma. J Allergy Clin Immunol 2007, 
119:1258-1266. 
175. Nadeau K, McDonald-Hyman C, Noth EM, Pratt B, Hammond SK, Balmes J, 
Tager I: Ambient air pollution impairs regulatory T-cell function in asthma. J Allergy Clin 
Immunol 2010, 126:845-852 e810. 
176. Brunst KJ, Leung YK, Ryan PH, Khurana Hershey GK, Levin L, Ji H, Lemasters 
GK, Ho SM: Forkhead box protein 3 (FOXP3) hypermethylation is associated with 
diesel exhaust exposure and risk for childhood asthma. J Allergy Clin Immunol 2012. 
177. Krishnamoorthy N, Khare A, Oriss TB, Raundhal M, Morse C, Yarlagadda M, 
Wenzel SE, Moore ML, Peebles RS, Jr., Ray A, et al.: Early infection with respiratory 
syncytial virus impairs regulatory T cell function and increases susceptibility to allergic 
asthma. Nat Med 2012, 18:1525-1530. 
178. Mantel PY, Kuipers H, Boyman O, Rhyner C, Ouaked N, Ruckert B, Karagiannidis 
C, Lambrecht BN, Hendriks RW, Crameri R, et al.: GATA3-driven Th2 responses inhibit 
TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS 
Biol 2007, 5:e329. 
243 | P a g e  
 
179. Hadjur S, Bruno L, Hertweck A, Cobb BS, Taylor B, Fisher AG, Merkenschlager 
M: IL4 blockade of inducible regulatory T cell differentiation: the role of Th2 cells, Gata3 
and PU.1. Immunol Lett 2009, 122:37-43. 
180. Larche M, Akdis CA, Valenta R: Immunological mechanisms of allergen-specific 
immunotherapy. Nat Rev Immunol 2006, 6:761-771. 
181. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, 
Thunberg S, Deniz G, Valenta R, Fiebig H, et al.: Immune responses in healthy and 
allergic individuals are characterized by a fine balance between allergen-specific T 
regulatory 1 and T helper 2 cells. J Exp Med 2004, 199:1567-1575. 
182. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M: In vivo switch to 
IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008, 
205:2887-2898. 
183. Adcock IM, Barnes PJ: Molecular mechanisms of corticosteroid resistance. Chest 
2008, 134:394-401. 
184. Leung DY, Bloom JW: Update on glucocorticoid action and resistance. J Allergy 
Clin Immunol 2003, 111:3-22; quiz 23. 
185. Peek EJ, Richards DF, Faith A, Lavender P, Lee TH, Corrigan CJ, Hawrylowicz 
CM: Interleukin-10-secreting "regulatory" T cells induced by glucocorticoids and beta2-
agonists. Am J Respir Cell Mol Biol 2005, 33:105-111. 
186. Mozo L, Suarez A, Gutierrez C: Glucocorticoids up-regulate constitutive 
interleukin-10 production by human monocytes. Clin Exp Allergy 2004, 34:406-412. 
187. Richards DF, Fernandez M, Caulfield J, Hawrylowicz CM: Glucocorticoids drive 
human CD8(+) T cell differentiation towards a phenotype with high IL-10 and reduced 
IL-4, IL-5 and IL-13 production. Eur J Immunol 2000, 30:2344-2354. 
244 | P a g e  
 
188. Karagiannidis C, Akdis M, Holopainen P, Woolley NJ, Hense G, Ruckert B, Mantel 
PY, Menz G, Akdis CA, Blaser K, et al.: Glucocorticoids upregulate FOXP3 expression 
and regulatory T cells in asthma. J Allergy Clin Immunol 2004, 114:1425-1433. 
189. Chan MT, Leung DY, Szefler SJ, Spahn JD: Difficult-to-control asthma: clinical 
characteristics of steroid-insensitive asthma. J Allergy Clin Immunol 1998, 101:594-
601. 
190. Schacke H, Docke WD, Asadullah K: Mechanisms involved in the side effects of 
glucocorticoids. Pharmacol Ther 2002, 96:23-43. 
191. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron 
JR, Fahy JV: T-helper type 2-driven inflammation defines major subphenotypes of 
asthma. Am J Respir Crit Care Med 2009, 180:388-395. 
192. Barnes PJ: Scientific rationale for inhaled combination therapy with long-acting 
beta2-agonists and corticosteroids. Eur Respir J 2002, 19:182-191. 
193. Reiss TF, Sorkness CA, Stricker W, Botto A, Busse WW, Kundu S, Zhang J: 
Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, 
on bronchodilation in asthmatic subjects treated with and without inhaled 
corticosteroids. Thorax 1997, 52:45-48. 
194. De Lepeleire I, Reiss TF, Rochette F, Botto A, Zhang J, Kundu S, Decramer M: 
Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the 
airways of patients with asthma. Clin Pharmacol Ther 1997, 61:83-92. 
195. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, 
Chanez P: Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, 
double-blind, placebo-controlled trial. Lancet 2012, 380:651-659. 
245 | P a g e  
 
196. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, 
Fowler-Taylor A, Matthews J, Busse WW, et al.: Effects of treatment with anti-
immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am 
J Respir Crit Care Med 2004, 170:583-593. 
197. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlen SE, Holgate 
ST, Meyers DA, Rabe KF, Antczak A, et al.: A randomized, double-blind, placebo-
controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. 
Am J Respir Crit Care Med 2009, 179:549-558. 
198. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST: The role of 
a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory 
asthma: a double blind, randomised, placebo controlled trial. Thorax 2008, 63:584-591. 
199. Simon HU, Seelbach H, Ehmann R, Schmitz M: Clinical and immunological effects 
of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma. 
Allergy 2003, 58:1250-1255. 
200. Barnes PJ: Theophylline: new perspectives for an old drug. Am J Respir Crit Care 
Med 2003, 167:813-818. 
201. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB, Jr., 
Boushey HA: The effect of an anti-IgE monoclonal antibody on the early- and late-
phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care 
Med 1997, 155:1828-1834. 
202. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M: Effect of an interleukin-4 
variant on late phase asthmatic response to allergen challenge in asthmatic patients: 
results of two phase 2a studies. Lancet 2007, 370:1422-1431. 
203. von Mutius E: Gene-environment interactions in asthma. J Allergy Clin Immunol 
2009, 123:3-11; quiz 12-13. 
246 | P a g e  
 
204. Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, Torrey 
D, Pandit S, McKenny J, Braunschweiger K, et al.: Association of the ADAM33 gene 
with asthma and bronchial hyperresponsiveness. Nature 2002, 418:426-430. 
205. Hall IP, Blakey JD, Al Balushi KA, Wheatley A, Sayers I, Pembrey ME, Ring SM, 
McArdle WL, Strachan DP: Beta2-adrenoceptor polymorphisms and asthma from 
childhood to middle age in the British 1958 birth cohort: a genetic association study. 
Lancet 2006, 368:771-779. 
206. Lipworth B, Koppelman GH, Wheatley AP, Le Jeune I, Coutie W, Meurs H, 
Kauffman HF, Postma DS, Hall IP: Beta2 adrenoceptor promoter polymorphisms: 
extended haplotypes and functional effects in peripheral blood mononuclear cells. 
Thorax 2002, 57:61-66. 
207. Smit LA, Siroux V, Bouzigon E, Oryszczyn MP, Lathrop M, Demenais F, 
Kauffmann F, Epidemiological Study on the G, Environment of Asthma BH, Atopy 
Cooperative G: CD14 and toll-like receptor gene polymorphisms, country living, and 
asthma in adults. Am J Respir Crit Care Med 2009, 179:363-368. 
208. Sleiman PM, Flory J, Imielinski M, Bradfield JP, Annaiah K, Willis-Owen SA, 
Wang K, Rafaels NM, Michel S, Bonnelykke K, et al.: Variants of DENND1B associated 
with asthma in children. N Engl J Med 2010, 362:36-44. 
209. Wen HJ, Lin YC, Lee YL, Guo YL: Association between cord blood IgE and 
genetic polymorphisms of interleukin-4, the beta-subunit of the high-affinity receptor for 
IgE, lymphotoxin-alpha, and tumor necrosis factor-alpha. Pediatr Allergy Immunol 
2006, 17:489-494. 
210. Kim YK, Park HW, Yang JS, Oh SY, Chang YS, Shin ES, Lee JE, Kim S, Gho YS, 
Cho SH, et al.: Association and functional relevance of E237G, a polymorphism of the 
247 | P a g e  
 
high-affinity immunoglobulin E-receptor beta chain gene, to airway hyper-
responsiveness. Clin Exp Allergy 2007, 37:592-598. 
211. Zhao Y, Liu S, Liu Z, Ye Y, Mao M: Significant association between GSTT1 null 
genotype and risk of asthma during childhood in Caucasians. Mol Biol Rep 2013, 
40:1973-1978. 
212. Karam RA, Pasha HF, El-Shal AS, Rahman HM, Gad DM: Impact of glutathione-
S-transferase gene polymorphisms on enzyme activity, lung function and bronchial 
asthma susceptibility in Egyptian children. Gene 2012, 497:314-319. 
213. Fryer AA, Bianco A, Hepple M, Jones PW, Strange RC, Spiteri MA: Polymorphism 
at the glutathione S-transferase GSTP1 locus. A new marker for bronchial 
hyperresponsiveness and asthma. Am J Respir Crit Care Med 2000, 161:1437-1442. 
214. Li X, Howard TD, Zheng SL, Haselkorn T, Peters SP, Meyers DA, Bleecker ER: 
Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ 
regions. J Allergy Clin Immunol 2010, 125:328-335 e311. 
215. Ramasamy A, Kuokkanen M, Vedantam S, Gajdos ZK, Couto Alves A, Lyon HN, 
Ferreira MA, Strachan DP, Zhao JH, Abramson MJ, et al.: Genome-Wide Association 
Studies of Asthma in Population-Based Cohorts Confirm Known and Suggested Loci 
and Identify an Additional Association near HLA. PLoS One 2012, 7:e44008. 
216. Moffatt MF, Schou C, Faux JA, Abecasis GR, James A, Musk AW, Cookson WO: 
Association between quantitative traits underlying asthma and the HLA-DRB1 locus in 
a family-based population sample. Eur J Hum Genet 2001, 9:341-346. 
217. Dekker JW, Nizankowska E, Schmitz-Schumann M, Pile K, Bochenek G, Dyczek 
A, Cookson WO, Szczeklik A: Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 
genotypes. Clin Exp Allergy 1997, 27:574-577. 
248 | P a g e  
 
218. Noguchi E, Sakamoto H, Hirota T, Ochiai K, Imoto Y, Sakashita M, Kurosaka F, 
Akasawa A, Yoshihara S, Kanno N, et al.: Genome-wide association study identifies 
HLA-DP as a susceptibility gene for pediatric asthma in Asian populations. PLoS Genet 
2011, 7:e1002170. 
219. Wenzel SE, Balzar S, Ampleford E, Hawkins GA, Busse WW, Calhoun WJ, Castro 
M, Chung KF, Erzurum S, Gaston B, et al.: IL4R alpha mutations are associated with 
asthma exacerbations and mast cell/IgE expression. Am J Respir Crit Care Med 2007, 
175:570-576. 
220. Howard TD, Koppelman GH, Xu J, Zheng SL, Postma DS, Meyers DA, Bleecker 
ER: Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with 
asthma. Am J Hum Genet 2002, 70:230-236. 
221. Burchard EG, Silverman EK, Rosenwasser LJ, Borish L, Yandava C, Pillari A, 
Weiss ST, Hasday J, Lilly CM, Ford JG, et al.: Association between a sequence variant 
in the IL-4 gene promoter and FEV(1) in asthma. Am J Respir Crit Care Med 1999, 
160:919-922. 
222. Chatterjee R, Batra J, Kumar A, Mabalirajan U, Nahid S, Niphadkar PV, Ghosh B: 
Interleukin-10 promoter polymorphisms and atopic asthma in North Indians. Clin Exp 
Allergy 2005, 35:914-919. 
223. Karjalainen J, Hulkkonen J, Nieminen MM, Huhtala H, Aromaa A, Klaukka T, 
Hurme M: Interleukin-10 gene promoter region polymorphism is associated with 
eosinophil count and circulating immunoglobulin E in adult asthma. Clin Exp Allergy 
2003, 33:78-83. 
224. Lyon H, Lange C, Lake S, Silverman EK, Randolph AG, Kwiatkowski D, Raby BA, 
Lazarus R, Weiland KM, Laird N, et al.: IL10 gene polymorphisms are associated with 
asthma phenotypes in children. Genet Epidemiol 2004, 26:155-165. 
249 | P a g e  
 
225. Lim S, Crawley E, Woo P, Barnes PJ: Haplotype associated with low interleukin-
10 production in patients with severe asthma. Lancet 1998, 352:113. 
226. Hobbs K, Negri J, Klinnert M, Rosenwasser LJ, Borish L: Interleukin-10 and 
transforming growth factor-beta promoter polymorphisms in allergies and asthma. Am J 
Respir Crit Care Med 1998, 158:1958-1962. 
227. Ferreira MA, McRae AF, Medland SE, Nyholt DR, Gordon SD, Wright MJ, 
Henders AK, Madden PA, Visscher PM, Wray NR, et al.: Association between 
ORMDL3, IL1RL1 and a deletion on chromosome 17q21 with asthma risk in Australia. 
Eur J Hum Genet 2011, 19:458-464. 
228. Miller M, Tam AB, Cho JY, Doherty TA, Pham A, Khorram N, Rosenthal P, 
Mueller JL, Hoffman HM, Suzukawa M, et al.: ORMDL3 is an inducible lung epithelial 
gene regulating metalloproteases, chemokines, OAS, and ATF6. Proc Natl Acad Sci U 
S A 2012, 109:16648-16653. 
229. Galanter J, Choudhry S, Eng C, Nazario S, Rodriguez-Santana JR, Casal J, 
Torres-Palacios A, Salas J, Chapela R, Watson HG, et al.: ORMDL3 gene is 
associated with asthma in three ethnically diverse populations. Am J Respir Crit Care 
Med 2008, 177:1194-1200. 
230. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, Depner M, von 
Berg A, Bufe A, Rietschel E, et al.: Genetic variants regulating ORMDL3 expression 
contribute to the risk of childhood asthma. Nature 2007, 448:470-473. 
231. Oguma T, Palmer LJ, Birben E, Sonna LA, Asano K, Lilly CM: Role of prostanoid 
DP receptor variants in susceptibility to asthma. N Engl J Med 2004, 351:1752-1763. 
232. Himes BE, Hunninghake GM, Baurley JW, Rafaels NM, Sleiman P, Strachan DP, 
Wilk JB, Willis-Owen SA, Klanderman B, Lasky-Su J, et al.: Genome-wide association 
250 | P a g e  
 
analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet 2009, 
84:581-593. 
233. Gao PS, Mao XQ, Roberts MH, Arinobu Y, Akaiwa M, Enomoto T, Dake Y, Kawai 
M, Sasaki S, Hamasaki N, et al.: Variants of STAT6 (signal transducer and activator of 
transcription 6) in atopic asthma. J Med Genet 2000, 37:380-382. 
234. Duetsch G, Illig T, Loesgen S, Rohde K, Klopp N, Herbon N, Gohlke H, Altmueller 
J, Wjst M: STAT6 as an asthma candidate gene: polymorphism-screening, association 
and haplotype analysis in a Caucasian sib-pair study. Hum Mol Genet 2002, 11:613-
621. 
235. Zhang Y, Zhang J, Tian C, Xiao Y, He C, Li X, Bogati A, Huang J, Fan H: The -
308 G/A polymorphism in TNF-alpha gene is associated with asthma risk: an update by 
meta-analysis. J Clin Immunol 2011, 31:174-185. 
236. Vercelli D: Discovering susceptibility genes for asthma and allergy. Nat Rev 
Immunol 2008, 8:169-182. 
237. Battle NC, Choudhry S, Tsai HJ, Eng C, Kumar G, Beckman KB, Naqvi M, Meade 
K, Watson HG, Lenoir M, et al.: Ethnicity-specific gene-gene interaction between IL-13 
and IL-4Ralpha among African Americans with asthma. Am J Respir Crit Care Med 
2007, 175:881-887. 
238. Lind DL, Choudhry S, Ung N, Ziv E, Avila PC, Salari K, Ha C, Lovins EG, Coyle 
NE, Nazario S, et al.: ADAM33 is not associated with asthma in Puerto Rican or 
Mexican populations. Am J Respir Crit Care Med 2003, 168:1312-1316. 
239. Koeppen-Schomerus G, Stevenson J, Plomin R: Genes and environment in 
asthma: a study of 4 year old twins. Arch Dis Child 2001, 85:398-400. 
251 | P a g e  
 
240. Hopper JL, Hannah MC, Macaskill GT, Mathews JD: Twin concordance for a 
binary trait: III. A bivariate analysis of hay fever and asthma. Genet Epidemiol 1990, 
7:277-289. 
241. Fagnani C, Annesi-Maesano I, Brescianini S, D'Ippolito C, Medda E, Nistico L, 
Patriarca V, Rotondi D, Toccaceli V, Stazi MA: Heritability and shared genetic effects of 
asthma and hay fever: an Italian study of young twins. Twin Res Hum Genet 2008, 
11:121-131. 
242. Strachan DP: Hay fever, hygiene, and household size. BMJ 1989, 299:1259-1260. 
243. Okada H, Kuhn C, Feillet H, Bach JF: The 'hygiene hypothesis' for autoimmune 
and allergic diseases: an update. Clin Exp Immunol 2010, 160:1-9. 
244. Matricardi PM, Rosmini F, Panetta V, Ferrigno L, Bonini S: Hay fever and asthma 
in relation to markers of infection in the United States. J Allergy Clin Immunol 2002, 
110:381-387. 
245. Matricardi PM, Rosmini F, Ferrigno L, Nisini R, Rapicetta M, Chionne P, Stroffolini 
T, Pasquini P, D'Amelio R: Cross sectional retrospective study of prevalence of atopy 
among Italian military students with antibodies against hepatitis A virus. BMJ 1997, 
314:999-1003. 
246. Linneberg A, Ostergaard C, Tvede M, Andersen LP, Nielsen NH, Madsen F, 
Frolund L, Dirksen A, Jorgensen T: IgG antibodies against microorganisms and atopic 
disease in Danish adults: the Copenhagen Allergy Study. J Allergy Clin Immunol 2003, 
111:847-853. 
247. Janson C, Asbjornsdottir H, Birgisdottir A, Sigurjonsdottir RB, Gunnbjornsdottir M, 
Gislason D, Olafsson I, Cook E, Jogi R, Gislason T, et al.: The effect of infectious 
burden on the prevalence of atopy and respiratory allergies in Iceland, Estonia, and 
Sweden. J Allergy Clin Immunol 2007, 120:673-679. 
252 | P a g e  
 
248. Downs SH, Marks GB, Mitakakis TZ, Leuppi JD, Car NG, Peat JK: Having lived on 
a farm and protection against allergic diseases in Australia. Clin Exp Allergy 2001, 
31:570-575. 
249. Riedler J, Braun-Fahrlander C, Eder W, Schreuer M, Waser M, Maisch S, Carr D, 
Schierl R, Nowak D, von Mutius E, et al.: Exposure to farming in early life and 
development of asthma and allergy: a cross-sectional survey. Lancet 2001, 358:1129-
1133. 
250. Radon K, Windstetter D, Eckart J, Dressel H, Leitritz L, Reichert J, Schmid M, 
Praml G, Schosser M, von Mutius E, et al.: Farming exposure in childhood, exposure to 
markers of infections and the development of atopy in rural subjects. Clin Exp Allergy 
2004, 34:1178-1183. 
251. Jarvis D, Luczynska C, Chinn S, Burney P: The association of hepatitis A and 
Helicobacter pylori with sensitization to common allergens, asthma and hay fever in a 
population of young British adults. Allergy 2004, 59:1063-1067. 
252. Bodner C, Anderson WJ, Reid TS, Godden DJ: Childhood exposure to infection 
and risk of adult onset wheeze and atopy. Thorax 2000, 55:383-387. 
253. McLoughlin RM, Mills KH: Influence of gastrointestinal commensal bacteria on the 
immune responses that mediate allergy and asthma. J Allergy Clin Immunol 2011, 
127:1097-1107; quiz 1108-1099. 
254. Wold AE: The hygiene hypothesis revised: is the rising frequency of allergy due to 
changes in the intestinal flora? Allergy 1998, 53:20-25. 
255. Prescott SL, Macaubas C, Holt BJ, Smallacombe TB, Loh R, Sly PD, Holt PG: 
Transplacental priming of the human immune system to environmental allergens: 
universal skewing of initial T cell responses toward the Th2 cytokine profile. J Immunol 
1998, 160:4730-4737. 
253 | P a g e  
 
256. Bowman LM, Holt PG: Selective enhancement of systemic Th1 immunity in 
immunologically immature rats with an orally administered bacterial extract. Infect 
Immun 2001, 69:3719-3727. 
257. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL: An immunomodulatory 
molecule of symbiotic bacteria directs maturation of the host immune system. Cell 
2005, 122:107-118. 
258. Russell SL, Gold MJ, Hartmann M, Willing BP, Thorson L, Wlodarska M, Gill N, 
Blanchet MR, Mohn WW, McNagny KM, et al.: Early life antibiotic-driven changes in 
microbiota enhance susceptibility to allergic asthma. EMBO Rep 2012, 13:440-447. 
259. Eggleston PA, Buckley TJ, Breysse PN, Wills-Karp M, Kleeberger SR, Jaakkola 
JJ: The environment and asthma in U.S. inner cities. Environ Health Perspect 1999, 
107 Suppl 3:439-450. 
260. Schwartz J, Slater D, Larson TV, Pierson WE, Koenig JQ: Particulate air pollution 
and hospital emergency room visits for asthma in Seattle. Am Rev Respir Dis 1993, 
147:826-831. 
261. Knox RB, Suphioglu C, Taylor P, Desai R, Watson HC, Peng JL, Bursill LA: Major 
grass pollen allergen Lol p 1 binds to diesel exhaust particles: implications for asthma 
and air pollution. Clin Exp Allergy 1997, 27:246-251. 
262. Kelly F, Armstrong B, Atkinson R, Anderson HR, Barratt B, Beevers S, Cook D, 
Green D, Derwent D, Mudway I, et al.: The London low emission zone baseline study. 
Res Rep Health Eff Inst 2011:3-79. 
263. Kelly F, Anderson HR, Armstrong B, Atkinson R, Barratt B, Beevers S, Derwent D, 
Green D, Mudway I, Wilkinson P: The impact of the congestion charging scheme on air 
quality in London. Part 2. Analysis of the oxidative potential of particulate matter. Res 
Rep Health Eff Inst 2011:73-144. 
254 | P a g e  
 
264. Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, 
Printz MC, Lee WM, Shult PA, Reisdorf E, et al.: Wheezing rhinovirus illnesses in early 
life predict asthma development in high-risk children. Am J Respir Crit Care Med 2008, 
178:667-672. 
265. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, 
Kjellman B: Severe respiratory syncytial virus bronchiolitis in infancy and asthma and 
allergy at age 13. Am J Respir Crit Care Med 2005, 171:137-141. 
266. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B: Respiratory syncytial virus 
bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J 
Respir Crit Care Med 2000, 161:1501-1507. 
267. Wu P, Dupont WD, Griffin MR, Carroll KN, Mitchel EF, Gebretsadik T, Hartert TV: 
Evidence of a causal role of winter virus infection during infancy in early childhood 
asthma. Am J Respir Crit Care Med 2008, 178:1123-1129. 
268. Holick MF: Vitamin D: A millenium perspective. J Cell Biochem 2003, 88:296-307. 
269. Holick MF: Vitamin D deficiency. N Engl J Med 2007, 357:266-281. 
270. Ashwell M, Stone EM, Stolte H, Cashman KD, Macdonald H, Lanham-New S, 
Hiom S, Webb A, Fraser D: UK Food Standards Agency Workshop Report: an 
investigation of the relative contributions of diet and sunlight to vitamin D status. Br J 
Nutr 2010, 104:603-611. 
271. Hansdottir S, Monick MM, Lovan N, Powers L, Gerke A, Hunninghake GW: 
Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked 
chemokines and cytokines in airway epithelium while maintaining the antiviral state. J 
Immunol 2010, 184:965-974. 
255 | P a g e  
 
272. Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, Butcher EC: 
DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the 
epidermal chemokine CCL27. Nat Immunol 2007, 8:285-293. 
273. Fritsche J, Mondal K, Ehrnsperger A, Andreesen R, Kreutz M: Regulation of 25-
hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin 
D3 by human dendritic cells. Blood 2003, 102:3314-3316. 
274. Hewison M, Freeman L, Hughes SV, Evans KN, Bland R, Eliopoulos AG, Kilby 
MD, Moss PA, Chakraverty R: Differential regulation of vitamin D receptor and its 
ligand in human monocyte-derived dendritic cells. J Immunol 2003, 170:5382-5390. 
275. van Etten E, Mathieu C: Immunoregulation by 1,25-dihydroxyvitamin D3: basic 
concepts. J Steroid Biochem Mol Biol 2005, 97:93-101. 
276. Nagpal S, Na S, Rathnachalam R: Noncalcemic actions of vitamin D receptor 
ligands. Endocr Rev 2005, 26:662-687. 
277. Mora JR, Iwata M, von Andrian UH: Vitamin effects on the immune system: 
vitamins A and D take centre stage. Nat Rev Immunol 2008, 8:685-698. 
278. Devereux G, Macdonald H, Hawrylowicz C: Vitamin D and asthma: time for 
intervention? Am J Respir Crit Care Med 2009, 179:739-740. 
279. Hypponen E, Power C: Hypovitaminosis D in British adults at age 45 y: nationwide 
cohort study of dietary and lifestyle predictors. Am J Clin Nutr 2007, 85:860-868. 
280. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, 
Streeten EA, Ohlsson C, Koller DL, et al.: Common genetic determinants of vitamin D 
insufficiency: a genome-wide association study. Lancet 2010, 376:180-188. 
256 | P a g e  
 
281. Giovannucci E, Liu Y, Hollis BW, Rimm EB: 25-hydroxyvitamin D and risk of 
myocardial infarction in men: a prospective study. Arch Intern Med 2008, 168:1174-
1180. 
282. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED: 
Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 
1989, 2:1176-1178. 
283. Martinez ME, Giovannucci EL, Colditz GA, Stampfer MJ, Hunter DJ, Speizer FE, 
Wing A, Willett WC: Calcium, vitamin D, and the occurrence of colorectal cancer 
among women. J Natl Cancer Inst 1996, 88:1375-1382. 
284. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, Fuchs CS: 
Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J 
Clin Oncol 2008, 26:2984-2991. 
285. John EM, Schwartz GG, Dreon DM, Koo J: Vitamin D and breast cancer risk: the 
NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and 
Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 1999, 8:399-406. 
286. Gupta D, Lammersfeld CA, Trukova K, Lis CG: Vitamin D and prostate cancer 
risk: a review of the epidemiological literature. Prostate Cancer Prostatic Dis 2009, 
12:215-226. 
287. Chiu KC, Chu A, Go VL, Saad MF: Hypovitaminosis D is associated with insulin 
resistance and beta cell dysfunction. Am J Clin Nutr 2004, 79:820-825. 
288. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM: Intake of vitamin D 
and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358:1500-1503. 
289. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A: Serum 25-
hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838. 
257 | P a g e  
 
290. Mowry EM, Krupp LB, Milazzo M, Chabas D, Strober JB, Belman AL, McDonald 
JC, Oksenberg JR, Bacchetti P, Waubant E: Vitamin D status is associated with 
relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010, 67:618-624. 
291. Boraska V, Skrabic V, Zeggini E, Groves CJ, Buljubasic M, Peruzovic M, Zemunik 
T: Family-based analysis of vitamin D receptor gene polymorphisms and type 1 
diabetes in the population of South Croatia. J Hum Genet 2008, 53:210-214. 
292. Zemunik T, Skrabic V, Boraska V, Diklic D, Terzic IM, Capkun V, Peruzovic M, 
Terzic J: FokI polymorphism, vitamin D receptor, and interleukin-1 receptor haplotypes 
are associated with type 1 diabetes in the Dalmatian population. J Mol Diagn 2005, 
7:600-604. 
293. Poon AH, Laprise C, Lemire M, Montpetit A, Sinnett D, Schurr E, Hudson TJ: 
Association of vitamin D receptor genetic variants with susceptibility to asthma and 
atopy. Am J Respir Crit Care Med 2004, 170:967-973. 
294. Ramagopalan SV, Dyment DA, Cader MZ, Morrison KM, Disanto G, Morahan JM, 
Berlanga-Taylor AJ, Handel A, De Luca GC, Sadovnick AD, et al.: Rare variants in the 
CYP27B1 gene are associated with multiple sclerosis. Ann Neurol 2011, 70:881-886. 
295. Sundqvist E, Baarnhielm M, Alfredsson L, Hillert J, Olsson T, Kockum I: 
Confirmation of association between multiple sclerosis and CYP27B1. Eur J Hum 
Genet 2010, 18:1349-1352. 
296. Black PN, Scragg R: Relationship between serum 25-hydroxyvitamin d and 
pulmonary function in the third national health and nutrition examination survey. Chest 
2005, 128:3792-3798. 
297. Williams B, Williams AJ, Anderson ST: Vitamin D deficiency and insufficiency in 
children with tuberculosis. Pediatr Infect Dis J 2008, 27:941-942. 
258 | P a g e  
 
298. Wejse C, Olesen R, Rabna P, Kaestel P, Gustafson P, Aaby P, Andersen PL, 
Glerup H, Sodemann M: Serum 25-hydroxyvitamin D in a West African population of 
tuberculosis patients and unmatched healthy controls. Am J Clin Nutr 2007, 86:1376-
1383. 
299. Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, Garland CF, 
Giovannucci E: Epidemic influenza and vitamin D. Epidemiol Infect 2006, 134:1129-
1140. 
300. Laaksi I, Ruohola JP, Mattila V, Auvinen A, Ylikomi T, Pihlajamaki H: Vitamin D 
supplementation for the prevention of acute respiratory tract infection: a randomized, 
double-blinded trial among young Finnish men. J Infect Dis 2010, 202:809-814. 
301. Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buysschaert I, 
Coolen J, Mathieu C, Decramer M, Lambrechts D: Vitamin D deficiency is highly 
prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax 
2010, 65:215-220. 
302. Brehm JM, Celedon JC, Soto-Quiros ME, Avila L, Hunninghake GM, Forno E, 
Laskey D, Sylvia JS, Hollis BW, Weiss ST, et al.: Serum vitamin D levels and markers 
of severity of childhood asthma in Costa Rica. Am J Respir Crit Care Med 2009, 
179:765-771. 
303. Camargo CA, Jr., Rifas-Shiman SL, Litonjua AA, Rich-Edwards JW, Weiss ST, 
Gold DR, Kleinman K, Gillman MW: Maternal intake of vitamin D during pregnancy and 
risk of recurrent wheeze in children at 3 y of age. Am J Clin Nutr 2007, 85:788-795. 
304. Devereux G, Litonjua AA, Turner SW, Craig LC, McNeill G, Martindale S, Helms 
PJ, Seaton A, Weiss ST: Maternal vitamin D intake during pregnancy and early 
childhood wheezing. Am J Clin Nutr 2007, 85:853-859. 
259 | P a g e  
 
305. Sutherland ER, Goleva E, Jackson LP, Stevens AD, Leung DY: Vitamin D levels, 
lung function, and steroid response in adult asthma. Am J Respir Crit Care Med 2010, 
181:699-704. 
306. Bener A, Ehlayel MS, Tulic MK, Hamid Q: Vitamin D deficiency as a strong 
predictor of asthma in children. Int Arch Allergy Immunol 2012, 157:168-175. 
307. Brehm JM, Schuemann B, Fuhlbrigge AL, Hollis BW, Strunk RC, Zeiger RS, 
Weiss ST, Litonjua AA: Serum vitamin D levels and severe asthma exacerbations in 
the Childhood Asthma Management Program study. J Allergy Clin Immunol 2010, 
126:52-58 e55. 
308. Raby BA, Lazarus R, Silverman EK, Lake S, Lange C, Wjst M, Weiss ST: 
Association of vitamin D receptor gene polymorphisms with childhood and adult 
asthma. Am J Respir Crit Care Med 2004, 170:1057-1065. 
309. Michel S, Liang L, Depner M, Klopp N, Ruether A, Kumar A, Schedel M, 
Vogelberg C, von Mutius E, von Berg A, et al.: Unifying candidate gene and GWAS 
Approaches in Asthma. PLoS One 2010, 5:e13894. 
310. Chun RF, Lauridsen AL, Suon L, Zella LA, Pike JW, Modlin RL, Martineau AR, 
Wilkinson RJ, Adams J, Hewison M: Vitamin D-binding protein directs monocyte 
responses to 25-hydroxy- and 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab 2010, 
95:3368-3376. 
311. Gupta A, Dimeloe S, Richards DF, Bush A, Saglani S, Hawrylowicz CM: Vitamin D 
binding protein and asthma severity in children. J Allergy Clin Immunol 2012, 
129:1669-1671. 
312. Chambers ES, Nanzer AM, Richards DF, Ryanna K, Freeman AT, Timms PM, 
Martineau AR, Griffiths CJ, Corrigan CJ, Hawrylowicz CM: Serum 25-dihydroxyvitamin 
260 | P a g e  
 
D levels correlate with CD4(+)Foxp3(+) T-cell numbers in moderate/severe asthma. J 
Allergy Clin Immunol 2012, 130:542-544. 
313. Dimeloe S, Nanzer A, Ryanna K, Hawrylowicz C: Regulatory T cells, inflammation 
and the allergic response-The role of glucocorticoids and Vitamin D. J Steroid Biochem 
Mol Biol 2010, 120:86-95. 
314. Chambers ES, Hawrylowicz CM: The impact of vitamin D on regulatory T cells. 
Curr Allergy Asthma Rep 2011, 11:29-36. 
315. Liu PT, Stenger S, Tang DH, Modlin RL: Cutting edge: vitamin D-mediated human 
antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction 
of cathelicidin. J Immunol 2007, 179:2060-2063. 
316. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, 
Wu K, Meinken C, et al.: Toll-like receptor triggering of a vitamin D-mediated human 
antimicrobial response. Science 2006, 311:1770-1773. 
317. Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, Skolimowska K, 
Davidson RN, Sorensen OE, Kampmann B, Griffiths CJ, et al.: IFN-gamma- and TNF-
independent vitamin D-inducible human suppression of mycobacteria: the role of 
cathelicidin LL-37. J Immunol 2007, 178:7190-7198. 
318. Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, Lee ZW, Lee SH, Kim JM, 
Jo EK: Vitamin D3 induces autophagy in human monocytes/macrophages via 
cathelicidin. Cell Host Microbe 2009, 6:231-243. 
319. Shin DM, Yuk JM, Lee HM, Lee SH, Son JW, Harding CV, Kim JM, Modlin RL, Jo 
EK: Mycobacterial lipoprotein activates autophagy via TLR2/1/CD14 and a functional 
vitamin D receptor signalling. Cell Microbiol 2010, 12:1648-1665. 
261 | P a g e  
 
320. Wang TT, Dabbas B, Laperriere D, Bitton AJ, Soualhine H, Tavera-Mendoza LE, 
Dionne S, Servant MJ, Bitton A, Seidman EG, et al.: Direct and indirect induction by 
1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune 
pathway defective in Crohn disease. J Biol Chem 2010, 285:2227-2231. 
321. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, Tavera-Mendoza L, 
Lin R, Hanrahan JW, Mader S, et al.: Cutting edge: 1,25-dihydroxyvitamin D3 is a 
direct inducer of antimicrobial peptide gene expression. J Immunol 2004, 173:2909-
2912. 
322. Coussens A, Timms PM, Boucher BJ, Venton TR, Ashcroft AT, Skolimowska KH, 
Newton SM, Wilkinson KA, Davidson RN, Griffiths CJ, et al.: 1alpha,25-
dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium 
tuberculosis infection. Immunology 2009, 127:539-548. 
323. Yu XP, Bellido T, Manolagas SC: Down-regulation of NF-kappa B protein levels in 
activated human lymphocytes by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 
1995, 92:10990-10994. 
324. Mahon BD, Wittke A, Weaver V, Cantorna MT: The targets of vitamin D depend 
on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 
2003, 89:922-932. 
325. Alroy I, Towers TL, Freedman LP: Transcriptional repression of the interleukin-2 
gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear 
hormone receptor. Mol Cell Biol 1995, 15:5789-5799. 
326. Reichel H, Koeffler HP, Tobler A, Norman AW: 1 alpha,25-Dihydroxyvitamin D3 
inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. 
Proc Natl Acad Sci U S A 1987, 84:3385-3389. 
262 | P a g e  
 
327. Staeva-Vieira TP, Freedman LP: 1,25-dihydroxyvitamin D3 inhibits IFN-gamma 
and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. J Immunol 
2002, 168:1181-1189. 
328. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A: 1alpha,25-
Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the 
development of Th2 cells. J Immunol 2001, 167:4974-4980. 
329. Pichler J, Gerstmayr M, Szepfalusi Z, Urbanek R, Peterlik M, Willheim M: 1 
alpha,25(OH)2D3 inhibits not only Th1 but also Th2 differentiation in human cord blood 
T cells. Pediatr Res 2002, 52:12-18. 
330. Hypponen E, Berry DJ, Wjst M, Power C: Serum 25-hydroxyvitamin D and IgE - a 
significant but nonlinear relationship. Allergy 2009, 64:613-620. 
331. Tang J, Zhou R, Luger D, Zhu W, Silver PB, Grajewski RS, Su SB, Chan CC, 
Adorini L, Caspi RR: Calcitriol suppresses antiretinal autoimmunity through inhibitory 
effects on the Th17 effector response. J Immunol 2009, 182:4624-4632. 
332. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM: Immune modulatory 
treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a 
change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol 
Exp Ther 2008, 324:23-33. 
333. Palmer MT, Lee YK, Maynard CL, Oliver JR, Bikle DD, Jetten AM, Weaver CT: 
Lineage-specific effects of 1,25-dihydroxyvitamin D(3) on the development of effector 
CD4 T cells. J Biol Chem 2011, 286:997-1004. 
334. Penna G, Roncari A, Amuchastegui S, Daniel KC, Berti E, Colonna M, Adorini L: 
Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction 
of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 2005, 106:3490-
3497. 
263 | P a g e  
 
335. Sochorova K, Budinsky V, Rozkova D, Tobiasova Z, Dusilova-Sulkova S, Spisek 
R, Bartunkova J: Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-
dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and 
inhibit induction of antigen-specific T cells. Clin Immunol 2009, 133:69-77. 
336. Canning MO, Grotenhuis K, de Wit H, Ruwhof C, Drexhage HA: 1-alpha,25-
Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active 
immature dendritic cells from monocytes. Eur J Endocrinol 2001, 145:351-357. 
337. Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, Sozzani S, 
Adorini L: 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in 
myeloid but not plasmacytoid dendritic cells. J Immunol 2007, 178:145-153. 
338. Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO: Induction of Treg 
by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role 
for PD-L1. Eur J Immunol 2009, 39:3147-3159. 
339. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L: 
Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate 
mofetil treatment mediate transplantation tolerance. J Immunol 2001, 167:1945-1953. 
340. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L: A 1alpha,25-
dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune 
diabetes in NOD mice. Diabetes 2002, 51:1367-1374. 
341. Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, Hewison M, Walker LS, 
Lammas DA, Raza K, Sansom DM: 1,25-Dihydroxyvitamin D3 and IL-2 combine to 
inhibit T cell production of inflammatory cytokines and promote development of 
regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009, 183:5458-5467. 
342. Urry Z, Chambers ES, Xystrakis E, Dimeloe S, Richards DF, Gabrysova L, 
Christensen J, Gupta A, Saglani S, Bush A, et al.: The role of 1alpha,25-
264 | P a g e  
 
dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3(+) and IL-10(+) 
CD4(+) T cells. Eur J Immunol 2012, 42:2697-2708. 
343. Kang SW, Kim SH, Lee N, Lee WW, Hwang KA, Shin MS, Lee SH, Kim WU, Kang 
I: 1,25-Dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D 
response elements in its conserved noncoding sequence region. J Immunol 2012, 
188:5276-5282. 
344. Kreindler JL, Steele C, Nguyen N, Chan YR, Pilewski JM, Alcorn JF, Vyas YM, 
Aujla SJ, Finelli P, Blanchard M, et al.: Vitamin D3 attenuates Th2 responses to 
Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with 
allergic bronchopulmonary aspergillosis. J Clin Invest 2010, 120:3242-3254. 
345. Taher YA, van Esch BC, Hofman GA, Henricks PA, van Oosterhout AJ: 
1alpha,25-dihydroxyvitamin D3 potentiates the beneficial effects of allergen 
immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF-beta. J 
Immunol 2008, 180:5211-5221. 
346. Urry Z, E Xystrakis, D F Richards, J McDonald, Z Satter, D J Cousins, C J 
Corrigan, E Hickman, Z Brown, Hawrylowicz CM: Ligation of TLR9 induced on human 
IL-10-secreting Tregs by 1α,25-dihyrdoxyvitamin D3 abrogates regulatory function. The 
journal of Clinical Investigation 2009, 119:387-398. 
347. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, de Waal-
Malefyt R, Coffman RL, Hawrylowicz CM, O'Garra A: In vitro generation of interleukin 
10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and 
inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002, 
195:603-616. 
265 | P a g e  
 
348. Sutmuller RP, Morgan ME, Netea MG, Grauer O, Adema GJ: Toll-like receptors 
on regulatory T cells: expanding immune regulation. Trends Immunol 2006, 27:387-
393. 
349. Hawrylowicz C, Richards D, Loke TK, Corrigan C, Lee T: A defect in 
corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid-resistant 
asthmatic patients. J Allergy Clin Immunol 2002, 109:369-370. 
350. Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, Adikibi T, 
Pridgeon C, Dallman M, Loke TK, et al.: Reversing the defective induction of IL-10-
secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 
2006, 116:146-155. 
351. Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, 
Bleecker ER, Brightling CE, Burney P, Bush A, Busse WW, et al.: Uniform definition of 
asthma severity, control, and exacerbations: document presented for the World Health 
Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010, 126:926-
938. 
352. Schwartz HJ, Lowell FC, Melby JC: Steroid resistance in bronchial asthma. Ann 
Intern Med 1968, 69:493-499. 
353. Ito K, Chung KF, Adcock IM: Update on glucocorticoid action and resistance. J 
Allergy Clin Immunol 2006, 117:522-543. 
354. Cosio BG, Mann B, Ito K, Jazrawi E, Barnes PJ, Chung KF, Adcock IM: Histone 
acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in 
asthma. Am J Respir Crit Care Med 2004, 170:141-147. 
355. Hew M, Bhavsar P, Torrego A, Meah S, Khorasani N, Barnes PJ, Adcock I, Chung 
KF: Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe 
asthma. Am J Respir Crit Care Med 2006, 174:134-141. 
266 | P a g e  
 
356. Li LB, Leung DY, Martin RJ, Goleva E: Inhibition of histone deacetylase 2 
expression by elevated glucocorticoid receptor beta in steroid-resistant asthma. Am J 
Respir Crit Care Med 2010, 182:877-883. 
357. Hurley DM, Accili D, Stratakis CA, Karl M, Vamvakopoulos N, Rorer E, 
Constantine K, Taylor SI, Chrousos GP: Point mutation causing a single amino acid 
substitution in the hormone binding domain of the glucocorticoid receptor in familial 
glucocorticoid resistance. J Clin Invest 1991, 87:680-686. 
358. Karl M, Lamberts SW, Detera-Wadleigh SD, Encio IJ, Stratakis CA, Hurley DM, 
Accili D, Chrousos GP: Familial glucocorticoid resistance caused by a splice site 
deletion in the human glucocorticoid receptor gene. J Clin Endocrinol Metab 1993, 
76:683-689. 
359. Vottero A, Kino T, Combe H, Lecomte P, Chrousos GP: A novel, C-terminal 
dominant negative mutation of the GR causes familial glucocorticoid resistance through 
abnormal interactions with p160 steroid receptor coactivators. J Clin Endocrinol Metab 
2002, 87:2658-2667. 
360. Hamid QA, Wenzel SE, Hauk PJ, Tsicopoulos A, Wallaert B, Lafitte JJ, Chrousos 
GP, Szefler SJ, Leung DY: Increased glucocorticoid receptor beta in airway cells of 
glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 1999, 159:1600-1604. 
361. Sousa AR, Lane SJ, Cidlowski JA, Staynov DZ, Lee TH: Glucocorticoid resistance 
in asthma is associated with elevated in vivo expression of the glucocorticoid receptor 
beta-isoform. J Allergy Clin Immunol 2000, 105:943-950. 
362. Rogatsky I, Logan SK, Garabedian MJ: Antagonism of glucocorticoid receptor 
transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci U S A 
1998, 95:2050-2055. 
267 | P a g e  
 
363. Lane SJ, Adcock IM, Richards D, Hawrylowicz C, Barnes PJ, Lee TH: 
Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression 
in monocytes and T lymphocytes. J Clin Invest 1998, 102:2156-2164. 
364. Takahashi E, Onda K, Hirano T, Oka K, Maruoka N, Tsuyuguchi M, Matsumura Y, 
Niitsuma T, Hayashi T: Expression of c-fos, rather than c-jun or glucocorticoid-receptor 
mRNA, correlates with decreased glucocorticoid response of peripheral blood 
mononuclear cells in asthma. Int Immunopharmacol 2002, 2:1419-1427. 
365. Leung DY, Martin RJ, Szefler SJ, Sher ER, Ying S, Kay AB, Hamid Q: 
Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in 
steroid-resistant asthma. J Exp Med 1995, 181:33-40. 
366. Naseer T, Minshall EM, Leung DY, Laberge S, Ernst P, Martin RJ, Hamid Q: 
Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to 
steroid therapy. Am J Respir Crit Care Med 1997, 155:845-851. 
367. Goleva E, Li LB, Leung DY: IFN-gamma reverses IL-2- and IL-4-mediated T-cell 
steroid resistance. Am J Respir Cell Mol Biol 2009, 40:223-230. 
368. Sher ER, Leung DY, Surs W, Kam JC, Zieg G, Kamada AK, Szefler SJ: Steroid-
resistant asthma. Cellular mechanisms contributing to inadequate response to 
glucocorticoid therapy. J Clin Invest 1994, 93:33-39. 
369. Goleva E, Hauk PJ, Boguniewicz J, Martin RJ, Leung DY: Airway remodeling and 
lack of bronchodilator response in steroid-resistant asthma. J Allergy Clin Immunol 
2007, 120:1065-1072. 
370. Agache I, Ciobanu C, Agache C, Anghel M: Increased serum IL-17 is an 
independent risk factor for severe asthma. Respir Med 2010, 104:1131-1137. 
268 | P a g e  
 
371. Al-Ramli W, Prefontaine D, Chouiali F, Martin JG, Olivenstein R, Lemiere C, 
Hamid Q: T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy 
Clin Immunol 2009, 123:1185-1187. 
372. Goleva E, Searing DA, Jackson LP, Richers BN, Leung DY: Steroid requirements 
and immune associations with vitamin D are stronger in children than adults with 
asthma. J Allergy Clin Immunol 2012, 129:1243-1251. 
373. Gupta A, Sjoukes A, Richards D, Banya W, Hawrylowicz C, Bush A, Saglani S: 
Relationship between serum vitamin D, disease severity, and airway remodeling in 
children with asthma. Am J Respir Crit Care Med 2011, 184:1342-1349. 
374. Cella M, Dohring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A, 
Colonna M: A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, 
and dendritic cells involved in antigen processing. J Exp Med 1997, 185:1743-1751. 
375. Bouaziz JD, Calbo S, Maho-Vaillant M, Saussine A, Bagot M, Bensussan A, 
Musette P: IL-10 produced by activated human B cells regulates CD4(+) T-cell 
activation in vitro. Eur J Immunol 2010, 40:2686-2691. 
376. Navarro J, Aristimuno C, Sanchez-Ramon S, Vigil D, Martinez-Gines ML, 
Fernandez-Cruz E, de Andres C: Circulating dendritic cells subsets and regulatory T-
cells at multiple sclerosis relapse: differential short-term changes on corticosteroids 
therapy. J Neuroimmunol 2006, 176:153-161. 
377. Sbiera S, Dexneit T, Reichardt SD, Michel KD, van den Brandt J, Schmull S, 
Kraus L, Beyer M, Mlynski R, Wortmann S, et al.: Influence of short-term glucocorticoid 
therapy on regulatory T cells in vivo. PLoS One 2011, 6:e24345. 
378. Serra-Bonett N, Al Snih S, Rodriguez MA: Effect of low-dose prednisone on 
leukocyte counts and subpopulations in patients with rheumatoid arthritis. J Clin 
Rheumatol 2009, 15:148-149. 
269 | P a g e  
 
379. Shoenfeld Y, Gurewich Y, Gallant LA, Pinkhas J: Prednisone-induced 
leukocytosis. Influence of dosage, method and duration of administration on the degree 
of leukocytosis. Am J Med 1981, 71:773-778. 
380. Matta BM, Castellaneta A, Thomson AW: Tolerogenic plasmacytoid DC. Eur J 
Immunol 2010, 40:2667-2676. 
381. Goubier A, Dubois B, Gheit H, Joubert G, Villard-Truc F, Asselin-Paturel C, 
Trinchieri G, Kaiserlian D: Plasmacytoid dendritic cells mediate oral tolerance. 
Immunity 2008, 29:464-475. 
382. Ochando JC, Homma C, Yang Y, Hidalgo A, Garin A, Tacke F, Angeli V, Li Y, 
Boros P, Ding Y, et al.: Alloantigen-presenting plasmacytoid dendritic cells mediate 
tolerance to vascularized grafts. Nat Immunol 2006, 7:652-662. 
383. Krystyna MS, Jacek T, Sebastian R, Ewa B, Halina BP, Zbigniew S, Jacek R: 
Changes in circulating dendritic cells and B-cells in patients with multiple sclerosis 
relapse during corticosteroid therapy. J Neuroimmunol 2009, 207:107-110. 
384. Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, Chan JH, Wright T, 
Punaro M, Bolland S, et al.: TLR recognition of self nucleic acids hampers 
glucocorticoid activity in lupus. Nature 2010, 465:937-941. 
385. Piemonti L, Monti P, Allavena P, Sironi M, Soldini L, Leone BE, Socci C, Di Carlo 
V: Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 
1999, 162:6473-6481. 
386. Woltman AM, de Fijter JW, Kamerling SW, Paul LC, Daha MR, van Kooten C: The 
effect of calcineurin inhibitors and corticosteroids on the differentiation of human 
dendritic cells. Eur J Immunol 2000, 30:1807-1812. 
270 | P a g e  
 
387. Ling Y, Cao X, Yu Z, Ruan C: Circulating dendritic cells subsets and CD4+Foxp3+ 
regulatory T cells in adult patients with chronic ITP before and after treatment with 
high-dose dexamethasome. Eur J Haematol 2007, 79:310-316. 
388. Braitch M, Harikrishnan S, Robins RA, Nichols C, Fahey AJ, Showe L, 
Constantinescu CS: Glucocorticoids increase CD4CD25 cell percentage and Foxp3 
expression in patients with multiple sclerosis. Acta Neurol Scand 2009, 119:239-245. 
389. Chen X, Murakami T, Oppenheim JJ, Howard OM: Differential response of murine 
CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death. Eur J 
Immunol 2004, 34:859-869. 
390. Chen X, Oppenheim JJ, Winkler-Pickett RT, Ortaldo JR, Howard OM: 
Glucocorticoid amplifies IL-2-dependent expansion of functional 
FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to 
suppress EAE. Eur J Immunol 2006, 36:2139-2149. 
391. Majak P, Rychlik B, Stelmach I: The effect of oral steroids with and without vitamin 
D3 on early efficacy of immunotherapy in asthmatic children. Clin Exp Allergy 2009, 
39:1830-1841. 
392. Berry DJ, Hesketh K, Power C, Hypponen E: Vitamin D status has a linear 
association with seasonal infections and lung function in British adults. Br J Nutr 2011, 
106:1433-1440. 
393. Hypponen E, Berry D, Cortina-Borja M, Power C: 25-Hydroxyvitamin D and pre-
clinical alterations in inflammatory and hemostatic markers: a cross sectional analysis 
in the 1958 British Birth Cohort. PLoS One 2010, 5:e10801. 
394. Wu AC, Tantisira K, Li L, Fuhlbrigge AL, Weiss ST, Litonjua A, Childhood Asthma 
Management Program Research G: Effect of vitamin D and inhaled corticosteroid 
treatment on lung function in children. Am J Respir Crit Care Med 2012, 186:508-513. 
271 | P a g e  
 
395. Milliken SV, Wassall H, Lewis BJ, Logie J, Barker RN, Macdonald H, Vickers MA, 
Ormerod AD: Effects of ultraviolet light on human serum 25-hydroxyvitamin D and 
systemic immune function. J Allergy Clin Immunol 2012, 129:1554-1561. 
396. Smolders J, Thewissen M, Peelen E, Menheere P, Tervaert JW, Damoiseaux J, 
Hupperts R: Vitamin D status is positively correlated with regulatory T cell function in 
patients with multiple sclerosis. PLoS One 2009, 4:e6635. 
397. Chen K, McAleer JP, Lin Y, Paterson DL, Zheng M, Alcorn JF, Weaver CT, Kolls 
JK: Th17 cells mediate clade-specific, serotype-independent mucosal immunity. 
Immunity 2011, 35:997-1009. 
398. Huang W, Na L, Fidel PL, Schwarzenberger P: Requirement of interleukin-17A for 
systemic anti-Candida albicans host defense in mice. J Infect Dis 2004, 190:624-631. 
399. Happel KI, Dubin PJ, Zheng M, Ghilardi N, Lockhart C, Quinton LJ, Odden AR, 
Shellito JE, Bagby GJ, Nelson S, et al.: Divergent roles of IL-23 and IL-12 in host 
defense against Klebsiella pneumoniae. J Exp Med 2005, 202:761-769. 
400. Jones CE, Chan K: Interleukin-17 stimulates the expression of interleukin-8, 
growth-related oncogene-alpha, and granulocyte-colony-stimulating factor by human 
airway epithelial cells. Am J Respir Cell Mol Biol 2002, 26:748-753. 
401. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, 
Mineau F, Pelletier JP: IL-17 stimulates the production and expression of 
proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J 
Immunol 1998, 160:3513-3521. 
402. Cua DJ, Tato CM: Innate IL-17-producing cells: the sentinels of the immune 
system. Nat Rev Immunol 2010, 10:479-489. 
272 | P a g e  
 
403. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver 
P, Huang W, Zhang P, Zhang J, et al.: Requirement of interleukin 17 receptor signaling 
for lung CXC chemokine and granulocyte colony-stimulating factor expression, 
neutrophil recruitment, and host defense. J Exp Med 2001, 194:519-527. 
404. McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, Henry A, 
Irvin CG, Piganelli JD, Ray A, et al.: TH17 cells mediate steroid-resistant airway 
inflammation and airway hyperresponsiveness in mice. J Immunol 2008, 181:4089-
4097. 
405. Barczyk A, Pierzchala W, Sozanska E: Interleukin-17 in sputum correlates with 
airway hyperresponsiveness to methacholine. Respir Med 2003, 97:726-733. 
406. Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ, Ceuppens 
JL: IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and 
granulocytic influx? Respir Res 2006, 7:135. 
407. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, Olivenstein R, Elias J, 
Chakir J: IL-17 is increased in asthmatic airways and induces human bronchial 
fibroblasts to produce cytokines. J Allergy Clin Immunol 2001, 108:430-438. 
408. Wong CK, Ho CY, Ko FW, Chan CH, Ho AS, Hui DS, Lam CW: Proinflammatory 
cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and 
IL-13) in patients with allergic asthma. Clin Exp Immunol 2001, 125:177-183. 
409. Vazquez-Tello A, Semlali A, Chakir J, Martin JG, Leung DY, Eidelman DH, Hamid 
Q: Induction of glucocorticoid receptor-beta expression in epithelial cells of asthmatic 
airways by T-helper type 17 cytokines. Clin Exp Allergy 2010, 40:1312-1322. 
410. Nakagome K, Imamura M, Kawahata K, Harada H, Okunishi K, Matsumoto T, 
Sasaki O, Tanaka R, Kano MR, Chang H, et al.: High expression of IL-22 suppresses 
273 | P a g e  
 
antigen-induced immune responses and eosinophilic airway inflammation via an IL-10-
associated mechanism. J Immunol 2011, 187:5077-5089. 
411. Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC, 
Matthys P: Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-
induced arthritis in C57BL/6 mice. Arthritis Rheum 2009, 60:390-395. 
412. Chang H, Hanawa H, Liu H, Yoshida T, Hayashi M, Watanabe R, Abe S, Toba K, 
Yoshida K, Elnaggar R, et al.: Hydrodynamic-based delivery of an interleukin-22-Ig 
fusion gene ameliorates experimental autoimmune myocarditis in rats. J Immunol 
2006, 177:3635-3643. 
413. Joshi S, Pantalena LC, Liu XK, Gaffen SL, Liu H, Rohowsky-Kochan C, Ichiyama 
K, Yoshimura A, Steinman L, Christakos S, et al.: 1,25-dihydroxyvitamin D(3) 
ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol 
Cell Biol 2011, 31:3653-3669. 
414. Chang JH, Cha HR, Lee DS, Seo KY, Kweon MN: 1,25-Dihydroxyvitamin D3 
inhibits the differentiation and migration of T(H)17 cells to protect against experimental 
autoimmune encephalomyelitis. PLoS One 2010, 5:e12925. 
415. Takei-Taniguchi R, Imai Y, Ishikawa C, Sakaguchi Y, Nakagawa N, Tsuda T, 
Hollenberg MD, Yamanishi K: Interleukin-17- and protease-activated receptor 2-
mediated production of CXCL1 and CXCL8 modulated by cyclosporine A, vitamin D3 
and glucocorticoids in human keratinocytes. J Dermatol 2012, 39:625-631. 
416. Bruce D, Yu S, Ooi JH, Cantorna MT: Converging pathways lead to 
overproduction of IL-17 in the absence of vitamin D signaling. Int Immunol 2011, 
23:519-528. 
274 | P a g e  
 
417. Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF, Borregaard N, 
Modlin RL, Hewison M: Vitamin d-directed rheostatic regulation of monocyte 
antibacterial responses. J Immunol 2009, 182:4289-4295. 
418. Dwyer KM, Hanidziar D, Putheti P, Hill PA, Pommey S, McRae JL, Winterhalter A, 
Doherty G, Deaglio S, Koulmanda M, et al.: Expression of CD39 by human peripheral 
blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant 
2010, 10:2410-2420. 
419. Moncrieffe H, Nistala K, Kamhieh Y, Evans J, Eddaoudi A, Eaton S, Wedderburn 
LR: High expression of the ectonucleotidase CD39 on T cells from the inflamed site 
identifies two distinct populations, one regulatory and one memory T cell population. J 
Immunol 2010, 185:134-143. 
420. Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC: CD39 and 
control of cellular immune responses. Purinergic Signal 2007, 3:171-180. 
421. Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, Quesniaux V, 
Fossiez F, Ryffel B, Schnyder B: Interleukin-17 is a negative regulator of established 
allergic asthma. J Exp Med 2006, 203:2715-2725. 
422. Newcomb DC, Boswell MG, Huckabee MM, Goleniewska K, Dulek DE, Reiss S, 
Lukacs NW, Kolls JK, Peebles RS, Jr.: IL-13 regulates Th17 secretion of IL-17A in an 
IL-10-dependent manner. J Immunol 2012, 188:1027-1035. 
423. Huber S, Gagliani N, Esplugues E, O'Connor W, Jr., Huber FJ, Chaudhry A, 
Kamanaka M, Kobayashi Y, Booth CJ, Rudensky AY, et al.: Th17 cells express 
interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4+ T 
cells in an interleukin-10-dependent manner. Immunity 2011, 34:554-565. 
424. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, 
Wunderlich FT, Bruning JC, Muller W, et al.: Interleukin-10 signaling in regulatory T 
275 | P a g e  
 
cells is required for suppression of Th17 cell-mediated inflammation. Immunity 2011, 
34:566-578. 
425. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, 
Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage 
distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132. 
426. Doe C, Bafadhel M, Siddiqui S, Desai D, Mistry V, Rugman P, McCormick M, 
Woods J, May R, Sleeman MA, et al.: Expression of the T helper 17-associated 
cytokines IL-17A and IL-17F in asthma and COPD. Chest 2010, 138:1140-1147. 
427. Regateiro FS, Howie D, Nolan KF, Agorogiannis EI, Greaves DR, Cobbold SP, 
Waldmann H: Generation of anti-inflammatory adenosine by leukocytes is regulated by 
TGF-beta. Eur J Immunol 2011, 41:2955-2965. 
428. Dalla Libera D, Di Mitri D, Bergami A, Centonze D, Gasperini C, Grasso MG, 
Galgani S, Martinelli V, Comi G, Avolio C, et al.: T regulatory cells are markers of 
disease activity in multiple sclerosis patients. PLoS One 2011, 6:e21386. 
429. Peelen E, Damoiseaux J, Smolders J, Knippenberg S, Menheere P, Tervaert JW, 
Hupperts R, Thewissen M: Th17 expansion in MS patients is counterbalanced by an 
expanded CD39+ regulatory T cell population during remission but not during relapse. 
J Neuroimmunol 2011, 240-241:97-103. 
430. Zhou Q, Yan J, Putheti P, Wu Y, Sun X, Toxavidis V, Tigges J, Kassam N, Enjyoji 
K, Robson SC, et al.: Isolated CD39 expression on CD4+ T cells denotes both 
regulatory and memory populations. Am J Transplant 2009, 9:2303-2311. 
431. Doherty GA, Bai A, Hanidziar D, Longhi MS, Lawlor GO, Putheti P, Csizmadia E, 
Nowak M, Cheifetz AS, Moss AC, et al.: CD73 is a phenotypic marker of effector 
memory Th17 cells in inflammatory bowel disease. Eur J Immunol 2012, 42:3062-3072. 
276 | P a g e  
 
432. Chakir J, Shannon J, Molet S, Fukakusa M, Elias J, Laviolette M, Boulet LP, 
Hamid Q: Airway remodeling-associated mediators in moderate to severe asthma: 
effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. 
J Allergy Clin Immunol 2003, 111:1293-1298. 
433. Damera G, Fogle HW, Lim P, Goncharova EA, Zhao H, Banerjee A, Tliba O, 
Krymskaya VP, Panettieri RA, Jr.: Vitamin D inhibits growth of human airway smooth 
muscle cells through growth factor-induced phosphorylation of retinoblastoma protein 
and checkpoint kinase 1. Br J Pharmacol 2009, 158:1429-1441. 
434. Dimeloe S, Richards DF, Urry ZL, Gupta A, Stratigou V, Farooque S, Saglani S, 
Bush A, Hawrylowicz CM: 1alpha,25-dihydroxyvitamin D3 promotes CD200 expression 
by human peripheral and airway-resident T cells. Thorax 2012, 67:574-581. 
435. Gorman S, Kuritzky LA, Judge MA, Dixon KM, McGlade JP, Mason RS, Finlay-
Jones JJ, Hart PH: Topically applied 1,25-dihydroxyvitamin D3 enhances the 
suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol 2007, 
179:6273-6283. 
436. Morales-Tirado V, Wichlan DG, Leimig TE, Street SE, Kasow KA, Riberdy JM: 
1alpha,25-dihydroxyvitamin D3 (vitamin D3) catalyzes suppressive activity on human 
natural regulatory T cells, uniquely modulates cell cycle progression, and augments 
FOXP3. Clin Immunol 2011, 138:212-221. 
437. Urry Z, Xystrakis E, Richards DF, McDonald J, Sattar Z, Cousins DJ, Corrigan CJ, 
Hickman E, Brown Z, Hawrylowicz CM: Ligation of TLR9 induced on human IL-10-
secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function. J Clin 
Invest 2009, 119:387-398. 
438. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I: Ulcerative colitis-like 
disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75:253-261. 
277 | P a g e  
 
439. Kramer S, Schimpl A, Hunig T: Immunopathology of interleukin (IL) 2-deficient 
mice: thymus dependence and suppression by thymus-dependent cells with an intact 
IL-2 gene. J Exp Med 1995, 182:1769-1776. 
440. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY: A function for interleukin 2 
in Foxp3-expressing regulatory T cells. Nat Immunol 2005, 6:1142-1151. 
441. Malek TR, Yu A, Vincek V, Scibelli P, Kong L: CD4 regulatory T cells prevent 
lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant 
function of IL-2. Immunity 2002, 17:167-178. 
442. Setoguchi R, Hori S, Takahashi T, Sakaguchi S: Homeostatic maintenance of 
natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction 
of autoimmune disease by IL-2 neutralization. J Exp Med 2005, 201:723-735. 
443. Taylor PA, Lees CJ, Blazar BR: The infusion of ex vivo activated and expanded 
CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. 
Blood 2002, 99:3493-3499. 
444. Lord JD, McIntosh BC, Greenberg PD, Nelson BH: The IL-2 receptor promotes 
lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the 
trans-activation domain of Stat5. J Immunol 2000, 164:2533-2541. 
445. Gouilleux F, Wakao H, Mundt M, Groner B: Prolactin induces phosphorylation of 
Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. 
EMBO J 1994, 13:4361-4369. 
446. Wakao H, Gouilleux F, Groner B: Mammary gland factor (MGF) is a novel 
member of the cytokine regulated transcription factor gene family and confers the 
prolactin response. EMBO J 1994, 13:2182-2191. 
278 | P a g e  
 
447. Oida T, Weiner HL: Overexpression of TGF-ss 1 gene induces cell surface 
localized glucose-regulated protein 78-associated latency-associated peptide/TGF-ss. 
J Immunol 2010, 185:3529-3535. 
448. Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R: Processing of 
transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 
1995, 270:10618-10624. 
449. Kanzaki T, Olofsson A, Moren A, Wernstedt C, Hellman U, Miyazono K, Claesson-
Welsh L, Heldin CH: TGF-beta 1 binding protein: a component of the large latent 
complex of TGF-beta 1 with multiple repeat sequences. Cell 1990, 61:1051-1061. 
450. ten Dijke P, Arthur HM: Extracellular control of TGFbeta signalling in vascular 
development and disease. Nat Rev Mol Cell Biol 2007, 8:857-869. 
451. Stockis J, Colau D, Coulie PG, Lucas S: Membrane protein GARP is a receptor 
for latent TGF-beta on the surface of activated human Treg. Eur J Immunol 2009, 
39:3315-3322. 
452. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM: GARP 
(LRRC32) is essential for the surface expression of latent TGF-beta on platelets and 
activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A 2009, 106:13445-
13450. 
453. Wang R, Wan Q, Kozhaya L, Fujii H, Unutmaz D: Identification of a regulatory T 
cell specific cell surface molecule that mediates suppressive signals and induces 
Foxp3 expression. PLoS One 2008, 3:e2705. 
454. Tran DQ: TGF-beta: the sword, the wand, and the shield of FOXP3(+) regulatory 
T cells. J Mol Cell Biol 2012, 4:29-37. 
279 | P a g e  
 
455. Regateiro FS, Howie D, Cobbold SP, Waldmann H: TGF-beta in transplantation 
tolerance. Curr Opin Immunol 2011, 23:660-669. 
456. Jeffery LE, Wood AM, Qureshi OS, Hou TZ, Gardner D, Briggs Z, Kaur S, Raza K, 
Sansom DM: Availability of 25-hydroxyvitamin D(3) to APCs controls the balance 
between regulatory and inflammatory T cell responses. J Immunol 2012, 189:5155-
5164. 
457. Cejas PJ, Walsh MC, Pearce EL, Han D, Harms GM, Artis D, Turka LA, Choi Y: 
TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2. Blood 
2010, 115:4750-4757. 
458. Chen Q, Kim YC, Laurence A, Punkosdy GA, Shevach EM: IL-2 controls the 
stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo. J Immunol 
2011, 186:6329-6337. 
459. Tischner D, Wiegers GJ, Fiegl H, Drach M, Villunger A: Mutual antagonism of 
TGF-beta and Interleukin-2 in cell survival and lineage commitment of induced 
regulatory T cells. Cell Death Differ 2012, 19:1277-1287. 
460. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA: IL-2 is essential for TGF-beta 
to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for 
expansion of these cells. J Immunol 2007, 178:2018-2027. 
461. Luderer HF, Nazarian RM, Zhu ED, Demay MB: Ligand-Dependent Actions of the 
Vitamin D Receptor Are Required for Activation of TGF-beta Signaling during the 
Inflammatory Response to Cutaneous Injury. Endocrinology 2013, 154:16-24. 
462. Lysandropoulos AP, Jaquiery E, Jilek S, Pantaleo G, Schluep M, Du Pasquier RA: 
Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early 
multiple sclerosis and healthy control subjects. J Neuroimmunol 2011, 233:240-244. 
280 | P a g e  
 
463. Isik S, Ozuguz U, Tutuncu YA, Erden G, Berker D, Acar K, Aydin Y, Akbaba G, 
Helvaci N, Guler S: Serum transforming growth factor-beta levels in patients with 
vitamin D deficiency. Eur J Intern Med 2012, 23:93-97. 
464. Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P: Therapeutic effect of 
vitamin D3 in multiple sclerosis patients. Immunol Invest 2011, 40:627-639. 
465. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT: Cytokine profile in 
patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 
2003, 134:128-132. 
466. Bonacci B, Edwards B, Jia S, Williams CB, Hessner MJ, Gauld SB, Verbsky JW: 
Requirements for growth and IL-10 expression of highly purified human T regulatory 
cells. J Clin Immunol 2012, 32:1118-1128. 
467. Joseph RW, Bayraktar UD, Kim TK, St John LS, Popat U, Khalili J, Molldrem JJ, 
Wieder ED, Komanduri KV: Vitamin D receptor upregulation in alloreactive human T 
cells. Hum Immunol 2012, 73:693-698. 
468. von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C: 
Vitamin D controls T cell antigen receptor signaling and activation of human T cells. 
Nat Immunol 2010, 11:344-349. 
469. Hu Y, Tian W, Zhang LL, Liu H, Yin GP, He BS, Mao XM: Function of regulatory 
T-cells improved by dexamethasone in Graves' disease. Eur J Endocrinol 2012, 
166:641-646. 
470. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins 
PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, et al.: Secukinumab, a human 
anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected 
results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-1700. 
281 | P a g e  
 
471. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, 
Aelion JA, Lee SH, Codding CE, Kellner H, et al.: Efficacy and safety of secukinumab 
in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, 
placebo controlled study. Ann Rheum Dis 2012. 
472. McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, 
Wollenhaupt J, Schulze-Koops H, Kogan J, et al.: Efficacy and safety of secukinumab, 
a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-
severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, 
phase II proof-of-concept trial. Ann Rheum Dis 2013. 
473. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, 
Roseau K, Harfst E, Guettner A, et al.: Secukinumab induction and maintenance 
therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-
controlled, phase II regimen-finding study. Br J Dermatol 2013, 168:402-411. 
474. Fallahi-Sichani M, Flynn JL, Linderman JJ, Kirschner DE: Differential risk of 
tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and 
permeability. J Immunol 2012, 188:3169-3178. 
475. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, Pallot-Prades 
B, Pouplin S, Sacchi A, Chichemanian RM, et al.: Risk of tuberculosis is higher with 
anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor 
necrosis factor receptor therapy: The three-year prospective French Research Axed on 
Tolerance of Biotherapies registry. Arthritis Rheum 2009, 60:1884-1894. 
476. Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, Fanger A, Tannapfel A, 
Fontenot JD, Ramsdell F, Powrie F: Characterization of Foxp3+CD4+CD25+ and IL-
10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol 2006, 177:5852-
5860. 
282 | P a g e  
 
477. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT: Grass pollen 
immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J 
Allergy Clin Immunol 2008, 121:1467-1472, 1472 e1461. 
478. Kamanaka M, Kim ST, Wan YY, Sutterwala FS, Lara-Tejero M, Galan JE, Harhaj 
E, Flavell RA: Expression of interleukin-10 in intestinal lymphocytes detected by an 
interleukin-10 reporter knockin tiger mouse. Immunity 2006, 25:941-952. 
479. Manz M, Vavricka SR, Wanner R, Lakatos PL, Rogler G, Frei P, Safroneeva E, 
Schoepfer AM: Therapy of steroid-resistant inflammatory bowel disease. Digestion 
2012, 86 Suppl 1:11-15. 
480. Berger M, Biasin E, Saglio F, Fagioli F: Innovative approaches to treat steroid-














284 | P a g e  
 
 
285 | P a g e  
 
 








287 | P a g e  
 
 
288 | P a g e  
 
 
289 | P a g e  
 
 
290 | P a g e  
 
 
291 | P a g e  
 
 
292 | P a g e  
 
 
293 | P a g e  
 
 


































298 | P a g e  
 
 
299 | P a g e  
 
 





















302 | P a g e  
 
 





































307 | P a g e  
 
 
 
 
 
 
